PMID-sentid	Pub_year	Sent_text	comp_official_name	comp_offset	protein_name	organism	prot_offset
26048912-4	2015	Of these four CYP2J2 inhibitors, danazol strongly inhibited CYP2J2-mediated albendazole, astemizole, ebastine, and terfenadine metabolism in a substrate-independent manner, with IC50 values of 0.05, 0.07, 0.18, and 0.34 muM, respectively.	ebastine	101-109	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	60-66
25601761-0	2015	Cytochrome P450 2J2, a new key enzyme in cyclophosphamide bioactivation and a potential biomarker for hematological malignancies.	Cyclophosphamide	41-57	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	0-19
25601761-1	2015	The role of cytochrome P450 2J2 (CYP2J2) in cyclophosphamide (Cy) bioactivation was investigated in patients, cells and microsomes.	Cyclophosphamide	44-60	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	12-31
25601761-1	2015	The role of cytochrome P450 2J2 (CYP2J2) in cyclophosphamide (Cy) bioactivation was investigated in patients, cells and microsomes.	Cyclophosphamide	44-60	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	33-39
25601761-1	2015	The role of cytochrome P450 2J2 (CYP2J2) in cyclophosphamide (Cy) bioactivation was investigated in patients, cells and microsomes.	Cyclophosphamide	62-64	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	12-31
25601761-1	2015	The role of cytochrome P450 2J2 (CYP2J2) in cyclophosphamide (Cy) bioactivation was investigated in patients, cells and microsomes.	Cyclophosphamide	62-64	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	33-39
25601761-4	2015	Cy bioactivation was significantly correlated to CYP2J2 expression.	Cyclophosphamide	0-2	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	49-55
25601761-5	2015	Studies in HL-60 cells expressing CYP2J2 showed reduced cell viability when incubated with Cy (half maximal inhibitory concentration=3.6 mM).	Cyclophosphamide	91-93	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	34-40
25601761-6	2015	Inhibition of CYP2J2 using telmisartan reduced Cy bioactivation by 50% and improved cell survival.	Telmisartan	27-38	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	14-20
25601761-6	2015	Inhibition of CYP2J2 using telmisartan reduced Cy bioactivation by 50% and improved cell survival.	Cyclophosphamide	47-49	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	14-20
25601761-8	2015	This is the first study demonstrating that CYP2J2 is equally important to CYP2B6 in Cy metabolism.	Cyclophosphamide	84-86	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	43-49
26048912-0	2015	Danazol Inhibits Cytochrome P450 2J2 Activity in a Substrate-independent Manner.	Danazol	0-7	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	17-36
26048912-1	2015	Cytochrome P450 2J2 (CYP2J2) is an enzyme responsible for the metabolism of endogenous substrates including arachidonic acid, as well as therapeutic drugs such as albendazole, astemizole, ebastine, and terfenadine.	Arachidonic Acid	108-124	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	0-19
26048912-1	2015	Cytochrome P450 2J2 (CYP2J2) is an enzyme responsible for the metabolism of endogenous substrates including arachidonic acid, as well as therapeutic drugs such as albendazole, astemizole, ebastine, and terfenadine.	Arachidonic Acid	108-124	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	21-27
26209360-0	2015	Inhibition of cytochrome P450 2J2 by tanshinone IIA induces apoptotic cell death in hepatocellular carcinoma HepG2 cells.	tanshinone	37-51	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	14-33
26209360-3	2015	To identify CYP2J2 inhibitors, 10 terpenoids obtained from plants were screened using astemizole as a CYP2J2 probe substrate in human liver microsomes (HLMs).	Terpenes	34-44	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	12-18
26209360-4	2015	Of these, tanshinone IIA dose-dependently and non-competitively inhibited CYP2J2-mediated astemizole O-demethylation activity.	Astemizole	90-100	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	74-80
26048912-4	2015	Of these four CYP2J2 inhibitors, danazol strongly inhibited CYP2J2-mediated albendazole, astemizole, ebastine, and terfenadine metabolism in a substrate-independent manner, with IC50 values of 0.05, 0.07, 0.18, and 0.34 muM, respectively.	Terfenadine	115-126	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	60-66
26048912-1	2015	Cytochrome P450 2J2 (CYP2J2) is an enzyme responsible for the metabolism of endogenous substrates including arachidonic acid, as well as therapeutic drugs such as albendazole, astemizole, ebastine, and terfenadine.	Albendazole	163-174	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	0-19
26048912-1	2015	Cytochrome P450 2J2 (CYP2J2) is an enzyme responsible for the metabolism of endogenous substrates including arachidonic acid, as well as therapeutic drugs such as albendazole, astemizole, ebastine, and terfenadine.	Albendazole	163-174	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	21-27
26048912-1	2015	Cytochrome P450 2J2 (CYP2J2) is an enzyme responsible for the metabolism of endogenous substrates including arachidonic acid, as well as therapeutic drugs such as albendazole, astemizole, ebastine, and terfenadine.	Astemizole	176-186	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	0-19
26048912-5	2015	Danazol noncompetitively inhibited CYP2J2-mediated astemizole O-demethylation activities with a Ki value of 0.06 muM.	Danazol	0-7	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	35-41
26048912-1	2015	Cytochrome P450 2J2 (CYP2J2) is an enzyme responsible for the metabolism of endogenous substrates including arachidonic acid, as well as therapeutic drugs such as albendazole, astemizole, ebastine, and terfenadine.	Astemizole	176-186	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	21-27
26048912-1	2015	Cytochrome P450 2J2 (CYP2J2) is an enzyme responsible for the metabolism of endogenous substrates including arachidonic acid, as well as therapeutic drugs such as albendazole, astemizole, ebastine, and terfenadine.	ebastine	188-196	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	0-19
26048912-5	2015	Danazol noncompetitively inhibited CYP2J2-mediated astemizole O-demethylation activities with a Ki value of 0.06 muM.	Astemizole	51-61	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	35-41
26048912-1	2015	Cytochrome P450 2J2 (CYP2J2) is an enzyme responsible for the metabolism of endogenous substrates including arachidonic acid, as well as therapeutic drugs such as albendazole, astemizole, ebastine, and terfenadine.	ebastine	188-196	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	21-27
26048912-6	2015	Terfenadone strongly inhibited CYP2J2-mediated albendazole, astemizole, and terfenadine metabolism (IC50 < 0.21 muM), whereas it showed weak inhibition against CYP2J2-catalyzed ebastine hydroxylase activity (IC50 = 6.04 muM).	terfenadone	0-11	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	31-37
26048912-1	2015	Cytochrome P450 2J2 (CYP2J2) is an enzyme responsible for the metabolism of endogenous substrates including arachidonic acid, as well as therapeutic drugs such as albendazole, astemizole, ebastine, and terfenadine.	Terfenadine	202-213	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	0-19
26048912-1	2015	Cytochrome P450 2J2 (CYP2J2) is an enzyme responsible for the metabolism of endogenous substrates including arachidonic acid, as well as therapeutic drugs such as albendazole, astemizole, ebastine, and terfenadine.	Terfenadine	202-213	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	21-27
26048912-3	2015	To find representative CYP2J2 index inhibitors, we evaluated the inhibitory potential of danazol, hydroxyebastine, telmisartan, and terfenadone against CYP2J2 activity for four representative CYP2J2 substrates (albendazole, astemizole, ebastine, and terfenadine) using recombinant CYP2J2.	Danazol	89-96	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	152-158
26048912-3	2015	To find representative CYP2J2 index inhibitors, we evaluated the inhibitory potential of danazol, hydroxyebastine, telmisartan, and terfenadone against CYP2J2 activity for four representative CYP2J2 substrates (albendazole, astemizole, ebastine, and terfenadine) using recombinant CYP2J2.	Danazol	89-96	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	152-158
26048912-3	2015	To find representative CYP2J2 index inhibitors, we evaluated the inhibitory potential of danazol, hydroxyebastine, telmisartan, and terfenadone against CYP2J2 activity for four representative CYP2J2 substrates (albendazole, astemizole, ebastine, and terfenadine) using recombinant CYP2J2.	Danazol	89-96	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	152-158
26048912-6	2015	Terfenadone strongly inhibited CYP2J2-mediated albendazole, astemizole, and terfenadine metabolism (IC50 < 0.21 muM), whereas it showed weak inhibition against CYP2J2-catalyzed ebastine hydroxylase activity (IC50 = 6.04 muM).	Albendazole	47-58	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	31-37
26048912-3	2015	To find representative CYP2J2 index inhibitors, we evaluated the inhibitory potential of danazol, hydroxyebastine, telmisartan, and terfenadone against CYP2J2 activity for four representative CYP2J2 substrates (albendazole, astemizole, ebastine, and terfenadine) using recombinant CYP2J2.	hydroxyebastine	98-113	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	152-158
26048912-3	2015	To find representative CYP2J2 index inhibitors, we evaluated the inhibitory potential of danazol, hydroxyebastine, telmisartan, and terfenadone against CYP2J2 activity for four representative CYP2J2 substrates (albendazole, astemizole, ebastine, and terfenadine) using recombinant CYP2J2.	hydroxyebastine	98-113	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	152-158
26048912-3	2015	To find representative CYP2J2 index inhibitors, we evaluated the inhibitory potential of danazol, hydroxyebastine, telmisartan, and terfenadone against CYP2J2 activity for four representative CYP2J2 substrates (albendazole, astemizole, ebastine, and terfenadine) using recombinant CYP2J2.	hydroxyebastine	98-113	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	152-158
26048912-3	2015	To find representative CYP2J2 index inhibitors, we evaluated the inhibitory potential of danazol, hydroxyebastine, telmisartan, and terfenadone against CYP2J2 activity for four representative CYP2J2 substrates (albendazole, astemizole, ebastine, and terfenadine) using recombinant CYP2J2.	Telmisartan	115-126	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	152-158
26048912-3	2015	To find representative CYP2J2 index inhibitors, we evaluated the inhibitory potential of danazol, hydroxyebastine, telmisartan, and terfenadone against CYP2J2 activity for four representative CYP2J2 substrates (albendazole, astemizole, ebastine, and terfenadine) using recombinant CYP2J2.	Telmisartan	115-126	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	152-158
26048912-3	2015	To find representative CYP2J2 index inhibitors, we evaluated the inhibitory potential of danazol, hydroxyebastine, telmisartan, and terfenadone against CYP2J2 activity for four representative CYP2J2 substrates (albendazole, astemizole, ebastine, and terfenadine) using recombinant CYP2J2.	Telmisartan	115-126	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	152-158
26048912-6	2015	Terfenadone strongly inhibited CYP2J2-mediated albendazole, astemizole, and terfenadine metabolism (IC50 < 0.21 muM), whereas it showed weak inhibition against CYP2J2-catalyzed ebastine hydroxylase activity (IC50 = 6.04 muM).	Astemizole	60-70	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	31-37
26048912-6	2015	Terfenadone strongly inhibited CYP2J2-mediated albendazole, astemizole, and terfenadine metabolism (IC50 < 0.21 muM), whereas it showed weak inhibition against CYP2J2-catalyzed ebastine hydroxylase activity (IC50 = 6.04 muM).	Terfenadine	76-87	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	31-37
26048912-8	2015	Taken together, these data suggest that danazol may be used as a CYP2J2 index inhibitor in reaction phenotyping studies.	Danazol	40-47	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	65-71
25870948-2	2015	The cytochrome P450 epoxygenase 2J2 (CYP2J2) metabolizes arachidonic acid to epoxyeicosatrienoic acids (EETs), which exert an anti-inflammatory effect on the cardiovascular system.	Arachidonic Acid	57-73	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	4-35
26048912-3	2015	To find representative CYP2J2 index inhibitors, we evaluated the inhibitory potential of danazol, hydroxyebastine, telmisartan, and terfenadone against CYP2J2 activity for four representative CYP2J2 substrates (albendazole, astemizole, ebastine, and terfenadine) using recombinant CYP2J2.	terfenadone	132-143	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	152-158
26048912-3	2015	To find representative CYP2J2 index inhibitors, we evaluated the inhibitory potential of danazol, hydroxyebastine, telmisartan, and terfenadone against CYP2J2 activity for four representative CYP2J2 substrates (albendazole, astemizole, ebastine, and terfenadine) using recombinant CYP2J2.	terfenadone	132-143	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	152-158
26048912-3	2015	To find representative CYP2J2 index inhibitors, we evaluated the inhibitory potential of danazol, hydroxyebastine, telmisartan, and terfenadone against CYP2J2 activity for four representative CYP2J2 substrates (albendazole, astemizole, ebastine, and terfenadine) using recombinant CYP2J2.	terfenadone	132-143	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	152-158
26048912-3	2015	To find representative CYP2J2 index inhibitors, we evaluated the inhibitory potential of danazol, hydroxyebastine, telmisartan, and terfenadone against CYP2J2 activity for four representative CYP2J2 substrates (albendazole, astemizole, ebastine, and terfenadine) using recombinant CYP2J2.	ebastine	105-113	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	152-158
26048912-3	2015	To find representative CYP2J2 index inhibitors, we evaluated the inhibitory potential of danazol, hydroxyebastine, telmisartan, and terfenadone against CYP2J2 activity for four representative CYP2J2 substrates (albendazole, astemizole, ebastine, and terfenadine) using recombinant CYP2J2.	ebastine	105-113	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	152-158
26048912-3	2015	To find representative CYP2J2 index inhibitors, we evaluated the inhibitory potential of danazol, hydroxyebastine, telmisartan, and terfenadone against CYP2J2 activity for four representative CYP2J2 substrates (albendazole, astemizole, ebastine, and terfenadine) using recombinant CYP2J2.	ebastine	105-113	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	152-158
26048912-4	2015	Of these four CYP2J2 inhibitors, danazol strongly inhibited CYP2J2-mediated albendazole, astemizole, ebastine, and terfenadine metabolism in a substrate-independent manner, with IC50 values of 0.05, 0.07, 0.18, and 0.34 muM, respectively.	Danazol	33-40	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	14-20
26048912-4	2015	Of these four CYP2J2 inhibitors, danazol strongly inhibited CYP2J2-mediated albendazole, astemizole, ebastine, and terfenadine metabolism in a substrate-independent manner, with IC50 values of 0.05, 0.07, 0.18, and 0.34 muM, respectively.	Danazol	33-40	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	60-66
26048912-4	2015	Of these four CYP2J2 inhibitors, danazol strongly inhibited CYP2J2-mediated albendazole, astemizole, ebastine, and terfenadine metabolism in a substrate-independent manner, with IC50 values of 0.05, 0.07, 0.18, and 0.34 muM, respectively.	Albendazole	76-87	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	14-20
26048912-4	2015	Of these four CYP2J2 inhibitors, danazol strongly inhibited CYP2J2-mediated albendazole, astemizole, ebastine, and terfenadine metabolism in a substrate-independent manner, with IC50 values of 0.05, 0.07, 0.18, and 0.34 muM, respectively.	Albendazole	76-87	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	60-66
26048912-4	2015	Of these four CYP2J2 inhibitors, danazol strongly inhibited CYP2J2-mediated albendazole, astemizole, ebastine, and terfenadine metabolism in a substrate-independent manner, with IC50 values of 0.05, 0.07, 0.18, and 0.34 muM, respectively.	Astemizole	89-99	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	60-66
25857771-6	2015	RESULTS: We show that drug-related compounds, debrisoquine and terfenadine derivatives, subtrates of CYP2D6 and CYP2J2, are hydroxylated by recombinant CYP2U1 with regioselectivities different from those reported for CYP2D6 and 2J2.	Debrisoquin	46-58	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	112-118
25857771-6	2015	RESULTS: We show that drug-related compounds, debrisoquine and terfenadine derivatives, subtrates of CYP2D6 and CYP2J2, are hydroxylated by recombinant CYP2U1 with regioselectivities different from those reported for CYP2D6 and 2J2.	Terfenadine	63-74	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	112-118
26053032-0	2015	CYP2J2 overexpression ameliorates hyperlipidemia via increased fatty acid oxidation mediated by the AMPK pathway.	Fatty Acids	63-73	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	0-6
26053032-1	2015	OBJECTIVE: The study aims to investigate the effect of cytochrome P450 2J2 (CYP2J2) overexpression on hyperlipidemia in mice and further to explore its effect on fatty acid oxidation in vivo and in vitro.	Fatty Acids	162-172	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	76-82
26053032-2	2015	METHODS: The effects and mechanisms of endothelial-specific CYP2J2 transgene (Tie2-CYP2J2-Tr) on lipid and fatty acid metabolism were investigated in high-fat diet (HFD) -treated mice.	Fatty Acids	107-117	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	60-66
26053032-4	2015	RESULTS: Tie2-CYP2J2-Tr mice had significantly lower plasma and liver triglycerides, lower liver cholesterol and fatty acids, and reduced HFD-induced lipid accumulation.	Triglycerides	70-83	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	14-20
26053032-4	2015	RESULTS: Tie2-CYP2J2-Tr mice had significantly lower plasma and liver triglycerides, lower liver cholesterol and fatty acids, and reduced HFD-induced lipid accumulation.	Cholesterol	97-108	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	14-20
26053032-4	2015	RESULTS: Tie2-CYP2J2-Tr mice had significantly lower plasma and liver triglycerides, lower liver cholesterol and fatty acids, and reduced HFD-induced lipid accumulation.	Fatty Acids	113-124	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	14-20
26053032-6	2015	In FFA-treated HepG2, LO2, and HUVECs, both CYP2J2 overexpression and EETs significantly decreased lipid accumulation and increased fatty acid oxidation via activating the AMPK and PPARalpha pathways.	Fatty Acids	132-142	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	44-50
26053032-8	2015	CYP2J2 ameliorates FFA-induced dyslipidemia via increased fatty acid oxidation mediated by the AMPK and PPARalpha pathways.	Fatty Acids, Nonesterified	19-22	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	0-6
26053032-8	2015	CYP2J2 ameliorates FFA-induced dyslipidemia via increased fatty acid oxidation mediated by the AMPK and PPARalpha pathways.	Fatty Acids	58-68	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	0-6
25388680-6	2015	EPHX2 55Arg, CYP2J2*7, CYP2C8*1B, and CYP2C8 g.36785A allele carriers had lower EET and DHET CSF levels.	EET	80-83	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	13-19
25388680-6	2015	EPHX2 55Arg, CYP2J2*7, CYP2C8*1B, and CYP2C8 g.36785A allele carriers had lower EET and DHET CSF levels.	dhet	88-92	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	13-19
25840911-4	2015	Zinc-finger nuclease-mediated targeted gene deletion of the major rat macrophage epoxygenase Cyp2j4 (ortholog of human CYP2J2) resulted in reduced epoxyeicosatrienoic acid synthesis.	epoxyeicosatrienoic acid	147-171	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	119-125
25560582-3	2015	CYP2C8, CYP2C9 and CYP2J2 gene involved in the metabolism of arachidonic acid, generates epoxyeicosatrienoic acids (EETs) that mediate dilation of coronary arteries improving post-ischemic cardiac contractile function, reduce vascular inflammation, and increase intravascular fibrinolysis.	Arachidonic Acid	61-77	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	19-25
25560582-3	2015	CYP2C8, CYP2C9 and CYP2J2 gene involved in the metabolism of arachidonic acid, generates epoxyeicosatrienoic acids (EETs) that mediate dilation of coronary arteries improving post-ischemic cardiac contractile function, reduce vascular inflammation, and increase intravascular fibrinolysis.	epoxyeicosatrienoic acids	89-114	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	19-25
25870948-2	2015	The cytochrome P450 epoxygenase 2J2 (CYP2J2) metabolizes arachidonic acid to epoxyeicosatrienoic acids (EETs), which exert an anti-inflammatory effect on the cardiovascular system.	Arachidonic Acid	57-73	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	37-43
25870948-2	2015	The cytochrome P450 epoxygenase 2J2 (CYP2J2) metabolizes arachidonic acid to epoxyeicosatrienoic acids (EETs), which exert an anti-inflammatory effect on the cardiovascular system.	epoxyeicosatrienoic acids	77-102	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	4-35
25870948-2	2015	The cytochrome P450 epoxygenase 2J2 (CYP2J2) metabolizes arachidonic acid to epoxyeicosatrienoic acids (EETs), which exert an anti-inflammatory effect on the cardiovascular system.	epoxyeicosatrienoic acids	77-102	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	37-43
25870948-2	2015	The cytochrome P450 epoxygenase 2J2 (CYP2J2) metabolizes arachidonic acid to epoxyeicosatrienoic acids (EETs), which exert an anti-inflammatory effect on the cardiovascular system.	eets	104-108	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	4-35
25870948-2	2015	The cytochrome P450 epoxygenase 2J2 (CYP2J2) metabolizes arachidonic acid to epoxyeicosatrienoic acids (EETs), which exert an anti-inflammatory effect on the cardiovascular system.	eets	104-108	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	37-43
24973543-0	2014	Investigating the contribution of CYP2J2 to ritonavir metabolism in vitro and in vivo.	Ritonavir	44-53	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	34-40
25245389-6	2014	Tie2-CYP2J2 transgenic mice, fed a high-fat diet, had a reduction in body weight gain, blood glucose, insulin levels, and inflammatory markers.	Blood Glucose	87-100	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	5-11
25277139-0	2014	Endocannabinoids anandamide and 2-arachidonoylglycerol are substrates for human CYP2J2 epoxygenase.	Endocannabinoids	0-16	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	80-86
25277139-0	2014	Endocannabinoids anandamide and 2-arachidonoylglycerol are substrates for human CYP2J2 epoxygenase.	anandamide	17-27	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	80-86
25277139-0	2014	Endocannabinoids anandamide and 2-arachidonoylglycerol are substrates for human CYP2J2 epoxygenase.	glyceryl 2-arachidonate	32-54	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	80-86
25277139-2	2014	CYP2J2 is the primary cytochrome P450 in the human heart and is most well known for the metabolism of AA to the biologically active epoxyeicosatrienoic acids.	epoxyeicosatrienoic acids	132-157	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	0-6
25277139-3	2014	In this study, we demonstrate that both 2-AG and AEA are substrates for metabolism by CYP2J2 epoxygenase in the model membrane bilayers of nanodiscs.	glyceryl 2-arachidonate	40-44	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	86-92
25277139-3	2014	In this study, we demonstrate that both 2-AG and AEA are substrates for metabolism by CYP2J2 epoxygenase in the model membrane bilayers of nanodiscs.	anandamide	49-52	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	86-92
25277139-4	2014	Reactions of CYP2J2 with AEA formed four AEA-epoxyeicosatrienoic acids, whereas incubations with 2-AG yielded detectable levels of only two 2-AG epoxides.	anandamide	25-28	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	13-19
25277139-4	2014	Reactions of CYP2J2 with AEA formed four AEA-epoxyeicosatrienoic acids, whereas incubations with 2-AG yielded detectable levels of only two 2-AG epoxides.	aea-epoxyeicosatrienoic acids	41-70	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	13-19
25277139-5	2014	Notably, 2-AG was shown to undergo enzymatic oxidative cleavage to form AA through a NADPH-dependent reaction with CYP2J2 and cytochrome P450 reductase.	NADP	85-90	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	115-121
25277139-8	2014	The experimental and theoretical data were in agreement, which showed that substitution of the AA carboxylic acid with the 2-AG ester-glycerol changes the binding interaction of these lipids within the CYP2J2 active site, leading to different product distributions.	Carboxylic Acids	98-113	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	202-208
25277139-8	2014	The experimental and theoretical data were in agreement, which showed that substitution of the AA carboxylic acid with the 2-AG ester-glycerol changes the binding interaction of these lipids within the CYP2J2 active site, leading to different product distributions.	2-ag ester	123-133	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	202-208
25277139-8	2014	The experimental and theoretical data were in agreement, which showed that substitution of the AA carboxylic acid with the 2-AG ester-glycerol changes the binding interaction of these lipids within the CYP2J2 active site, leading to different product distributions.	Glycerol	134-142	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	202-208
24882266-2	2014	The main human CYP epoxygenases, i.e. CYP2C8, CYP2C9, CYP2C19 and CYP2J2, convert AA to four regioisomer epoxyeicosatrienoic acids (EETs).	epoxyeicosatrienoic acids	105-130	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	66-72
24882266-2	2014	The main human CYP epoxygenases, i.e. CYP2C8, CYP2C9, CYP2C19 and CYP2J2, convert AA to four regioisomer epoxyeicosatrienoic acids (EETs).	eets	132-136	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	66-72
24997310-0	2014	A note on CYP2J2-mediated terfenadine hydroxylation in human liver microsomes.	Terfenadine	26-37	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	10-16
24998194-0	2014	Response to comment: "A note on CYP2J2-mediated terfenadine hydroxylation in human liver microsomes".	Terfenadine	48-59	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	32-38
24788058-2	2014	To identify a CYP2J2 inhibitor, 50 natural products obtained from plants were screened using astemizole as a CYP2J2 probe substrate in human liver microsomes.	Astemizole	93-103	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	109-115
24788058-3	2014	Of these, decursin noncompetitively inhibited CYP2J2-mediated astemizole O-demethylation and terfenadine hydroxylation activities with Ki values of 8.34 and 15.8muM, respectively.	Astemizole	62-72	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	46-52
24788058-3	2014	Of these, decursin noncompetitively inhibited CYP2J2-mediated astemizole O-demethylation and terfenadine hydroxylation activities with Ki values of 8.34 and 15.8muM, respectively.	Terfenadine	93-104	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	46-52
24973543-3	2014	This investigation revealed that CYP2J2, along with CYP3A4/5 and CYP2D6, efficiently metabolizes ritonavir, and to a CYP2J2-specific (minor) metabolite.	Ritonavir	97-106	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	33-39
24973543-8	2014	A modest (2-6%) contribution of CYP2J2 to ritonavir clearance is predicted which increases to more than 20% in subjects carrying CYP2D6 poor metabolizer polymorphisms and CYP3A4 irreversible inhibition.	Ritonavir	42-51	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	32-38
24903033-8	2014	Moreover, we observed that exogenous EETs, or CYP2J2 overexpression, enhanced cell viability, decreased intracellular reactive oxygen species (ROS) generation, inhibited mitochondrial dysfunction, and attenuated several apoptotic signaling events in a human pulmonary artery endothelial cells (HPAECs)-based anoxia/reoxygenation model.	Reactive Oxygen Species	118-141	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	46-52
24631907-7	2014	In conclusion, human endothelial cells contain a TLR-4 regulated epoxygenase CYP2J2 and metabolize linoleic acid>eicosapentaenoic acid > arachidonic acid>docosahexaenoic acid to products with anti-inflammatory activity.	Linoleic Acid	99-112	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	77-83
24631907-7	2014	In conclusion, human endothelial cells contain a TLR-4 regulated epoxygenase CYP2J2 and metabolize linoleic acid>eicosapentaenoic acid > arachidonic acid>docosahexaenoic acid to products with anti-inflammatory activity.	Eicosapentaenoic Acid	116-137	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	77-83
24631907-7	2014	In conclusion, human endothelial cells contain a TLR-4 regulated epoxygenase CYP2J2 and metabolize linoleic acid>eicosapentaenoic acid > arachidonic acid>docosahexaenoic acid to products with anti-inflammatory activity.	Arachidonic Acid	143-159	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	77-83
24631907-7	2014	In conclusion, human endothelial cells contain a TLR-4 regulated epoxygenase CYP2J2 and metabolize linoleic acid>eicosapentaenoic acid > arachidonic acid>docosahexaenoic acid to products with anti-inflammatory activity.	Docosahexaenoic Acids	163-183	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	77-83
24795797-1	2014	The human cytochrome P450 2J2 catalyzes an epoxygenase reaction to oxidize various fatty acids including arachidonic acid.	Fatty Acids	83-94	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	10-29
24795797-1	2014	The human cytochrome P450 2J2 catalyzes an epoxygenase reaction to oxidize various fatty acids including arachidonic acid.	Arachidonic Acid	105-121	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	10-29
24788058-1	2014	CYP2J2 enzyme is highly expressed in human tumors and carcinoma cell lines, and epoxyeicosatrienoic acids, CYP2J2-mediated metabolites, have been implicated in the pathologic development of human cancers.	epoxyeicosatrienoic acids	80-105	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	0-6
24788058-1	2014	CYP2J2 enzyme is highly expressed in human tumors and carcinoma cell lines, and epoxyeicosatrienoic acids, CYP2J2-mediated metabolites, have been implicated in the pathologic development of human cancers.	epoxyeicosatrienoic acids	80-105	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	107-113
24788058-2	2014	To identify a CYP2J2 inhibitor, 50 natural products obtained from plants were screened using astemizole as a CYP2J2 probe substrate in human liver microsomes.	Astemizole	93-103	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	14-20
24903033-8	2014	Moreover, we observed that exogenous EETs, or CYP2J2 overexpression, enhanced cell viability, decreased intracellular reactive oxygen species (ROS) generation, inhibited mitochondrial dysfunction, and attenuated several apoptotic signaling events in a human pulmonary artery endothelial cells (HPAECs)-based anoxia/reoxygenation model.	Reactive Oxygen Species	143-146	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	46-52
23474289-1	2013	Cytochrome p450 (CYP)2J2 is an epoxygenase enzyme that metabolises arachidonic acid to epoxyeicosatrienoic acids (EETs).	Arachidonic Acid	67-83	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	0-24
24021950-1	2013	Cytochrome P450 2J2 plays a significant role in the epoxidation of arachidonic acid to signaling molecules important in cardiovascular events.	Arachidonic Acid	67-83	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	0-19
24021950-2	2013	CYP2J2 also contributes to drug metabolism and is responsible for the intestinal clearance of ebastine.	ebastine	94-102	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	0-6
24021950-8	2013	Compared with recombinant CYP2J2, terfenadine was hydroxylated in cardiomyocytes at a similar K(m) value of 1.5 muM.	Terfenadine	34-45	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	26-32
24021950-10	2013	CYP2J2 activity in the cell line was inhibited by danazol, astemizole, and ketoconazole in submicromolar range, but also by xenobiotics known to cause cardiac adverse effects.	Danazol	50-57	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	0-6
24021950-10	2013	CYP2J2 activity in the cell line was inhibited by danazol, astemizole, and ketoconazole in submicromolar range, but also by xenobiotics known to cause cardiac adverse effects.	Astemizole	59-69	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	0-6
24021950-10	2013	CYP2J2 activity in the cell line was inhibited by danazol, astemizole, and ketoconazole in submicromolar range, but also by xenobiotics known to cause cardiac adverse effects.	Ketoconazole	75-87	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	0-6
25204827-0	2014	Research/review: Insights into the mutation-induced dysfunction of arachidonic acid metabolism from modeling of human CYP2J2.	Arachidonic Acid	67-83	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	118-124
25204827-1	2014	As a kind of monooxygenase with the function of catalyzing many reactions involved in drug metabolism and synthesis of cholesterol, steroids and other lipids, CYP2J2 is an important member of the cytochrome P450 superfamily.	Cholesterol	119-130	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	159-165
25204827-1	2014	As a kind of monooxygenase with the function of catalyzing many reactions involved in drug metabolism and synthesis of cholesterol, steroids and other lipids, CYP2J2 is an important member of the cytochrome P450 superfamily.	Steroids	132-140	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	159-165
25204827-2	2014	Located at the endoplasmic reticulum, CYP2J2 is responsible for epoxidation of endogenous arachidonic acid in cardiac tissue to produce cis-epoxyeicosatrienoic acids (EETs), which have anti-inflammatory and antifibrinolytic properties, and can protect endothelial cells from ischemic or hypoxic injuries.	Arachidonic Acid	90-106	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	38-44
25204827-2	2014	Located at the endoplasmic reticulum, CYP2J2 is responsible for epoxidation of endogenous arachidonic acid in cardiac tissue to produce cis-epoxyeicosatrienoic acids (EETs), which have anti-inflammatory and antifibrinolytic properties, and can protect endothelial cells from ischemic or hypoxic injuries.	cis-epoxyeicosatrienoic acids	136-165	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	38-44
25204827-2	2014	Located at the endoplasmic reticulum, CYP2J2 is responsible for epoxidation of endogenous arachidonic acid in cardiac tissue to produce cis-epoxyeicosatrienoic acids (EETs), which have anti-inflammatory and antifibrinolytic properties, and can protect endothelial cells from ischemic or hypoxic injuries.	eets	167-171	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	38-44
25204827-3	2014	Some polymorphisms, e.g., CYP2J2 with mutation T143A, R158C, I192N or N404Y, could significantly reduce the metabolism of the arachidonic acid, causing or deteriorating the coronary artery disease.	Arachidonic Acid	126-142	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	26-32
25204827-5	2014	To reveal its mechanism, a 3D (three-dimensional) structure for human CYP2J2 was developed, followed by docking the arachidonic acid ligand into the active site of the receptor.	Arachidonic Acid	116-132	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	70-76
25204827-6	2014	It was observed based on the binding mode thus found that Gly486 and Leu378 in the active site of the receptor played a key role in recognizing and positioning the carboxyl group of the ligand via hydrogen bonding interactions, and that any of the aforementioned five mutations might have, either directly or indirectly, impact to their role and hence causing the mutation-induced dysfunction of CYP2J2-mediated arachidonic acid metabolism.	Arachidonic Acid	412-428	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	396-402
23474289-1	2013	Cytochrome p450 (CYP)2J2 is an epoxygenase enzyme that metabolises arachidonic acid to epoxyeicosatrienoic acids (EETs).	epoxyeicosatrienoic acids	87-112	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	0-24
23474289-1	2013	Cytochrome p450 (CYP)2J2 is an epoxygenase enzyme that metabolises arachidonic acid to epoxyeicosatrienoic acids (EETs).	eets	114-118	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	0-24
23305158-7	2013	A significant increase in rivaroxaban exposure was demonstrated with the strong CYP3A4, P-gp/Bcrp (ABCG2) inhibitors (and potential CYP2J2 inhibitors) ketoconazole (158% increase [95% CI 136%, 182%] for a 400 mg once daily dose) and ritonavir (153% increase [95% CI 134%, 174%]).	Rivaroxaban	26-37	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	132-138
24148690-4	2013	14,15-DHETs can be considered a relevant marker of CYP2J2 activity.	14,15-dihydroxyeicosatrienoic acid	0-11	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	51-57
24058654-6	2013	The CYP2J2 arachidonic acid products 11,12-EET and 14,15-EET inhibited LPS induced TNFalpha release.	Arachidonic Acid	11-27	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	4-10
24058654-6	2013	The CYP2J2 arachidonic acid products 11,12-EET and 14,15-EET inhibited LPS induced TNFalpha release.	11,12-epoxy-5,8,14-eicosatrienoic acid	37-46	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	4-10
24058654-6	2013	The CYP2J2 arachidonic acid products 11,12-EET and 14,15-EET inhibited LPS induced TNFalpha release.	14,15-epoxy-5,8,11-eicosatrienoic acid	51-60	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	4-10
23959307-0	2013	CYP2J2 and CYP2C19 are the major enzymes responsible for metabolism of albendazole and fenbendazole in human liver microsomes and recombinant P450 assay systems.	Albendazole	71-82	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	0-6
23959307-0	2013	CYP2J2 and CYP2C19 are the major enzymes responsible for metabolism of albendazole and fenbendazole in human liver microsomes and recombinant P450 assay systems.	Fenbendazole	87-99	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	0-6
23959307-4	2013	Of the 10 recombinant P450s, CYP2J2 and/or CYP2C19 was the predominant enzyme catalyzing the hydroxylation of albendazole and fenbendazole.	Albendazole	110-121	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	29-35
23959307-4	2013	Of the 10 recombinant P450s, CYP2J2 and/or CYP2C19 was the predominant enzyme catalyzing the hydroxylation of albendazole and fenbendazole.	Fenbendazole	126-138	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	29-35
23959307-6	2013	Correlation analysis between the known P450 enzyme activities and the rate of hydroxyalbendazole and hydroxyfenbendazole formation in samples from 14 human liver microsomes showed that albendazole hydroxylation correlates with CYP2J2 activity and fenbendazole hydroxylation correlates with CYP2C19 and CYP2J2 activities.	hydroxyalbendazole	78-96	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	227-233
23959307-6	2013	Correlation analysis between the known P450 enzyme activities and the rate of hydroxyalbendazole and hydroxyfenbendazole formation in samples from 14 human liver microsomes showed that albendazole hydroxylation correlates with CYP2J2 activity and fenbendazole hydroxylation correlates with CYP2C19 and CYP2J2 activities.	4-hydroxyfenbendazole	101-120	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	227-233
23959307-6	2013	Correlation analysis between the known P450 enzyme activities and the rate of hydroxyalbendazole and hydroxyfenbendazole formation in samples from 14 human liver microsomes showed that albendazole hydroxylation correlates with CYP2J2 activity and fenbendazole hydroxylation correlates with CYP2C19 and CYP2J2 activities.	4-hydroxyfenbendazole	101-120	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	302-308
23959307-6	2013	Correlation analysis between the known P450 enzyme activities and the rate of hydroxyalbendazole and hydroxyfenbendazole formation in samples from 14 human liver microsomes showed that albendazole hydroxylation correlates with CYP2J2 activity and fenbendazole hydroxylation correlates with CYP2C19 and CYP2J2 activities.	Albendazole	85-96	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	227-233
23959307-6	2013	Correlation analysis between the known P450 enzyme activities and the rate of hydroxyalbendazole and hydroxyfenbendazole formation in samples from 14 human liver microsomes showed that albendazole hydroxylation correlates with CYP2J2 activity and fenbendazole hydroxylation correlates with CYP2C19 and CYP2J2 activities.	Albendazole	85-96	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	302-308
23959307-6	2013	Correlation analysis between the known P450 enzyme activities and the rate of hydroxyalbendazole and hydroxyfenbendazole formation in samples from 14 human liver microsomes showed that albendazole hydroxylation correlates with CYP2J2 activity and fenbendazole hydroxylation correlates with CYP2C19 and CYP2J2 activities.	Fenbendazole	108-120	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	227-233
23959307-6	2013	Correlation analysis between the known P450 enzyme activities and the rate of hydroxyalbendazole and hydroxyfenbendazole formation in samples from 14 human liver microsomes showed that albendazole hydroxylation correlates with CYP2J2 activity and fenbendazole hydroxylation correlates with CYP2C19 and CYP2J2 activities.	Fenbendazole	108-120	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	302-308
23959307-8	2013	In conclusion, our data for the first time suggest that albendazole hydroxylation is primarily catalyzed by CYP2J2, whereas fenbendazole hydroxylation is preferentially catalyzed by CYP2C19 and CYP2J2.	Albendazole	56-67	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	108-114
23959307-8	2013	In conclusion, our data for the first time suggest that albendazole hydroxylation is primarily catalyzed by CYP2J2, whereas fenbendazole hydroxylation is preferentially catalyzed by CYP2C19 and CYP2J2.	Fenbendazole	124-136	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	194-200
23305158-7	2013	A significant increase in rivaroxaban exposure was demonstrated with the strong CYP3A4, P-gp/Bcrp (ABCG2) inhibitors (and potential CYP2J2 inhibitors) ketoconazole (158% increase [95% CI 136%, 182%] for a 400 mg once daily dose) and ritonavir (153% increase [95% CI 134%, 174%]).	Ketoconazole	151-163	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	132-138
22173545-3	2012	Several SNPs, some recognized as functional, in human genes implicated in EETs/20-HETE biosynthesis and metabolism, such as CYP2J2 and CYP4A11, have been tested for association with blood pressure, hypertension and its long-term cardiovascular consequences in different populations, with conflicting results.	20-hydroxy-5,8,11,14-eicosatetraenoic acid	79-86	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	124-130
24058654-8	2013	Epoxygenase inhibition using a non-selective inhibitor SKF525A or a selective CYP2J2 inhibitor Compound 4, inhibited E. coli particle phagocytosis, which could be specifically reversed by 11,12-EET.	11,12-epoxy-5,8,14-eicosatrienoic acid	188-197	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	78-84
23684773-1	2013	BACKGROUND: Cytochrome P450 (CYP) 2J2 is expressed in the vascular endothelium and metabolizes arachidonic acid to biologically active epoxyeicosatrienoic acids (EETs).	Arachidonic Acid	95-111	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	12-37
23684773-1	2013	BACKGROUND: Cytochrome P450 (CYP) 2J2 is expressed in the vascular endothelium and metabolizes arachidonic acid to biologically active epoxyeicosatrienoic acids (EETs).	epoxyeicosatrienoic acids	135-160	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	12-37
23684773-1	2013	BACKGROUND: Cytochrome P450 (CYP) 2J2 is expressed in the vascular endothelium and metabolizes arachidonic acid to biologically active epoxyeicosatrienoic acids (EETs).	eets	162-166	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	12-37
23647230-2	2013	In cardiac tissues, CYP2J2 can adopt arachidonic acid as a major substrate to produce epoxyeicosatrienoic acids (EETs), which can protect endothelial cells from ischemic or hypoxic injuries and have been implicated in the pathogenesis of coronary artery disease and hypertension.	Arachidonic Acid	37-53	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	20-26
23647230-2	2013	In cardiac tissues, CYP2J2 can adopt arachidonic acid as a major substrate to produce epoxyeicosatrienoic acids (EETs), which can protect endothelial cells from ischemic or hypoxic injuries and have been implicated in the pathogenesis of coronary artery disease and hypertension.	epoxyeicosatrienoic acids	86-111	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	20-26
23647230-2	2013	In cardiac tissues, CYP2J2 can adopt arachidonic acid as a major substrate to produce epoxyeicosatrienoic acids (EETs), which can protect endothelial cells from ischemic or hypoxic injuries and have been implicated in the pathogenesis of coronary artery disease and hypertension.	eets	113-117	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	20-26
23647230-3	2013	However, some CYP2J2 polymorphisms, i.e., T143A and N404Y, significantly reduce the metabolism of arachidonic acid.	Arachidonic Acid	98-114	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	14-20
23647230-4	2013	Lacking experimental structural data for CYP2J2, the detailed mechanism for the mutation-induced dysfunction in the metabolism of arachidonic acid is still unknown.	Arachidonic Acid	130-146	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	41-47
23647230-6	2013	The structural analysis of the computational models showed that the wild-type CYP2J2 exhibited a typical CYP fold with 12 alpha-helices and three beta-sheets on one side and with the heme group buried deeply inside the core.	Heme	183-187	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	78-84
23865864-2	2013	During the past 15 years, CYP2J2 has attracted much attention for its epoxygenase activity in arachidonic acid (AA) metabolism.	Arachidonic Acid	94-110	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	26-32
24216999-7	2013	Similarly CYP2J2, CYP4F2 and CYPA22 mRNAs were significantly (p < 0.05) down-regulated by EA treatment.	Ellagic Acid	93-95	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	10-16
23283969-2	2013	Roles for the arachidonic acid epoxygenase metabolites, the epoxyeicosatrienoic acids (EETs), in ENaC activity have been identified; however, their mechanisms of action remain unknown.	eets	87-91	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	14-42
23274569-7	2013	We have experimentally confirmed that each CYP isozyme can be effectively differentiated by their unique isozyme-specific tryptic peptide(s).	Peptides	130-137	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	43-46
23688134-11	2013	CYP2J2 and its role in the metabolism of arachidonic acid to epoxyeicosatrienoic acids and angiogenesis will also be examined.	Arachidonic Acid	41-57	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	0-6
23688134-11	2013	CYP2J2 and its role in the metabolism of arachidonic acid to epoxyeicosatrienoic acids and angiogenesis will also be examined.	epoxyeicosatrienoic acids	61-86	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	0-6
23688135-8	2013	Additionally, specific inhibitors of CYP2J2, derived from terfenadine, exhibit strong anti-tumor activity in vitro and in vivo.	Terfenadine	58-69	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	37-43
23033255-6	2013	In particular, telmisartan and flunarizine have CYP2J2 inhibition IC(50) values of 0.42 muM and 0.94 muM, respectively, which are at least 10-fold more selective against all other major metabolizing CYPs; moreover, they are not substrates of CYP2J2 and show no time-dependent inhibition toward this CYP.	Telmisartan	15-26	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	48-54
23033255-6	2013	In particular, telmisartan and flunarizine have CYP2J2 inhibition IC(50) values of 0.42 muM and 0.94 muM, respectively, which are at least 10-fold more selective against all other major metabolizing CYPs; moreover, they are not substrates of CYP2J2 and show no time-dependent inhibition toward this CYP.	Telmisartan	15-26	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	242-248
23033255-6	2013	In particular, telmisartan and flunarizine have CYP2J2 inhibition IC(50) values of 0.42 muM and 0.94 muM, respectively, which are at least 10-fold more selective against all other major metabolizing CYPs; moreover, they are not substrates of CYP2J2 and show no time-dependent inhibition toward this CYP.	Flunarizine	31-42	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	48-54
23033255-6	2013	In particular, telmisartan and flunarizine have CYP2J2 inhibition IC(50) values of 0.42 muM and 0.94 muM, respectively, which are at least 10-fold more selective against all other major metabolizing CYPs; moreover, they are not substrates of CYP2J2 and show no time-dependent inhibition toward this CYP.	Flunarizine	31-42	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	242-248
23033255-7	2013	The results of enzyme kinetics studies, supported by molecular modeling, have also elucidated that telmisartan is a mixed-type inhibitor, and flunarizine competitively inhibits CYP2J2.	Flunarizine	142-153	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	177-183
23155181-6	2012	The CYP2J2 metabolites, 5,6-epoxyeicosatrienoic acid (EET), 14,15-EET, and the corresponding dihydroxyeicosatrienoic acids, were elevated in preeclamptic women compared with controls in the latter two thirds of pregnancy and after delivery.	5,6-epoxy-8,11,14-eicosatrienoic acid	24-52	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	4-10
23155181-6	2012	The CYP2J2 metabolites, 5,6-epoxyeicosatrienoic acid (EET), 14,15-EET, and the corresponding dihydroxyeicosatrienoic acids, were elevated in preeclamptic women compared with controls in the latter two thirds of pregnancy and after delivery.	5,6-epoxy-8,11,14-eicosatrienoic acid	54-57	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	4-10
23155181-6	2012	The CYP2J2 metabolites, 5,6-epoxyeicosatrienoic acid (EET), 14,15-EET, and the corresponding dihydroxyeicosatrienoic acids, were elevated in preeclamptic women compared with controls in the latter two thirds of pregnancy and after delivery.	dihydroxyeicosatrienoic acids	93-122	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	4-10
22369694-1	2012	We retrospectively examined the association of polymorphisms in the CYP3A, CYP2J2, CYP2C8, and ABCB1 genes with pharmacokinetic (PKs) and pharmacodynamic (PDs) parameters of tacrolimus in 103 renal transplant recipients for a period of 1 year.	Tacrolimus	174-184	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	75-81
22328583-1	2012	CYP2J2, an arachidonic acid epoxygenase, is recognized for its role in the first-pass metabolism of astemizole and ebastine.	Astemizole	100-110	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	0-6
22328583-1	2012	CYP2J2, an arachidonic acid epoxygenase, is recognized for its role in the first-pass metabolism of astemizole and ebastine.	ebastine	115-123	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	0-6
22328583-3	2012	In this study, we report amiodarone 4-hydoxylation as a specific CYP2J2-catalyzed reaction with no CYP3A4, or other drug-metabolizing enzyme, involvement.	Amiodarone	25-35	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	65-71
22328583-4	2012	Amiodarone 4-hydroxylation enabled the determination of liver relative activity factor and intersystem extrapolation factor for CYP2J2.	Amiodarone	0-10	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	128-134
22328583-6	2012	To identify a specific CYP2J2 inhibitor, 138 drugs were screened using terfenadine and astemizole as probe substrates with recombinant CYP2J2.	Terfenadine	71-82	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	23-29
22328583-6	2012	To identify a specific CYP2J2 inhibitor, 138 drugs were screened using terfenadine and astemizole as probe substrates with recombinant CYP2J2.	Astemizole	87-97	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	23-29
22328583-11	2012	Thus, danazol, amiodarone, and astemizole will facilitate the ability to determine the metabolic role of CYP2J2 in hepatic and extrahepatic tissues.	Danazol	6-13	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	105-111
22328583-11	2012	Thus, danazol, amiodarone, and astemizole will facilitate the ability to determine the metabolic role of CYP2J2 in hepatic and extrahepatic tissues.	Amiodarone	15-25	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	105-111
22328583-11	2012	Thus, danazol, amiodarone, and astemizole will facilitate the ability to determine the metabolic role of CYP2J2 in hepatic and extrahepatic tissues.	Astemizole	31-41	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	105-111
21846841-7	2011	Moreover, the CYP2J2-specific inhibitor compound 26 enhanced arsenic cytotoxicity to a clinically relevant concentration of ATO (1-2 muM).	Arsenic	61-68	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	14-20
21656078-1	2012	BACKGROUND: It has recently been found that 5-lipoxygenase (5-LO) and cytochrome P450-2J2 (CYP2J2), molecules capable of arachidonic acid (AA) metabolism, might promote cancer cell viability through several mechanisms similar to those of cyclooxygenase-2 (COX-2).	Arachidonic Acid	121-137	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	70-89
21656078-1	2012	BACKGROUND: It has recently been found that 5-lipoxygenase (5-LO) and cytochrome P450-2J2 (CYP2J2), molecules capable of arachidonic acid (AA) metabolism, might promote cancer cell viability through several mechanisms similar to those of cyclooxygenase-2 (COX-2).	Arachidonic Acid	121-137	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	91-97
21656078-5	2012	Inhibition of COX-2 resulted in increased production of LTB(4) and 14-15-DHET/EET, metabolites of 5-LO and CYP2J2, respectively.	Leukotriene B4	56-59	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	107-113
21656078-5	2012	Inhibition of COX-2 resulted in increased production of LTB(4) and 14-15-DHET/EET, metabolites of 5-LO and CYP2J2, respectively.	14,15-dihydroxyeicosatrienoic acid	67-77	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	107-113
21656078-5	2012	Inhibition of COX-2 resulted in increased production of LTB(4) and 14-15-DHET/EET, metabolites of 5-LO and CYP2J2, respectively.	EET	78-81	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	107-113
21846841-7	2011	Moreover, the CYP2J2-specific inhibitor compound 26 enhanced arsenic cytotoxicity to a clinically relevant concentration of ATO (1-2 muM).	Arsenic Trioxide	124-127	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	14-20
21642892-1	2011	OBJECTIVE: Common polymorphisms within cytochrome P450 2J2 (CYP2J2) and epoxide hydrolase 2 (EPHX2), which are involved in the generation or hydrolysis of epoxyeicosatrienoic acids, may determine susceptibility to the development of cardiovascular disease.	epoxyeicosatrienoic acids	155-180	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	39-58
21642892-1	2011	OBJECTIVE: Common polymorphisms within cytochrome P450 2J2 (CYP2J2) and epoxide hydrolase 2 (EPHX2), which are involved in the generation or hydrolysis of epoxyeicosatrienoic acids, may determine susceptibility to the development of cardiovascular disease.	epoxyeicosatrienoic acids	155-180	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	60-66
21477627-9	2011	Importantly, soluble epoxide hydrolase (sEH) inhibitors are anti-hypertensive and anti-inflammatory and, therefore, protect the heart from damage, whereas the terfenadine-related, specific inhibitors of CYP2J2 exhibit strong anti-tumor activity in vitro and in vivo.	Terfenadine	159-170	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	203-209
21476972-7	2011	It has been demonstrated that CYP2J2 generates cardioprotective EETs, whereas another isozyme in the heart, CYP2C, generates EETs as well as detrimental ROS.	Reactive Oxygen Species	153-156	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	30-36
21383522-6	2011	Using immunoinhibitory antibodies and chemical inhibitors, we showed that the higher intestinal CL(int) values of the human CYP2J2 and CYP2C substrates in cynomolgus monkeys might be caused by monkey CYP4F and CYP2C subfamily members, respectively.	cl(int)	96-103	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	124-130
21030485-1	2011	Cytochrome P450 2J2 (CYP2J2) epoxygenase converts arachidonic acid to four regioisomeric epoxyeicosatrienoic acids (EETs) that exert multiple biological effects in the cardiovascular system and in various human solid cancers.	Arachidonic Acid	50-66	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	0-19
21030485-1	2011	Cytochrome P450 2J2 (CYP2J2) epoxygenase converts arachidonic acid to four regioisomeric epoxyeicosatrienoic acids (EETs) that exert multiple biological effects in the cardiovascular system and in various human solid cancers.	Arachidonic Acid	50-66	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	21-27
21030485-1	2011	Cytochrome P450 2J2 (CYP2J2) epoxygenase converts arachidonic acid to four regioisomeric epoxyeicosatrienoic acids (EETs) that exert multiple biological effects in the cardiovascular system and in various human solid cancers.	epoxyeicosatrienoic acids	89-114	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	0-19
21030485-1	2011	Cytochrome P450 2J2 (CYP2J2) epoxygenase converts arachidonic acid to four regioisomeric epoxyeicosatrienoic acids (EETs) that exert multiple biological effects in the cardiovascular system and in various human solid cancers.	epoxyeicosatrienoic acids	89-114	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	21-27
21030485-1	2011	Cytochrome P450 2J2 (CYP2J2) epoxygenase converts arachidonic acid to four regioisomeric epoxyeicosatrienoic acids (EETs) that exert multiple biological effects in the cardiovascular system and in various human solid cancers.	eets	116-120	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	0-19
21030485-1	2011	Cytochrome P450 2J2 (CYP2J2) epoxygenase converts arachidonic acid to four regioisomeric epoxyeicosatrienoic acids (EETs) that exert multiple biological effects in the cardiovascular system and in various human solid cancers.	eets	116-120	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	21-27
21030485-6	2011	Addition of the selective CYP2J2 inhibitor compound 26 (C26; 1-[4-(vinyl) phenyl]-4-[4-(diphenyl-hydroxymethyl)-piperidinyl]-butanone hydrochloride) inhibited cell proliferation and increased apoptosis, an effect that was significantly reversed by EET.	1-[4-(vinyl) phenyl]-4-[4-(diphenyl-hydroxymethyl)-piperidinyl]-butanone hydrochloride	61-147	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	26-32
20194533-1	2010	Cytochrome P450 2J2 oxidizes arachidonic acid to a series of epoxyeicosatrienoic acid (EET) isomers in human tissues.	Arachidonic Acid	29-45	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	0-19
20118222-4	2010	We investigated whether gene delivery with the human cytochrome P450 epoxygenase 2J2 (CYP2J2) ameliorates monocrotaline (MCT)-induced pulmonary hypertension in rats.	Monocrotaline	106-119	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	53-84
20118222-4	2010	We investigated whether gene delivery with the human cytochrome P450 epoxygenase 2J2 (CYP2J2) ameliorates monocrotaline (MCT)-induced pulmonary hypertension in rats.	Monocrotaline	106-119	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	86-92
20118222-4	2010	We investigated whether gene delivery with the human cytochrome P450 epoxygenase 2J2 (CYP2J2) ameliorates monocrotaline (MCT)-induced pulmonary hypertension in rats.	Monocrotaline	121-124	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	53-84
20118222-4	2010	We investigated whether gene delivery with the human cytochrome P450 epoxygenase 2J2 (CYP2J2) ameliorates monocrotaline (MCT)-induced pulmonary hypertension in rats.	Monocrotaline	121-124	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	86-92
20412023-1	2010	Human mesenchymal stem cells (MSCs) expressed substantial levels of CYP2J2, a major CYP450 involved in epoxyeicosatrienoic acid (EET) formation.	epoxyeicosatrienoic acid	103-127	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	68-74
20412023-1	2010	Human mesenchymal stem cells (MSCs) expressed substantial levels of CYP2J2, a major CYP450 involved in epoxyeicosatrienoic acid (EET) formation.	EET	129-132	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	68-74
20495177-4	2010	Compared to wild-type littermate controls, an attenuated afferent arteriole constrictor response to endothelin-1 and enhanced dilator response to acetylcholine was observed in CYP2J2 and CYP2C8 transgenic mice.	Acetylcholine	146-159	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	176-182
20495177-6	2010	However, mean arterial pressure was significantly lower in both CYP2J2 and CYP2C8 transgenic mice during coadministration of N-nitro-l-arginine methyl ester and indomethacin.	n-nitro-l-arginine methyl ester	125-156	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	64-70
20495177-6	2010	However, mean arterial pressure was significantly lower in both CYP2J2 and CYP2C8 transgenic mice during coadministration of N-nitro-l-arginine methyl ester and indomethacin.	Indomethacin	161-173	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	64-70
20495177-8	2010	The angiotensin/high-salt-induced increase in systolic blood pressure, proteinuria, and glomerular injury was significantly attenuated in CYP2J2 and CYP2C8 transgenic mice compared to wild-type controls.	Salts	21-25	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	138-144
19940026-6	2010	Experiments with human cDNA-expressed P450 enzymes and P450 chemical inhibitors and correlation with P450 activities in individual human liver microsomes demonstrated that the oxidative metabolism of apixaban for formation of all metabolites was predominantly catalyzed by CYP3A4/5 with a minor contribution of CYP1A2 and CYP2J2 for formation of M2.	apixaban	200-208	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	322-328
20093140-4	2010	CYP epoxygenases such as CYP1A2, CYP2C, and CYP2J2 metabolize arachidonic acid to epoxyeicosatrienoic acids (EETs) which generally possess vasodilating, anti-inflammatory, anti-apoptotic, anti-thrombotic, natriuretic, and cardioprotective effects.	Arachidonic Acid	62-78	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	44-50
20926621-11	2011	Formation of M20 by human liver microsomes was inhibited 89% by ketoconazole, 75% by astemizole (a CYP2J2 inhibitor), and 43% by CYP3A4 monoclonal antibody.	Astemizole	85-95	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	99-105
20597138-1	2010	The cytochromes P450 epoxygenases CYP2J2 synthesize epoxyeicosatrienoic, which regulate endothelial function.	epoxyeicosatrienoic	52-71	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	34-40
20140850-1	2010	BACKGROUND: Cytochrome P450 (CYP) 2J2 is a regulatory enzyme in the biosynthesis of biologically active CIS-epoxyeicosatrienoic acids (EETs).	cis-epoxyeicosatrienoic acids	104-133	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	12-37
20140850-1	2010	BACKGROUND: Cytochrome P450 (CYP) 2J2 is a regulatory enzyme in the biosynthesis of biologically active CIS-epoxyeicosatrienoic acids (EETs).	eets	135-139	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	12-37
20194533-0	2010	Up-regulation of human CYP2J2 in HepG2 cells by butylated hydroxyanisole is mediated by c-Jun and Nrf2.	Butylated Hydroxyanisole	48-72	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	23-29
20180943-1	2010	BACKGROUND AND PURPOSE: Human cytochrome P450 2J2 (CYP2J2) generates epoxyfatty acids that modulate cellular apoptosis and proliferation.	epoxyfatty acids	69-85	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	30-49
20180943-1	2010	BACKGROUND AND PURPOSE: Human cytochrome P450 2J2 (CYP2J2) generates epoxyfatty acids that modulate cellular apoptosis and proliferation.	epoxyfatty acids	69-85	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	51-57
20194533-1	2010	Cytochrome P450 2J2 oxidizes arachidonic acid to a series of epoxyeicosatrienoic acid (EET) isomers in human tissues.	epoxyeicosatrienoic acid	61-85	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	0-19
20194533-1	2010	Cytochrome P450 2J2 oxidizes arachidonic acid to a series of epoxyeicosatrienoic acid (EET) isomers in human tissues.	EET	87-90	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	0-19
19923256-7	2010	Extracted ion chromatograms of metabolites observed for albendazole, amiodarone, astemizole, thioridazine, mesoridazine, and danazol showed marked differences in the regioselectivity of CYP2J2 and CYP3A4.	Astemizole	81-91	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	186-192
20093140-4	2010	CYP epoxygenases such as CYP1A2, CYP2C, and CYP2J2 metabolize arachidonic acid to epoxyeicosatrienoic acids (EETs) which generally possess vasodilating, anti-inflammatory, anti-apoptotic, anti-thrombotic, natriuretic, and cardioprotective effects.	epoxyeicosatrienoic acids	82-107	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	44-50
20093140-4	2010	CYP epoxygenases such as CYP1A2, CYP2C, and CYP2J2 metabolize arachidonic acid to epoxyeicosatrienoic acids (EETs) which generally possess vasodilating, anti-inflammatory, anti-apoptotic, anti-thrombotic, natriuretic, and cardioprotective effects.	eets	109-113	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	44-50
19923256-7	2010	Extracted ion chromatograms of metabolites observed for albendazole, amiodarone, astemizole, thioridazine, mesoridazine, and danazol showed marked differences in the regioselectivity of CYP2J2 and CYP3A4.	Thioridazine	93-105	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	186-192
19923256-7	2010	Extracted ion chromatograms of metabolites observed for albendazole, amiodarone, astemizole, thioridazine, mesoridazine, and danazol showed marked differences in the regioselectivity of CYP2J2 and CYP3A4.	Mesoridazine	107-119	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	186-192
19923256-7	2010	Extracted ion chromatograms of metabolites observed for albendazole, amiodarone, astemizole, thioridazine, mesoridazine, and danazol showed marked differences in the regioselectivity of CYP2J2 and CYP3A4.	Danazol	125-132	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	186-192
19923256-9	2010	Although the CYP2J2 active site can accommodate large substrates, it may be more narrow than CYP3A4, limiting metabolism to moieties that can extend closer toward the active heme iron.	Heme	174-178	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	13-19
19923256-9	2010	Although the CYP2J2 active site can accommodate large substrates, it may be more narrow than CYP3A4, limiting metabolism to moieties that can extend closer toward the active heme iron.	Iron	179-183	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	13-19
19923256-10	2010	For albendazole, CYP2J2 forms a unique metabolite compared with CYP3A4.	Albendazole	4-15	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	17-23
19923256-12	2010	The Michaelis-Menten-derived intrinsic clearance of N-desethyl amiodarone was 4.6 greater in HLM than in HIM and 17-fold greater in recombinant CYP3A4 than in recombinant CYP2J2.	desethylamiodarone	52-73	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	171-177
19550113-1	2009	BACKGROUND AND OBJECTIVE: Cytochrome P450 arachidonic acid epoxygenase 2J2 (CYP2J2) is a new metabolic pathway of arachidonic acid.	Arachidonic Acid	42-58	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	76-82
19851119-1	2010	BACKGROUND: CYP2J2 is responsible for the production of 5,6 8,9 11,12 and 14,15-epoxyeicosatrienoic acids, vasodilator and anti-inflammatory substances.	14,15-epoxy-5,8,11-eicosatrienoic acid	74-105	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	12-18
20021200-5	2010	The purified enzyme was catalytically active towards aminopyrine, all-trans-retinoic acid, and particularly arachidonic acid forming 20-HETE, 19-HETE, and 18-HETE (about 86% of the total) and 14,15-, 11,12-, 8,9-, and 5,6-EETs (cis-epoxyeicosatrienoic acids; about 14% of total), with a regioselectivity similar to that shown by the mammalian CYP2J2s.	Aminopyrine	53-64	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	343-349
20021200-5	2010	The purified enzyme was catalytically active towards aminopyrine, all-trans-retinoic acid, and particularly arachidonic acid forming 20-HETE, 19-HETE, and 18-HETE (about 86% of the total) and 14,15-, 11,12-, 8,9-, and 5,6-EETs (cis-epoxyeicosatrienoic acids; about 14% of total), with a regioselectivity similar to that shown by the mammalian CYP2J2s.	Tretinoin	66-89	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	343-349
20021200-5	2010	The purified enzyme was catalytically active towards aminopyrine, all-trans-retinoic acid, and particularly arachidonic acid forming 20-HETE, 19-HETE, and 18-HETE (about 86% of the total) and 14,15-, 11,12-, 8,9-, and 5,6-EETs (cis-epoxyeicosatrienoic acids; about 14% of total), with a regioselectivity similar to that shown by the mammalian CYP2J2s.	Arachidonic Acid	108-124	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	343-349
20021200-5	2010	The purified enzyme was catalytically active towards aminopyrine, all-trans-retinoic acid, and particularly arachidonic acid forming 20-HETE, 19-HETE, and 18-HETE (about 86% of the total) and 14,15-, 11,12-, 8,9-, and 5,6-EETs (cis-epoxyeicosatrienoic acids; about 14% of total), with a regioselectivity similar to that shown by the mammalian CYP2J2s.	Hydroxyeicosatetraenoic Acids	136-140	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	343-349
20021200-5	2010	The purified enzyme was catalytically active towards aminopyrine, all-trans-retinoic acid, and particularly arachidonic acid forming 20-HETE, 19-HETE, and 18-HETE (about 86% of the total) and 14,15-, 11,12-, 8,9-, and 5,6-EETs (cis-epoxyeicosatrienoic acids; about 14% of total), with a regioselectivity similar to that shown by the mammalian CYP2J2s.	cis-epoxyeicosatrienoic acids	228-257	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	343-349
19454483-1	2009	17alpha-Ethinyl estradiol (EE) was systematically evaluated as a reversible and time-dependent inhibitor of 11 human drug-metabolizing cytochromes P450 (P450s) (CYP1A1, CYP1A2, CYP1B1, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP2J2, CYP3A4, and CYP3A5) in vitro.	Ethinyl Estradiol	0-25	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	226-232
19286836-5	2009	Phenobarbital suppressed the expression of CYP2R1 in fibroblasts and CYP2J2 in LNCaP cells.	Phenobarbital	0-13	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	69-75
19923256-1	2010	Several antihistamine drugs including terfenadine, ebastine, and astemizole have been identified as substrates for CYP2J2.	Terfenadine	38-49	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	115-121
19923256-1	2010	Several antihistamine drugs including terfenadine, ebastine, and astemizole have been identified as substrates for CYP2J2.	ebastine	51-59	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	115-121
19923256-1	2010	Several antihistamine drugs including terfenadine, ebastine, and astemizole have been identified as substrates for CYP2J2.	Astemizole	65-75	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	115-121
19923256-7	2010	Extracted ion chromatograms of metabolites observed for albendazole, amiodarone, astemizole, thioridazine, mesoridazine, and danazol showed marked differences in the regioselectivity of CYP2J2 and CYP3A4.	Albendazole	56-67	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	186-192
19923256-7	2010	Extracted ion chromatograms of metabolites observed for albendazole, amiodarone, astemizole, thioridazine, mesoridazine, and danazol showed marked differences in the regioselectivity of CYP2J2 and CYP3A4.	Amiodarone	69-79	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	186-192
19944311-0	2009	Eicosapentaenoic acid increases cytochrome P-450 2J2 gene expression and epoxyeicosatrienoic acid production via peroxisome proliferator-activated receptor gamma in endothelial cells.	Eicosapentaenoic Acid	0-21	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	32-52
19944311-2	2009	Cytochrome P-450 (CYP) 2J2 that is expressed in endothelial cells metabolizes arachidonic acids to biologically active epoxyeicosatrienoic acids (EETs) that possess anti-inflammatory and anti-thrombotic effects.	Arachidonic Acids	78-95	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	0-26
19944311-2	2009	Cytochrome P-450 (CYP) 2J2 that is expressed in endothelial cells metabolizes arachidonic acids to biologically active epoxyeicosatrienoic acids (EETs) that possess anti-inflammatory and anti-thrombotic effects.	epoxyeicosatrienoic acids	119-144	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	0-26
19944311-2	2009	Cytochrome P-450 (CYP) 2J2 that is expressed in endothelial cells metabolizes arachidonic acids to biologically active epoxyeicosatrienoic acids (EETs) that possess anti-inflammatory and anti-thrombotic effects.	eets	146-150	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	0-26
19944311-3	2009	We studied the effects of EPA and DHA on the expression of CYP 2J2 mRNA by reverse transcription-polymerase chain reaction in cultured human umbilical vein endothelial cells and found that EPA, but not DHA, increased the expression of CYP 2J2 mRNA in a dose-dependent and a time-dependent manner.	Eicosapentaenoic Acid	26-29	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	59-66
19944311-3	2009	We studied the effects of EPA and DHA on the expression of CYP 2J2 mRNA by reverse transcription-polymerase chain reaction in cultured human umbilical vein endothelial cells and found that EPA, but not DHA, increased the expression of CYP 2J2 mRNA in a dose-dependent and a time-dependent manner.	Docosahexaenoic Acids	34-37	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	59-66
19944311-3	2009	We studied the effects of EPA and DHA on the expression of CYP 2J2 mRNA by reverse transcription-polymerase chain reaction in cultured human umbilical vein endothelial cells and found that EPA, but not DHA, increased the expression of CYP 2J2 mRNA in a dose-dependent and a time-dependent manner.	Docosahexaenoic Acids	34-37	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	235-242
19944311-3	2009	We studied the effects of EPA and DHA on the expression of CYP 2J2 mRNA by reverse transcription-polymerase chain reaction in cultured human umbilical vein endothelial cells and found that EPA, but not DHA, increased the expression of CYP 2J2 mRNA in a dose-dependent and a time-dependent manner.	Eicosapentaenoic Acid	189-192	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	59-66
19944311-3	2009	We studied the effects of EPA and DHA on the expression of CYP 2J2 mRNA by reverse transcription-polymerase chain reaction in cultured human umbilical vein endothelial cells and found that EPA, but not DHA, increased the expression of CYP 2J2 mRNA in a dose-dependent and a time-dependent manner.	Eicosapentaenoic Acid	189-192	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	235-242
19944311-4	2009	EPA-induced CYP 2J2 expression was significantly inhibited by pretreatment with a peroxisome proliferator-activated receptor (PPAR) gamma antagonist, GW9662.	Eicosapentaenoic Acid	0-3	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	12-19
19944311-4	2009	EPA-induced CYP 2J2 expression was significantly inhibited by pretreatment with a peroxisome proliferator-activated receptor (PPAR) gamma antagonist, GW9662.	2-chloro-5-nitrobenzanilide	150-156	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	12-19
19944311-6	2009	These data demonstrate that EPA increases CYP 2J2 mRNA expression and 11,12-EET production via PPARgamma in endothelial cells and indicate a novel protective role of EPA and PPARgamma against vascular inflammation.	Eicosapentaenoic Acid	28-31	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	42-49
19429816-0	2009	Overexpression of CYP2J2 provides protection against doxorubicin-induced cardiotoxicity.	Doxorubicin	53-64	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	18-24
19429816-8	2009	However, cardiac function, assessed by measurement of fractional shortening with M-mode transthoracic echocardiography, was significantly higher in CYP2J2 Tr than WT hearts after chronic Dox treatment (WT 37 +/- 2%, CYP2J2 Tr 47 +/- 1%).	Doxorubicin	187-190	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	148-154
19429816-12	2009	Together, these data suggest that cardiac-specific overexpression of CYP2J2 limited Dox-induced toxicity.	Doxorubicin	84-87	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	69-75
19289568-0	2009	Selective inhibitors of CYP2J2 related to terfenadine exhibit strong activity against human cancers in vitro and in vivo.	Terfenadine	42-53	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	24-30
19289568-1	2009	The cytochrome P450 epoxygenase, CYP2J2, converts arachidonic acid to four regioisomeric epoxyeicosatrienoic acids (EETs).	Arachidonic Acid	50-66	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	33-39
19289568-1	2009	The cytochrome P450 epoxygenase, CYP2J2, converts arachidonic acid to four regioisomeric epoxyeicosatrienoic acids (EETs).	epoxyeicosatrienoic acids	89-114	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	33-39
19289568-1	2009	The cytochrome P450 epoxygenase, CYP2J2, converts arachidonic acid to four regioisomeric epoxyeicosatrienoic acids (EETs).	eets	116-120	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	33-39
19289568-3	2009	In the present study, we tested the hypothesis that specific inhibitors of CYP2J2 related to the drug terfenadine are effective antitumor agents.	Terfenadine	102-113	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	75-81
18303964-1	2008	UNLABELLED: The cytochrome P450 enzymes CYP2C8, CYP2C9 and CYP2J2 generate 8,9-, 11,12-, and 14,15-epoxyeicosatrienic acid (EET) from arachidonic acid, and these EETs are then hydrolyzed to dihydroxyeicosatrienoic acids (DHET) before excretion into the urine.	8,9-, 11,12-, and 14,15-epoxyeicosatrienic acid	75-122	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	59-65
19448409-6	2009	RESULTS: Infection of Tca-8113, A549, Ncl-H446 and HepG2 cells with rAAV-CYP2J2 and rAAVCYPF87V significantly increased the proliferation of tumor cells by 1.7-, 1.4-, 1.6- and 2.2-fold, and 2.0-, 1.5-, 1.8- and 2.0-fold respectively, as compared with control cells.	Trichloroacetic Acid	22-25	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	73-79
19219743-7	2009	In addition, intestinal microsomes metabolized eperisone to M3 and M4 via CYP2J2- and CYP3A4-mediated reactions, which are supposed to contribute to presystemic metabolism of eperisone.	eperisone	47-56	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	74-80
19219743-7	2009	In addition, intestinal microsomes metabolized eperisone to M3 and M4 via CYP2J2- and CYP3A4-mediated reactions, which are supposed to contribute to presystemic metabolism of eperisone.	eperisone	175-184	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	74-80
19105833-2	2008	One of the CYP2J2 products, 11, 12-epoxyeicosatrienoic acid, has several vasoprotective effects.	11,12-epoxy-5,8,14-eicosatrienoic acid	28-59	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	11-17
18729130-1	2008	Human cytochrome P450 2J2 (CYP2J2) is abundant in cardiovascular tissue and active in the metabolism of arachidonic acid to eicosanoids that have potent vasodilatory properties.	Arachidonic Acid	104-120	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	6-25
18729130-1	2008	Human cytochrome P450 2J2 (CYP2J2) is abundant in cardiovascular tissue and active in the metabolism of arachidonic acid to eicosanoids that have potent vasodilatory properties.	Arachidonic Acid	104-120	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	27-33
18729130-1	2008	Human cytochrome P450 2J2 (CYP2J2) is abundant in cardiovascular tissue and active in the metabolism of arachidonic acid to eicosanoids that have potent vasodilatory properties.	Eicosanoids	124-135	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	6-25
18729130-1	2008	Human cytochrome P450 2J2 (CYP2J2) is abundant in cardiovascular tissue and active in the metabolism of arachidonic acid to eicosanoids that have potent vasodilatory properties.	Eicosanoids	124-135	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	27-33
18675280-1	2008	CYP2J2 is one of the cytochrome P450 epoxygenases involved in the metabolism of arachidonic acid.	Arachidonic Acid	80-96	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	0-6
18675280-3	2008	CYP2J2 has cardiovascular effects, as epoxyeicosatrienoic acid, one of its metabolites, has anti-inflammatory and vasodilative activities.	epoxyeicosatrienoic acid	38-62	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	0-6
18675280-6	2008	Furthermore, the expression of CYP2J2 mRNA increased when the human monocytic cell line THP-1 cells and human monocytes were stimulated with phorbol 12-myristate 13-acetate and macrophage-colony stimulating factor in combination with granulocyte/macrophage-colony stimulating factor, respectively.	Tetradecanoylphorbol Acetate	141-172	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	31-37
18675280-7	2008	These results suggest that expression of CYP2J2 was up-regulated when human monocytes differentiated into macrophages and that human monocytic cells and macrophages have a pathway to metabolize arachidonic acid using CYP epoxygenases.	Arachidonic Acid	194-210	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	41-47
18496133-2	2008	CYP2J2, CYP2C8, and CYP2C9 are known to be a source of epoxyeicosatrienoic acids in cardiac tissues.	epoxyeicosatrienoic acids	55-80	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	0-6
18769365-2	2008	Cytochrome P450 2C8 (CYP2C8) and CYP2J2 are polymorphic enzymes expressed in the kidney that metabolize arachidonic acid (AA) to epoxyeicosatrienoic acids, promoting kidney homeostasis.	Arachidonic Acid	104-120	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	33-39
18769365-2	2008	Cytochrome P450 2C8 (CYP2C8) and CYP2J2 are polymorphic enzymes expressed in the kidney that metabolize arachidonic acid (AA) to epoxyeicosatrienoic acids, promoting kidney homeostasis.	epoxyeicosatrienoic acids	129-154	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	33-39
18303964-1	2008	UNLABELLED: The cytochrome P450 enzymes CYP2C8, CYP2C9 and CYP2J2 generate 8,9-, 11,12-, and 14,15-epoxyeicosatrienic acid (EET) from arachidonic acid, and these EETs are then hydrolyzed to dihydroxyeicosatrienoic acids (DHET) before excretion into the urine.	EET	124-127	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	59-65
18303964-1	2008	UNLABELLED: The cytochrome P450 enzymes CYP2C8, CYP2C9 and CYP2J2 generate 8,9-, 11,12-, and 14,15-epoxyeicosatrienic acid (EET) from arachidonic acid, and these EETs are then hydrolyzed to dihydroxyeicosatrienoic acids (DHET) before excretion into the urine.	Arachidonic Acid	134-150	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	59-65
18303964-1	2008	UNLABELLED: The cytochrome P450 enzymes CYP2C8, CYP2C9 and CYP2J2 generate 8,9-, 11,12-, and 14,15-epoxyeicosatrienic acid (EET) from arachidonic acid, and these EETs are then hydrolyzed to dihydroxyeicosatrienoic acids (DHET) before excretion into the urine.	dihydroxyeicosatrienoic acids	190-219	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	59-65
18303964-1	2008	UNLABELLED: The cytochrome P450 enzymes CYP2C8, CYP2C9 and CYP2J2 generate 8,9-, 11,12-, and 14,15-epoxyeicosatrienic acid (EET) from arachidonic acid, and these EETs are then hydrolyzed to dihydroxyeicosatrienoic acids (DHET) before excretion into the urine.	dhet	221-225	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	59-65
17652182-1	2007	CYP2J2 is abundant in cardiac tissue and active in the biosynthesis of eicosanoids such as epoxyeicosatrienoic acids (EETs).	Eicosanoids	71-82	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	0-6
17940135-10	2008	In addition, we found significant correlations between the expression of AHR, ARNT, and CYP1A1 and between PXR and P450 involved in leukotriene metabolism (CYP2C, CYP4F2, CYP4A11, CYP2J2, and CYP11B2).	Leukotrienes	132-143	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	180-186
18216721-2	2008	This study investigated whether two common polymorphisms in genes believed to be influential in regulating circulating levels of epoxyeicosatrienoic acids, namely cytochrome P450 2J2 (CYP2J2) G-50T and soluble epoxide hydrolase (EPHX2) G860A, were associated with ischemic stroke risk in a Chinese population.	epoxyeicosatrienoic acids	129-154	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	163-182
18216721-2	2008	This study investigated whether two common polymorphisms in genes believed to be influential in regulating circulating levels of epoxyeicosatrienoic acids, namely cytochrome P450 2J2 (CYP2J2) G-50T and soluble epoxide hydrolase (EPHX2) G860A, were associated with ischemic stroke risk in a Chinese population.	epoxyeicosatrienoic acids	129-154	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	184-190
17126841-1	2007	OBJECTIVES: Cytochrome P450 (CYP) 2J2 is expressed in vascular endothelium and metabolizes arachidonic acid to biologically active epoxyeicosatrienoic acids (EETs), which are potent endogenous vasodilators and inhibitors of vascular inflammation.	Arachidonic Acid	91-107	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	12-37
17126841-1	2007	OBJECTIVES: Cytochrome P450 (CYP) 2J2 is expressed in vascular endothelium and metabolizes arachidonic acid to biologically active epoxyeicosatrienoic acids (EETs), which are potent endogenous vasodilators and inhibitors of vascular inflammation.	epoxyeicosatrienoic acids	131-156	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	12-37
17126841-1	2007	OBJECTIVES: Cytochrome P450 (CYP) 2J2 is expressed in vascular endothelium and metabolizes arachidonic acid to biologically active epoxyeicosatrienoic acids (EETs), which are potent endogenous vasodilators and inhibitors of vascular inflammation.	eets	158-162	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	12-37
17652182-1	2007	CYP2J2 is abundant in cardiac tissue and active in the biosynthesis of eicosanoids such as epoxyeicosatrienoic acids (EETs).	epoxyeicosatrienoic acids	91-116	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	0-6
17652182-1	2007	CYP2J2 is abundant in cardiac tissue and active in the biosynthesis of eicosanoids such as epoxyeicosatrienoic acids (EETs).	eets	118-122	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	0-6
17652182-7	2007	N-Methylsulphonyl-6-(2-proparglyloxy-phenyl)hexanamide (MS-PPOH), a specific inhibitor of EET biosynthesis, significantly reduced I(to,peak) and increased APD in CYP2J2 Tr cardiomyocytes but not in Wt cells.	n-methylsulphonyl-6-(2-proparglyloxy-phenyl)hexanamide	0-54	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	162-168
17652182-7	2007	N-Methylsulphonyl-6-(2-proparglyloxy-phenyl)hexanamide (MS-PPOH), a specific inhibitor of EET biosynthesis, significantly reduced I(to,peak) and increased APD in CYP2J2 Tr cardiomyocytes but not in Wt cells.	N-methylsulfonyl-6-(2-propargyloxyphenyl)hexanamide	56-63	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	162-168
17652182-9	2007	Addition of 11,12-EET or 8-bromo-cAMP significantly reversed the MS-PPOH- or monoclonal antibody-induced changes in I(to,peak) and APD in CYP2J2 Tr cells.	11,12-epoxy-5,8,14-eicosatrienoic acid	12-21	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	138-144
17652182-9	2007	Addition of 11,12-EET or 8-bromo-cAMP significantly reversed the MS-PPOH- or monoclonal antibody-induced changes in I(to,peak) and APD in CYP2J2 Tr cells.	8-Bromo Cyclic Adenosine Monophosphate	25-37	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	138-144
17652182-9	2007	Addition of 11,12-EET or 8-bromo-cAMP significantly reversed the MS-PPOH- or monoclonal antibody-induced changes in I(to,peak) and APD in CYP2J2 Tr cells.	propenylphosphonic acid	68-72	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	138-144
17652182-10	2007	Together, our data demonstrate that shortening of the action potential in CYP2J2 Tr cardiomyocytes is associated with enhanced I(to,peak) via an EET-dependent, cAMP-mediated mechanism.	Cyclic AMP	160-164	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	74-80
17470359-1	2007	Twenty five derivatives of the drugs terfenadine and ebastine have been designed, synthesized and evaluated as inhibitors of recombinant human CYP2J2.	Terfenadine	37-48	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	143-149
17705402-1	2007	The oxidation of six derivatives of terfenadone by recombinant human CYP2J2 (CYP = cytochrome P450) was studied by high-performance liquid chromatography coupled to mass spectrometry (MS) using tandem MS techniques and by 1H NMR spectroscopy.	terfenadone	36-47	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	69-75
17705402-1	2007	The oxidation of six derivatives of terfenadone by recombinant human CYP2J2 (CYP = cytochrome P450) was studied by high-performance liquid chromatography coupled to mass spectrometry (MS) using tandem MS techniques and by 1H NMR spectroscopy.	Hydrogen	222-224	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	69-75
17705402-6	2007	Dynamic docking of terfenadone derivatives in the CYP2J2 active site allowed one to interpret the unexpected regioselectivity of the hydroxylation of these substrates by CYP2J2, which is mainly based on this restricted access to the iron.	terfenadone	19-30	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	50-56
17705402-6	2007	Dynamic docking of terfenadone derivatives in the CYP2J2 active site allowed one to interpret the unexpected regioselectivity of the hydroxylation of these substrates by CYP2J2, which is mainly based on this restricted access to the iron.	terfenadone	19-30	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	170-176
17705402-6	2007	Dynamic docking of terfenadone derivatives in the CYP2J2 active site allowed one to interpret the unexpected regioselectivity of the hydroxylation of these substrates by CYP2J2, which is mainly based on this restricted access to the iron.	Iron	233-237	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	50-56
17705402-6	2007	Dynamic docking of terfenadone derivatives in the CYP2J2 active site allowed one to interpret the unexpected regioselectivity of the hydroxylation of these substrates by CYP2J2, which is mainly based on this restricted access to the iron.	Iron	233-237	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	170-176
17979511-3	2007	In humans, functionally relevant polymorphisms, which may significantly modulate epoxyeicosatrienoic acid levels in vivo, have been identified in the genes encoding CYP2J2, CYP2C8, CYP2C9 and soluble epoxide hydrolase.	epoxyeicosatrienoic acid	81-105	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	165-171
17470359-1	2007	Twenty five derivatives of the drugs terfenadine and ebastine have been designed, synthesized and evaluated as inhibitors of recombinant human CYP2J2.	ebastine	53-61	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	143-149
17470359-2	2007	Compound 14, which has an imidazole substituent, is a good non-competitive inhibitor of CYP2J2 (IC(50)=400nM).	imidazole	26-35	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	88-94
17470359-4	2007	Compounds 4, 5 and 13, which have a propyl, allyl and benzo-1,3-dioxole terminal group, respectively, are selective CYP2J2 inhibitors.	1,3-dioxole	60-71	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	116-122
17470359-7	2007	Inactivation of CYP2J2 by 13 is due to the formation of a stable iron-carbene bond which occurs upon CYP2J2-catalyzed oxidation of 13 with a partition ratio of 18+/-3.	Iron	65-69	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	16-22
17470359-7	2007	Inactivation of CYP2J2 by 13 is due to the formation of a stable iron-carbene bond which occurs upon CYP2J2-catalyzed oxidation of 13 with a partition ratio of 18+/-3.	Iron	65-69	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	101-107
17470359-7	2007	Inactivation of CYP2J2 by 13 is due to the formation of a stable iron-carbene bond which occurs upon CYP2J2-catalyzed oxidation of 13 with a partition ratio of 18+/-3.	carbene	70-77	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	16-22
17475630-1	2007	BACKGROUND: Cytochrome P-450 2J2 (CYP2J2) has recently been shown to be an important enzyme in the metabolism of epoxygenase-derived eicosanoids that play important functional roles in pulmonary physiology and may contribute to the pathogenesis of asthma.	Eicosanoids	133-144	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	12-32
17470359-7	2007	Inactivation of CYP2J2 by 13 is due to the formation of a stable iron-carbene bond which occurs upon CYP2J2-catalyzed oxidation of 13 with a partition ratio of 18+/-3.	carbene	70-77	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	101-107
17475630-1	2007	BACKGROUND: Cytochrome P-450 2J2 (CYP2J2) has recently been shown to be an important enzyme in the metabolism of epoxygenase-derived eicosanoids that play important functional roles in pulmonary physiology and may contribute to the pathogenesis of asthma.	Eicosanoids	133-144	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	34-40
17475630-8	2007	CONCLUSIONS: Our data demonstrate for the first time that the CYP2J2 gene might be considered as a novel candidate gene for common susceptibility to asthma and highlight the importance of the P-450 epoxygenase pathway of metabolism of arachidonic acid in the pathogenesis of the disease.	Arachidonic Acid	235-251	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	62-68
16896065-3	2006	Although CYP3A4 and CYP2J2 have been implicated in ebastine N-dealkylation and hydroxylation, the enzyme catalyzing the subsequent metabolic steps (conversion of hydroxyebastine to desalkylebastine and carebastine) have not been identified.	ebastine	51-59	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	20-26
16842832-6	2006	Recombinant human CYP2J2 was overexpressed in Escherichia coli, purified, and assayed for vitamin D 25-hydroxylation activity.	Vitamin D	90-99	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	18-24
16842832-8	2006	Interestingly, human CYP2J2 hydroxylated vitamin D2, an exogenous vitamin D, at a higher rate than it did vitamin D3, an endogenous vitamin D, whereas, rat CYP2J3 hydroxylated vitamin D3 (1.4 min(-1)) more efficiently than vitamin D2 (0.86 min(-1)).	Ergocalciferols	41-51	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	21-27
16842832-8	2006	Interestingly, human CYP2J2 hydroxylated vitamin D2, an exogenous vitamin D, at a higher rate than it did vitamin D3, an endogenous vitamin D, whereas, rat CYP2J3 hydroxylated vitamin D3 (1.4 min(-1)) more efficiently than vitamin D2 (0.86 min(-1)).	Vitamin D	41-50	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	21-27
16842832-8	2006	Interestingly, human CYP2J2 hydroxylated vitamin D2, an exogenous vitamin D, at a higher rate than it did vitamin D3, an endogenous vitamin D, whereas, rat CYP2J3 hydroxylated vitamin D3 (1.4 min(-1)) more efficiently than vitamin D2 (0.86 min(-1)).	Cholecalciferol	106-116	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	21-27
16842832-8	2006	Interestingly, human CYP2J2 hydroxylated vitamin D2, an exogenous vitamin D, at a higher rate than it did vitamin D3, an endogenous vitamin D, whereas, rat CYP2J3 hydroxylated vitamin D3 (1.4 min(-1)) more efficiently than vitamin D2 (0.86 min(-1)).	Vitamin D	66-75	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	21-27
16842832-8	2006	Interestingly, human CYP2J2 hydroxylated vitamin D2, an exogenous vitamin D, at a higher rate than it did vitamin D3, an endogenous vitamin D, whereas, rat CYP2J3 hydroxylated vitamin D3 (1.4 min(-1)) more efficiently than vitamin D2 (0.86 min(-1)).	Cholecalciferol	176-186	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	21-27
16842832-8	2006	Interestingly, human CYP2J2 hydroxylated vitamin D2, an exogenous vitamin D, at a higher rate than it did vitamin D3, an endogenous vitamin D, whereas, rat CYP2J3 hydroxylated vitamin D3 (1.4 min(-1)) more efficiently than vitamin D2 (0.86 min(-1)).	Ergocalciferols	223-233	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	21-27
17429317-1	2007	OBJECTIVE: The cytochromes P450 epoxygenases CYP2J2 and CYP2C8 synthesize epoxyeicosatrienoic acids, which regulate endothelial function.	epoxyeicosatrienoic acids	74-99	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	45-51
17220242-1	2007	The cytochrome P450 (P450) enzymes CYP2C8, CYP2C9, and CYP2J2 metabolize arachidonic acid to epoxyeicosatrienoic acids, which are known to be vital in regulation of vascular tone and cardiovascular homeostasis.	Arachidonic Acid	73-89	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	55-61
17220242-1	2007	The cytochrome P450 (P450) enzymes CYP2C8, CYP2C9, and CYP2J2 metabolize arachidonic acid to epoxyeicosatrienoic acids, which are known to be vital in regulation of vascular tone and cardiovascular homeostasis.	epoxyeicosatrienoic acids	93-118	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	55-61
17264956-9	2007	The cytochrome P450 (CYP450) inhibitor, miconazole, and the arachidonic acid epoxygenase inhibitor MS-PPOH inhibited thrombin-stimulated t-PA release, while 5,6-EET-methyl ester stimulated t-PA release.	N-methylsulfonyl-6-(2-propargyloxyphenyl)hexanamide	99-106	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	60-88
16896065-11	2006	In conclusion, our data for the first time, to our knowledge, suggest that both CYP2J2 and CYP3A play important roles in ebastine sequential metabolism: dealkylation of ebastine and its metabolites is mainly catalyzed by CYP3A4, whereas the hydroxylation reactions are preferentially catalyzed by CYP2J2.	ebastine	169-177	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	297-303
16868033-1	2006	CYP2J2 metabolizes arachidonic acid to 20-hydroxyeicosatetraenoic acid and epoxyeicosatrienoic acids (EETs), which play a critical role in the regulation of renal, pulmonary, cardiac, and vascular function.	Arachidonic Acid	19-35	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	0-6
16868033-1	2006	CYP2J2 metabolizes arachidonic acid to 20-hydroxyeicosatetraenoic acid and epoxyeicosatrienoic acids (EETs), which play a critical role in the regulation of renal, pulmonary, cardiac, and vascular function.	20-hydroxy-5,8,11,14-eicosatetraenoic acid	39-70	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	0-6
16868033-1	2006	CYP2J2 metabolizes arachidonic acid to 20-hydroxyeicosatetraenoic acid and epoxyeicosatrienoic acids (EETs), which play a critical role in the regulation of renal, pulmonary, cardiac, and vascular function.	epoxyeicosatrienoic acids	75-100	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	0-6
16868033-1	2006	CYP2J2 metabolizes arachidonic acid to 20-hydroxyeicosatetraenoic acid and epoxyeicosatrienoic acids (EETs), which play a critical role in the regulation of renal, pulmonary, cardiac, and vascular function.	eets	102-106	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	0-6
16842392-0	2006	The effect of CYP2J2, CYP3A4, CYP3A5 and the MDR1 polymorphisms and gender on the urinary excretion of the metabolites of the H-receptor antihistamine ebastine: a pilot study.	antihistamine ebastine	137-159	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	14-20
16842392-1	2006	AIMS: To determine the effect of gender and the genetic polymorphisms of CYP2J2, CYP3A4, CYP3A5 and MDR1 on the urinary excretion of the H(1) antihistamine ebastine in healthy subjects.	h(1) antihistamine ebastine	137-164	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	73-79
16896065-3	2006	Although CYP3A4 and CYP2J2 have been implicated in ebastine N-dealkylation and hydroxylation, the enzyme catalyzing the subsequent metabolic steps (conversion of hydroxyebastine to desalkylebastine and carebastine) have not been identified.	hydroxyebastine	162-177	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	20-26
16896065-3	2006	Although CYP3A4 and CYP2J2 have been implicated in ebastine N-dealkylation and hydroxylation, the enzyme catalyzing the subsequent metabolic steps (conversion of hydroxyebastine to desalkylebastine and carebastine) have not been identified.	4-(Diphenylmethoxy)piperidine	181-197	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	20-26
16896065-3	2006	Although CYP3A4 and CYP2J2 have been implicated in ebastine N-dealkylation and hydroxylation, the enzyme catalyzing the subsequent metabolic steps (conversion of hydroxyebastine to desalkylebastine and carebastine) have not been identified.	carebastine	202-213	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	20-26
16896065-8	2006	Ebastine hydroxylation to hydroxyebastine is mainly mediated by CYP2J2 (0.45 microl/min/pmol P450; 22.5- and 7.5-fold higher than that for CYP3A4 and CYP3A5, respectively), whereas CYP2J2 and CYP3A4 contributed to the formation of carebastine from hydroxyebastine.	ebastine	0-8	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	64-70
16896065-8	2006	Ebastine hydroxylation to hydroxyebastine is mainly mediated by CYP2J2 (0.45 microl/min/pmol P450; 22.5- and 7.5-fold higher than that for CYP3A4 and CYP3A5, respectively), whereas CYP2J2 and CYP3A4 contributed to the formation of carebastine from hydroxyebastine.	ebastine	0-8	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	181-187
16896065-8	2006	Ebastine hydroxylation to hydroxyebastine is mainly mediated by CYP2J2 (0.45 microl/min/pmol P450; 22.5- and 7.5-fold higher than that for CYP3A4 and CYP3A5, respectively), whereas CYP2J2 and CYP3A4 contributed to the formation of carebastine from hydroxyebastine.	hydroxyebastine	26-41	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	64-70
16896065-8	2006	Ebastine hydroxylation to hydroxyebastine is mainly mediated by CYP2J2 (0.45 microl/min/pmol P450; 22.5- and 7.5-fold higher than that for CYP3A4 and CYP3A5, respectively), whereas CYP2J2 and CYP3A4 contributed to the formation of carebastine from hydroxyebastine.	hydroxyebastine	26-41	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	181-187
16896065-8	2006	Ebastine hydroxylation to hydroxyebastine is mainly mediated by CYP2J2 (0.45 microl/min/pmol P450; 22.5- and 7.5-fold higher than that for CYP3A4 and CYP3A5, respectively), whereas CYP2J2 and CYP3A4 contributed to the formation of carebastine from hydroxyebastine.	carebastine	231-242	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	64-70
16896065-8	2006	Ebastine hydroxylation to hydroxyebastine is mainly mediated by CYP2J2 (0.45 microl/min/pmol P450; 22.5- and 7.5-fold higher than that for CYP3A4 and CYP3A5, respectively), whereas CYP2J2 and CYP3A4 contributed to the formation of carebastine from hydroxyebastine.	hydroxyebastine	248-263	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	64-70
16896065-11	2006	In conclusion, our data for the first time, to our knowledge, suggest that both CYP2J2 and CYP3A play important roles in ebastine sequential metabolism: dealkylation of ebastine and its metabolites is mainly catalyzed by CYP3A4, whereas the hydroxylation reactions are preferentially catalyzed by CYP2J2.	ebastine	121-129	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	80-86
16896065-11	2006	In conclusion, our data for the first time, to our knowledge, suggest that both CYP2J2 and CYP3A play important roles in ebastine sequential metabolism: dealkylation of ebastine and its metabolites is mainly catalyzed by CYP3A4, whereas the hydroxylation reactions are preferentially catalyzed by CYP2J2.	ebastine	169-177	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	80-86
16839864-2	2006	One of the CYP2J2 products, 11,12-epoxyeicosatrienoic acid, has several vasoprotective effects.	11,12-epoxy-5,8,14-eicosatrienoic acid	28-58	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	11-17
15864120-1	2005	CYP2J2 and CYP2C8 metabolize arachidonic acid (AA) to cis-epoxyeicosatrienoic acids (EETs), which play a central role in regulating renal tubular fluid-electrolyte transport and vascular tone.	Arachidonic Acid	29-45	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	0-6
16495056-2	2006	This paper reports a first series of high-affinity, selective CYP2J2 inhibitors that are related to terfenadine, with K(i) values as low as 160nM, that should be useful tools to determine the biological roles of CYP2J2.	Terfenadine	100-111	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	62-68
16495056-2	2006	This paper reports a first series of high-affinity, selective CYP2J2 inhibitors that are related to terfenadine, with K(i) values as low as 160nM, that should be useful tools to determine the biological roles of CYP2J2.	Terfenadine	100-111	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	212-218
15930289-4	2005	In addition, forced overexpression of CYP2J2, and CYP BM3F87V or addition of epoxyeicosatrienoic acids (EET) in cultured carcinoma cell lines in vitro markedly accelerated proliferation by analyses of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide, cell accounts, and cell cycle analysis, and protected carcinoma cells from apoptosis induced by tumor necrosis factor alpha (TNF-alpha) in cultures.	EET	104-107	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	38-44
15930289-4	2005	In addition, forced overexpression of CYP2J2, and CYP BM3F87V or addition of epoxyeicosatrienoic acids (EET) in cultured carcinoma cell lines in vitro markedly accelerated proliferation by analyses of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide, cell accounts, and cell cycle analysis, and protected carcinoma cells from apoptosis induced by tumor necrosis factor alpha (TNF-alpha) in cultures.	thiazolyl blue	201-261	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	38-44
15581597-5	2005	CYP2J2 possesses vascular protective effects, which include but are not limited to, protection against ischemia-reperfusion injury, suppression of reactive oxygen species following hypoxia-reoxygenation, inhibition of the pro-inflammatory transcription factor, nuclear factor-kappaB (NF-kappaB), attenuation of vascular smooth muscle migration, and enhancement of a fibrinolytic pathway.	Reactive Oxygen Species	147-170	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	0-6
15581597-7	2005	Thus, CYP2J2 and its derived arachidonic acid metabolites may play important roles in regulating vascular function under normal and pathophysiological conditions.	Arachidonic Acid	29-45	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	6-12
16008525-1	2005	The human cytochrome P450 2J2 (CYP2J2) generates cytoprotective epoxyeicosatrienoic acids from arachidonic acid.	epoxyeicosatrienoic acids	64-89	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	10-29
16008525-1	2005	The human cytochrome P450 2J2 (CYP2J2) generates cytoprotective epoxyeicosatrienoic acids from arachidonic acid.	epoxyeicosatrienoic acids	64-89	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	31-37
16008525-1	2005	The human cytochrome P450 2J2 (CYP2J2) generates cytoprotective epoxyeicosatrienoic acids from arachidonic acid.	Arachidonic Acid	95-111	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	10-29
16008525-1	2005	The human cytochrome P450 2J2 (CYP2J2) generates cytoprotective epoxyeicosatrienoic acids from arachidonic acid.	Arachidonic Acid	95-111	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	31-37
16008525-2	2005	Expression of CYP2J2 is decreased in hypoxia, and the resultant decrease in CYP2J2-derived epoxyeicosanoids may contribute to the pathogenesis of cardiac ischaemia.	epoxyeicosanoids	91-107	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	14-20
16008525-2	2005	Expression of CYP2J2 is decreased in hypoxia, and the resultant decrease in CYP2J2-derived epoxyeicosanoids may contribute to the pathogenesis of cardiac ischaemia.	epoxyeicosanoids	91-107	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	76-82
15864120-1	2005	CYP2J2 and CYP2C8 metabolize arachidonic acid (AA) to cis-epoxyeicosatrienoic acids (EETs), which play a central role in regulating renal tubular fluid-electrolyte transport and vascular tone.	cis-epoxyeicosatrienoic acids	54-83	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	0-6
15864120-1	2005	CYP2J2 and CYP2C8 metabolize arachidonic acid (AA) to cis-epoxyeicosatrienoic acids (EETs), which play a central role in regulating renal tubular fluid-electrolyte transport and vascular tone.	eets	85-89	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	0-6
12851038-11	2003	All the chemicals inhibited astemizole O-demethylation in recombinant CYP2J2 microsomes.	Astemizole	28-38	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	70-76
15466638-1	2004	BACKGROUND: Cytochrome P450 (CYP) 2J2 is expressed in the vascular endothelium and metabolizes arachidonic acid to biologically active epoxyeicosatrienoic acids (EETs).	Arachidonic Acid	95-111	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	12-37
15466638-1	2004	BACKGROUND: Cytochrome P450 (CYP) 2J2 is expressed in the vascular endothelium and metabolizes arachidonic acid to biologically active epoxyeicosatrienoic acids (EETs).	epoxyeicosatrienoic acids	135-160	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	12-37
15466638-1	2004	BACKGROUND: Cytochrome P450 (CYP) 2J2 is expressed in the vascular endothelium and metabolizes arachidonic acid to biologically active epoxyeicosatrienoic acids (EETs).	eets	162-166	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	12-37
12851038-12	2003	The results suggest that CYP2J2 is involved in astemizole O-demethylation in both the human small intestine and liver; however, the contribution in the liver is lower than in the small intestine.	Astemizole	47-57	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	25-31
11901223-1	2002	CYP2J2 is abundant in cardiovascular tissue and active in the metabolism of arachidonic acid to eicosanoids that possess potent anti-inflammatory, vasodilatory, and fibrinolytic properties.	Arachidonic Acid	76-92	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	0-6
14575523-1	2003	OBJECTIVE: Cytochrome P450 (CYP) 2J2 plays an important role in the biosynthesis of the biologically active cis-epoxyeicosatrienoic acids.	cis-epoxyeicosatrienoic acids	108-137	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	11-36
14575523-2	2003	An allelic variant named CYP2J2*6, which encodes an enzyme that is almost inactive in the metabolism of arachidonic acid, has recently been described.	Arachidonic Acid	104-120	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	25-31
12386130-0	2002	Involvement of CYP2J2 on the intestinal first-pass metabolism of antihistamine drug, astemizole.	Astemizole	85-95	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	15-21
12386130-7	2002	A clear activity of astemizole O-demethylation was detected in recombinant CYP2J2 with K(m) = 0.65 microM and V(max) = 1129 pmol/nmol P450/min.	Astemizole	20-30	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	75-81
12386130-9	2002	Expression levels of the immunoreactive protein with the CYP2J2 antibody in the small intestine were well correlated with the activities of the astemizole O-demethylation (r = 0.901, n = 5, p < 0.05).	Astemizole	144-154	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	57-63
12386130-10	2002	The CYP2J2 substrates, arachidonic acid and ebastine, strongly inhibited the microsomal astemizole O-demethylation in the human small intestines and recombinant CYP2J2.	Arachidonic Acid	23-39	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	4-10
12386130-10	2002	The CYP2J2 substrates, arachidonic acid and ebastine, strongly inhibited the microsomal astemizole O-demethylation in the human small intestines and recombinant CYP2J2.	Arachidonic Acid	23-39	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	161-167
12386130-10	2002	The CYP2J2 substrates, arachidonic acid and ebastine, strongly inhibited the microsomal astemizole O-demethylation in the human small intestines and recombinant CYP2J2.	ebastine	44-52	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	4-10
12386130-10	2002	The CYP2J2 substrates, arachidonic acid and ebastine, strongly inhibited the microsomal astemizole O-demethylation in the human small intestines and recombinant CYP2J2.	ebastine	44-52	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	161-167
12386130-10	2002	The CYP2J2 substrates, arachidonic acid and ebastine, strongly inhibited the microsomal astemizole O-demethylation in the human small intestines and recombinant CYP2J2.	Astemizole	88-98	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	4-10
12386130-10	2002	The CYP2J2 substrates, arachidonic acid and ebastine, strongly inhibited the microsomal astemizole O-demethylation in the human small intestines and recombinant CYP2J2.	Astemizole	88-98	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	161-167
12386130-11	2002	These results indicate the involvement of CYP2J2 in the presystemic elimination of astemizole in the human small intestine.	Astemizole	83-93	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	42-48
11901223-1	2002	CYP2J2 is abundant in cardiovascular tissue and active in the metabolism of arachidonic acid to eicosanoids that possess potent anti-inflammatory, vasodilatory, and fibrinolytic properties.	Eicosanoids	96-107	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	0-6
11752129-7	2002	CYP2J2 was selected as a candidate expressed in the intestine and closely related to arachidonic acid metabolism.	Arachidonic Acid	85-101	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	0-6
11455018-1	2001	CYP2J2 is abundant in human heart and its arachidonic acid metabolites, the epoxyeicosatrienoic acids (EETs), have potent vasodilatory, antiinflammatory and cardioprotective properties.	Arachidonic Acid	42-58	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	0-6
11752129-0	2002	Involvement of CYP2J2 and CYP4F12 in the metabolism of ebastine in human intestinal microsomes.	ebastine	55-63	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	15-21
11455018-1	2001	CYP2J2 is abundant in human heart and its arachidonic acid metabolites, the epoxyeicosatrienoic acids (EETs), have potent vasodilatory, antiinflammatory and cardioprotective properties.	epoxyeicosatrienoic acids	76-101	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	0-6
11455018-1	2001	CYP2J2 is abundant in human heart and its arachidonic acid metabolites, the epoxyeicosatrienoic acids (EETs), have potent vasodilatory, antiinflammatory and cardioprotective properties.	eets	103-107	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	0-6
8631948-6	1996	Epoxidation of arachidonic acid by CYP2J2 at the 14,15-olefin was highly enantioselective for (14R, 15S)-epoxyeicosatrienoic acid (76% optical purity).	Arachidonic Acid	15-31	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	35-41
9048644-3	1997	Immunohistochemical staining of formalin-fixed paraffin-embedded rat and human pancreas using the anti-CYP2J2 IgG and avidin-biotin-peroxidase detection revealed that CYP2J2 protein expression was highly localized to cells in the islets of Langerhans, with minimal staining in pancreatic exocrine cells.	Formaldehyde	32-40	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	103-109
9048644-3	1997	Immunohistochemical staining of formalin-fixed paraffin-embedded rat and human pancreas using the anti-CYP2J2 IgG and avidin-biotin-peroxidase detection revealed that CYP2J2 protein expression was highly localized to cells in the islets of Langerhans, with minimal staining in pancreatic exocrine cells.	Formaldehyde	32-40	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	167-173
9048644-3	1997	Immunohistochemical staining of formalin-fixed paraffin-embedded rat and human pancreas using the anti-CYP2J2 IgG and avidin-biotin-peroxidase detection revealed that CYP2J2 protein expression was highly localized to cells in the islets of Langerhans, with minimal staining in pancreatic exocrine cells.	Paraffin	47-55	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	167-173
9048644-6	1997	Importantly, the levels of immunoreactive CYP2J2 in different human pancreatic tissues were highly correlated with endogenous epoxyeicosatrienoic acid concentrations.	epoxyeicosatrienoic acid	126-150	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	42-48
8995412-7	1997	Replacement of phenylalanine 87 with valine converted cytochrome P450 BM-3 into a regio- and stereoselective arachidonic acid epoxygenase ((14S,15R)-epoxyeicosatrienoic acid, 99% of total products).	epoxyeicosatrienoic acid	149-173	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	109-137
8631948-6	1996	Epoxidation of arachidonic acid by CYP2J2 at the 14,15-olefin was highly enantioselective for (14R, 15S)-epoxyeicosatrienoic acid (76% optical purity).	14,15-olefin	49-61	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	35-41
8631948-6	1996	Epoxidation of arachidonic acid by CYP2J2 at the 14,15-olefin was highly enantioselective for (14R, 15S)-epoxyeicosatrienoic acid (76% optical purity).	(14r, 15s)-epoxyeicosatrienoic acid	94-129	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	35-41
8631948-8	1996	The in vivo significance of CYP2J2 was suggested by documenting the presence of epoxyeicosatrienoic acids in the human heart using gas chromatography/mass spectroscopy.	epoxyeicosatrienoic acids	80-105	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	28-34
8631948-9	1996	Importantly, the chirality of CYP2J2 products matched that of the epoxyeicosatrienoic acid enantiomers present, in vivo, in human heart.	epoxyeicosatrienoic acid	66-90	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	30-36
8631948-10	1996	We propose that CYP2J2 is one of the enzymes responsible for epoxidation of endogenous arachidonic acid pools in human heart and that epoxyeicosatrienoic acids may, therefore, play important functional roles in cardiac physiology.	Arachidonic Acid	87-103	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	16-22
8631948-10	1996	We propose that CYP2J2 is one of the enzymes responsible for epoxidation of endogenous arachidonic acid pools in human heart and that epoxyeicosatrienoic acids may, therefore, play important functional roles in cardiac physiology.	epoxyeicosatrienoic acids	134-159	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	16-22
34666595-11	2021	Finally, our findings further verified that DAPT promotes the effects of CYP2J2 on cell viability, migration, and Notch signaling in hypoxia-induced HRVECs, while EDTA reversed the inhibitory effects of CYP2J2 on hypoxia-induced HRVECs.	dapt	44-48	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	73-79
33588415-3	2020	We investigated the effect of sEH inhibitor (TPPU) on the expression of villin, CYP2C8, CYP2C9, CYP2J2, and sEH in undifferentiated and in vitro differentiated HT-29 and Caco2 cell lines.	TPPU	45-49	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	96-102
34666595-11	2021	Finally, our findings further verified that DAPT promotes the effects of CYP2J2 on cell viability, migration, and Notch signaling in hypoxia-induced HRVECs, while EDTA reversed the inhibitory effects of CYP2J2 on hypoxia-induced HRVECs.	Edetic Acid	163-167	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	203-209
34405218-0	2021	(Endogenous protective effects of arachidonic acid epoxygenase metabolites, epoxyeicosatrienoic acids, in cardiovascular system).	epoxyeicosatrienoic acids	76-101	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	34-62
34837258-7	2022	KEY RESULTS: Mechanism-based inactivation (MBI) of CYP3A4-mediated rivaroxaban metabolism by both PKIs and MBI of CYP2J2 by erlotinib were established.	Erlotinib Hydrochloride	124-133	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	114-120
34418602-7	2021	Specifically, CYP phenotyping revealed that vemurafenib is primarily metabolized by CYP1A1 and to a lesser degree by CYP2J2 and CYP3A4.	Vemurafenib	44-55	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	117-123
33682565-1	2021	Human Cytochrome P450 2J2 (CYP2J2) as an important metabolic enzyme, plays a crucial role in metabolism of polyunsaturated fatty acids (PUFAs).	Fatty Acids, Unsaturated	107-134	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	6-25
33682565-1	2021	Human Cytochrome P450 2J2 (CYP2J2) as an important metabolic enzyme, plays a crucial role in metabolism of polyunsaturated fatty acids (PUFAs).	Fatty Acids, Unsaturated	107-134	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	27-33
33682565-1	2021	Human Cytochrome P450 2J2 (CYP2J2) as an important metabolic enzyme, plays a crucial role in metabolism of polyunsaturated fatty acids (PUFAs).	Fatty Acids, Unsaturated	136-141	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	6-25
33682565-1	2021	Human Cytochrome P450 2J2 (CYP2J2) as an important metabolic enzyme, plays a crucial role in metabolism of polyunsaturated fatty acids (PUFAs).	Fatty Acids, Unsaturated	136-141	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	27-33
33682565-3	2021	Herein, using a high-throughput screening approach based on enzymic activity of CYP2J2, we rapidly and effectively identified a novel natural inhibitor (Piperine, 9a) with IC50 value of 0.44 muM from 108 common herbal medicines.	piperine	153-161	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	80-86
33682565-4	2021	Next, a series of its derivatives were designed and synthesised based on the underlying interactions of Piperine with CYP2J2.	piperine	104-112	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	118-124
33682565-7	2021	Furthermore, the detailed interaction mechanism towards CYP2J2 was explicated by docking and molecular dynamics, and our results revealed the residue Thr114 and Thr 315 of CYP2J2 were the critical sites of action, moreover the spatial distance between the carbon atom of ligand methylene and Fe atom of iron porphyrin coenzyme was the vital interaction factor towards human CYP2J2.	Threonine	161-164	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	56-62
33682565-7	2021	Furthermore, the detailed interaction mechanism towards CYP2J2 was explicated by docking and molecular dynamics, and our results revealed the residue Thr114 and Thr 315 of CYP2J2 were the critical sites of action, moreover the spatial distance between the carbon atom of ligand methylene and Fe atom of iron porphyrin coenzyme was the vital interaction factor towards human CYP2J2.	Threonine	161-164	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	172-178
33682565-7	2021	Furthermore, the detailed interaction mechanism towards CYP2J2 was explicated by docking and molecular dynamics, and our results revealed the residue Thr114 and Thr 315 of CYP2J2 were the critical sites of action, moreover the spatial distance between the carbon atom of ligand methylene and Fe atom of iron porphyrin coenzyme was the vital interaction factor towards human CYP2J2.	Threonine	161-164	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	374-380
33682565-7	2021	Furthermore, the detailed interaction mechanism towards CYP2J2 was explicated by docking and molecular dynamics, and our results revealed the residue Thr114 and Thr 315 of CYP2J2 were the critical sites of action, moreover the spatial distance between the carbon atom of ligand methylene and Fe atom of iron porphyrin coenzyme was the vital interaction factor towards human CYP2J2.	Carbon	256-262	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	56-62
33682565-7	2021	Furthermore, the detailed interaction mechanism towards CYP2J2 was explicated by docking and molecular dynamics, and our results revealed the residue Thr114 and Thr 315 of CYP2J2 were the critical sites of action, moreover the spatial distance between the carbon atom of ligand methylene and Fe atom of iron porphyrin coenzyme was the vital interaction factor towards human CYP2J2.	Carbon	256-262	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	172-178
33682565-7	2021	Furthermore, the detailed interaction mechanism towards CYP2J2 was explicated by docking and molecular dynamics, and our results revealed the residue Thr114 and Thr 315 of CYP2J2 were the critical sites of action, moreover the spatial distance between the carbon atom of ligand methylene and Fe atom of iron porphyrin coenzyme was the vital interaction factor towards human CYP2J2.	Carbon	256-262	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	374-380
33682565-7	2021	Furthermore, the detailed interaction mechanism towards CYP2J2 was explicated by docking and molecular dynamics, and our results revealed the residue Thr114 and Thr 315 of CYP2J2 were the critical sites of action, moreover the spatial distance between the carbon atom of ligand methylene and Fe atom of iron porphyrin coenzyme was the vital interaction factor towards human CYP2J2.	Iron	292-294	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	56-62
33682565-7	2021	Furthermore, the detailed interaction mechanism towards CYP2J2 was explicated by docking and molecular dynamics, and our results revealed the residue Thr114 and Thr 315 of CYP2J2 were the critical sites of action, moreover the spatial distance between the carbon atom of ligand methylene and Fe atom of iron porphyrin coenzyme was the vital interaction factor towards human CYP2J2.	Iron	292-294	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	172-178
33682565-7	2021	Furthermore, the detailed interaction mechanism towards CYP2J2 was explicated by docking and molecular dynamics, and our results revealed the residue Thr114 and Thr 315 of CYP2J2 were the critical sites of action, moreover the spatial distance between the carbon atom of ligand methylene and Fe atom of iron porphyrin coenzyme was the vital interaction factor towards human CYP2J2.	Iron	292-294	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	374-380
33682565-7	2021	Furthermore, the detailed interaction mechanism towards CYP2J2 was explicated by docking and molecular dynamics, and our results revealed the residue Thr114 and Thr 315 of CYP2J2 were the critical sites of action, moreover the spatial distance between the carbon atom of ligand methylene and Fe atom of iron porphyrin coenzyme was the vital interaction factor towards human CYP2J2.	Iron	303-307	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	56-62
33682565-7	2021	Furthermore, the detailed interaction mechanism towards CYP2J2 was explicated by docking and molecular dynamics, and our results revealed the residue Thr114 and Thr 315 of CYP2J2 were the critical sites of action, moreover the spatial distance between the carbon atom of ligand methylene and Fe atom of iron porphyrin coenzyme was the vital interaction factor towards human CYP2J2.	Iron	303-307	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	172-178
33682565-7	2021	Furthermore, the detailed interaction mechanism towards CYP2J2 was explicated by docking and molecular dynamics, and our results revealed the residue Thr114 and Thr 315 of CYP2J2 were the critical sites of action, moreover the spatial distance between the carbon atom of ligand methylene and Fe atom of iron porphyrin coenzyme was the vital interaction factor towards human CYP2J2.	Iron	303-307	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	374-380
34621292-12	2021	We also discovered a novel association in a SNP downstream of CYP2J2 (rs10789082), a gene involved in 25-hydroxylation of vitamin D, with vitamin D in pregnant women (Beta=-7.68/G-allele, p=1.5x10-8), but not their offspring.	Vitamin D	122-131	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	62-68
34621292-12	2021	We also discovered a novel association in a SNP downstream of CYP2J2 (rs10789082), a gene involved in 25-hydroxylation of vitamin D, with vitamin D in pregnant women (Beta=-7.68/G-allele, p=1.5x10-8), but not their offspring.	Vitamin D	138-147	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	62-68
34707002-0	2021	CYP2J2-produced epoxyeicosatrienoic acids contribute to the ferroptosis resistance of pancreatic ductal adenocarcinoma in a PPARgamma-dependent manner.	epoxyeicosatrienoic acids	16-41	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	0-6
34707002-4	2021	Cytochrome P450 2J2 (CYP2J2) is the main enzyme which mediates arachidonic acid to produce epoxyeicosatrienoic acids (EETs) in human tissues.	Arachidonic Acid	63-79	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	0-19
34707002-4	2021	Cytochrome P450 2J2 (CYP2J2) is the main enzyme which mediates arachidonic acid to produce epoxyeicosatrienoic acids (EETs) in human tissues.	Arachidonic Acid	63-79	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	21-27
34707002-4	2021	Cytochrome P450 2J2 (CYP2J2) is the main enzyme which mediates arachidonic acid to produce epoxyeicosatrienoic acids (EETs) in human tissues.	epoxyeicosatrienoic acids	91-116	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	0-19
34707002-4	2021	Cytochrome P450 2J2 (CYP2J2) is the main enzyme which mediates arachidonic acid to produce epoxyeicosatrienoic acids (EETs) in human tissues.	epoxyeicosatrienoic acids	91-116	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	21-27
34707002-4	2021	Cytochrome P450 2J2 (CYP2J2) is the main enzyme which mediates arachidonic acid to produce epoxyeicosatrienoic acids (EETs) in human tissues.	eets	118-122	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	0-19
34707002-4	2021	Cytochrome P450 2J2 (CYP2J2) is the main enzyme which mediates arachidonic acid to produce epoxyeicosatrienoic acids (EETs) in human tissues.	eets	118-122	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	21-27
34707002-5	2021	It has been reported that EETs involve in the development of cancer, while the roles of EETs in PDAC and ferroptosis remain unclear.This study aims to explore the effect of CYP2J2/EETs on ferroptosis of human pancreatic ductal adenocarcinoma cells PANC-1 cells and the underlying mechanisms.	eets	88-92	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	173-179
34707002-12	2021	Lentivirus was used to construct a CYP2J2 knockdown cell line to observe its effect on the ferroptosis of PANC-1 cells induced by erastin.	erastin	130-137	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	35-41
35464300-0	2022	Artemether inhibits proliferation, invasion and migration of hepatocellular carcinoma cells via targeting of CYP2J2.	Artemether	0-10	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	109-115
35464300-3	2022	The present study aimed to investigate whether artemether is able to inhibit the proliferation, invasion and migration of HCC cells by targeting cytochrome P450 family 2 subfamily J member 2 (CYP2J2).	Artemether	47-57	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	145-190
35464300-3	2022	The present study aimed to investigate whether artemether is able to inhibit the proliferation, invasion and migration of HCC cells by targeting cytochrome P450 family 2 subfamily J member 2 (CYP2J2).	Artemether	47-57	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	192-198
35464300-7	2022	To determine the mechanism of the inhibitory effect of artemether on HCC, CYP2J2 was overexpressed and its expression in cells treated with artemether was confirmed using reverse transcription-quantitative PCR and western blot analysis.	Artemether	55-65	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	74-80
35464300-7	2022	To determine the mechanism of the inhibitory effect of artemether on HCC, CYP2J2 was overexpressed and its expression in cells treated with artemether was confirmed using reverse transcription-quantitative PCR and western blot analysis.	Artemether	140-150	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	74-80
35464300-8	2022	The effects of artemether on the viability, proliferation and migration of HCC cells overexpressing CYP2J2 were detected using CCK-8, colony-formation, wound-healing and Transwell assays, respectively.	Artemether	15-25	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	100-106
35464300-10	2022	Furthermore, artemether also inhibited CYP2J2 expression in Hep3B2.1-7 cells and CYP2J2 overexpression reversed the inhibitory effect of artemether on the proliferation, invasion and migration of HCC cells.	Artemether	13-23	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	39-45
35464300-10	2022	Furthermore, artemether also inhibited CYP2J2 expression in Hep3B2.1-7 cells and CYP2J2 overexpression reversed the inhibitory effect of artemether on the proliferation, invasion and migration of HCC cells.	Artemether	13-23	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	81-87
35464300-10	2022	Furthermore, artemether also inhibited CYP2J2 expression in Hep3B2.1-7 cells and CYP2J2 overexpression reversed the inhibitory effect of artemether on the proliferation, invasion and migration of HCC cells.	Artemether	137-147	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	39-45
35464300-10	2022	Furthermore, artemether also inhibited CYP2J2 expression in Hep3B2.1-7 cells and CYP2J2 overexpression reversed the inhibitory effect of artemether on the proliferation, invasion and migration of HCC cells.	Artemether	137-147	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	81-87
35464300-11	2022	Overall, these results indicated that artemether may inhibit HCC cell proliferation, invasion and migration via targeting CYP2J2.	Artemether	38-48	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	122-128
35078036-0	2022	Anthracycline derivatives inhibit cardiac CYP2J2.	Anthracyclines	0-13	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	42-48
35078036-2	2022	Cytochrome P450 2J2 (CYP2J2) is a cytochrome P450 epoxygenase in human cardiomyocytes that converts arachidonic acid (AA) to cardioprotective epoxyeicosatrienoic acid (EET) regioisomers.	Arachidonic Acid	100-116	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	0-19
35042700-0	2022	Linezolid Metabolism is Catalyzed by CYP2J2, CYP4F2 and CYP1B1.	Linezolid	0-9	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	37-43
35078036-2	2022	Cytochrome P450 2J2 (CYP2J2) is a cytochrome P450 epoxygenase in human cardiomyocytes that converts arachidonic acid (AA) to cardioprotective epoxyeicosatrienoic acid (EET) regioisomers.	Arachidonic Acid	100-116	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	21-27
35042700-2	2022	In this investigation it was revealed that three P450 enzymes that had not been previously explored in linezolid metabolism, CYP2J2, CYP4F1, and CYP1B1, catalyzed the 2-hydroxylation and deethyleneation of the morpholine moiety of linezolid.	Linezolid	103-112	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	125-131
35042700-2	2022	In this investigation it was revealed that three P450 enzymes that had not been previously explored in linezolid metabolism, CYP2J2, CYP4F1, and CYP1B1, catalyzed the 2-hydroxylation and deethyleneation of the morpholine moiety of linezolid.	morpholine	210-220	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	125-131
35042700-2	2022	In this investigation it was revealed that three P450 enzymes that had not been previously explored in linezolid metabolism, CYP2J2, CYP4F1, and CYP1B1, catalyzed the 2-hydroxylation and deethyleneation of the morpholine moiety of linezolid.	Linezolid	231-240	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	125-131
35042700-5	2022	These experiments suggest that CYP2J2 and CYP4F2 contribute about 50% each to linezolid hepatic metabolism.	Linezolid	78-87	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	31-37
35078036-2	2022	Cytochrome P450 2J2 (CYP2J2) is a cytochrome P450 epoxygenase in human cardiomyocytes that converts arachidonic acid (AA) to cardioprotective epoxyeicosatrienoic acid (EET) regioisomers.	epoxyeicosatrienoic acid	142-166	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	0-19
35078036-2	2022	Cytochrome P450 2J2 (CYP2J2) is a cytochrome P450 epoxygenase in human cardiomyocytes that converts arachidonic acid (AA) to cardioprotective epoxyeicosatrienoic acid (EET) regioisomers.	epoxyeicosatrienoic acid	142-166	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	21-27
35078036-2	2022	Cytochrome P450 2J2 (CYP2J2) is a cytochrome P450 epoxygenase in human cardiomyocytes that converts arachidonic acid (AA) to cardioprotective epoxyeicosatrienoic acid (EET) regioisomers.	EET	168-171	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	0-19
35078036-2	2022	Cytochrome P450 2J2 (CYP2J2) is a cytochrome P450 epoxygenase in human cardiomyocytes that converts arachidonic acid (AA) to cardioprotective epoxyeicosatrienoic acid (EET) regioisomers.	EET	168-171	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	21-27
35078036-3	2022	Herein, we performed biochemical studies to understand the interaction of anthracycline derivatives (daunorubicin, doxorubicin, epirubicin, idarubicin, 5-iminodaunorubicin, zorubicin, valrubicin, and aclarubicin) with CYP2J2.	Anthracyclines	74-87	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	218-224
35078036-5	2022	We found that aclarubicin bound the strongest to CYP2J2 despite it having large bulky groups.	Aclarubicin	14-25	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	49-55
35078036-7	2022	Molecular dynamics and ensemble docking revealed electrostatic interactions between the anthracyclines and CYP2J2, contributing to binding stability.	Anthracyclines	88-102	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	107-113
35078036-8	2022	In particular, the glycosamine groups in anthracyclines are stabilized by binding to glutamate and aspartate residues in CYP2J2 forming salt bridge interactions.	Glucosamine	19-30	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	121-127
35078036-8	2022	In particular, the glycosamine groups in anthracyclines are stabilized by binding to glutamate and aspartate residues in CYP2J2 forming salt bridge interactions.	Anthracyclines	41-55	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	121-127
35078036-8	2022	In particular, the glycosamine groups in anthracyclines are stabilized by binding to glutamate and aspartate residues in CYP2J2 forming salt bridge interactions.	Glutamic Acid	85-94	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	121-127
35078036-8	2022	In particular, the glycosamine groups in anthracyclines are stabilized by binding to glutamate and aspartate residues in CYP2J2 forming salt bridge interactions.	Aspartic Acid	99-108	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	121-127
35078036-10	2022	This was followed by experimental validation of CYP2J2-mediated metabolism of anthracycline derivatives using liquid chromatography tandem mass spectrometry fragmentation analysis and inhibition of CYP2J2-mediated AA metabolism by these derivatives.	Anthracyclines	78-91	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	48-54
35078036-11	2022	Taken together, we use both experimental and theoretical methodologies to unveil the interactions of anthracycline derivatives with CYP2J2.	Anthracyclines	101-114	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	132-138
3580381-0	1987	Arachidonic acid epoxygenase: detection of epoxyeicosatrienoic acids in human urine.	epoxyeicosatrienoic acids	43-68	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	0-28
35308176-0	2022	Acetylshikonin, A Novel CYP2J2 Inhibitor, Induces Apoptosis in RCC Cells via FOXO3 Activation and ROS Elevation.	acetylshikonin	0-14	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	24-30
35308176-11	2022	Acetylshikonin was formerly identified as a novel inhibitor of CYP2J2 protein in our previous study and it was evaluated that CYP2J2 was downregulated in acetylshikonin-treated RCC.	acetylshikonin	0-14	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	63-69
35308176-11	2022	Acetylshikonin was formerly identified as a novel inhibitor of CYP2J2 protein in our previous study and it was evaluated that CYP2J2 was downregulated in acetylshikonin-treated RCC.	acetylshikonin	0-14	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	126-132
35308176-11	2022	Acetylshikonin was formerly identified as a novel inhibitor of CYP2J2 protein in our previous study and it was evaluated that CYP2J2 was downregulated in acetylshikonin-treated RCC.	acetylshikonin	154-168	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	63-69
35308176-11	2022	Acetylshikonin was formerly identified as a novel inhibitor of CYP2J2 protein in our previous study and it was evaluated that CYP2J2 was downregulated in acetylshikonin-treated RCC.	acetylshikonin	154-168	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	126-132
35308176-12	2022	CYP2J2 siRNA transfection augmented that apoptotic effect of acetylshikonin in A498 and ACHN via up-regulation of FOXO3 expression.	acetylshikonin	61-75	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	0-6
35308176-13	2022	In conclusion, we showed that the apoptotic potential of acetylshikonin against RCC is mediated via increase of intracellular ROS level, activation of FOXO3, and inhibition of CYP2J2 expressions.	acetylshikonin	57-71	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	176-182
35308176-14	2022	This study offers that acetylshikonin may be a considerable alternative therapeutic option for RCC treatment by targeting FOXO3 and CYP2J2.	acetylshikonin	23-37	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	132-138
2563927-1	1989	Growth hormone secretion was stimulated in vitro by products of arachidonic acid epoxygenase, the epoxyeicosatrienoic acids.	epoxyeicosatrienoic acids	98-123	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	64-92
2563927-4	1989	In contrast, pretreatment of somatotrophs with an 11,12-isonitrile analogue of arachidonic acid that inhibits arachidonic acid epoxygenase, resulted in a 20-25% inhibition of growth hormone-releasing hormone-stimulated growth hormone release.	11,12-isonitrile	50-66	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	110-138
2563927-4	1989	In contrast, pretreatment of somatotrophs with an 11,12-isonitrile analogue of arachidonic acid that inhibits arachidonic acid epoxygenase, resulted in a 20-25% inhibition of growth hormone-releasing hormone-stimulated growth hormone release.	Arachidonic Acid	79-95	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	110-138
33740842-3	2021	Furthermore, CYP2J2 as the primary CYP of cardiomyocytes, is also directly involved in the metabolism of the phytocannabinoids [3].	phytocannabinoids	109-126	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	13-19
34044117-0	2021	Atypical kinetics of cytochrome P450 2J2: epoxidation of arachidonic acid and reversible inhibition by xenobiotic inhibitors.	Arachidonic Acid	57-73	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	21-40
34044117-1	2021	Extrahepatic CYP2J2 metabolism of arachidonic acid (AA) to bioactive regioisomeric epoxyeicosatrienoic acids (EETs) is implicated in both physiological and pathological conditions.	Arachidonic Acid	34-50	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	13-19
34044117-1	2021	Extrahepatic CYP2J2 metabolism of arachidonic acid (AA) to bioactive regioisomeric epoxyeicosatrienoic acids (EETs) is implicated in both physiological and pathological conditions.	epoxyeicosatrienoic acids	83-108	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	13-19
34044117-1	2021	Extrahepatic CYP2J2 metabolism of arachidonic acid (AA) to bioactive regioisomeric epoxyeicosatrienoic acids (EETs) is implicated in both physiological and pathological conditions.	eets	110-114	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	13-19
34044117-6	2021	The distance between heme-iron and omega6 (C14, C15) double bond of AA in OBS also increased from 7.5 +- 1.4 A to 8.5 +- 1.8 A when CYP2J2 was simulated with only AA in OBS versus the presence of AA in both OBS and SBS (p<0.001), supporting the observed in vitro substrate inhibition phenomenon.	Heme	21-25	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	132-138
34044117-6	2021	The distance between heme-iron and omega6 (C14, C15) double bond of AA in OBS also increased from 7.5 +- 1.4 A to 8.5 +- 1.8 A when CYP2J2 was simulated with only AA in OBS versus the presence of AA in both OBS and SBS (p<0.001), supporting the observed in vitro substrate inhibition phenomenon.	Iron	26-30	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	132-138
33411110-0	2022	Identifying the Dominant Contribution of Human Cytochrome P450 2J2 to the Metabolism of Rivaroxaban, an Oral Anticoagulant.	Rivaroxaban	88-99	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	47-66
33716791-8	2021	The EET-related drug development against cardiac remodeling is also discussed, including the overexpression of CYP2J2, inhibition of sEH, and the analogs of EET.	EET	4-7	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	111-117
33411110-6	2022	RESULTS: Multiple CYP isoforms were involved in the hydroxylation of rivaroxaban, with decreasing catalytic rates as follows: CYP2J2 > 3A4 > 2D6 > 4F3 > 1A1 > 3A5 > 3A7 > 2A6 > 2E1 > 2C9 > 2C19.	Rivaroxaban	69-80	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	126-132
33411110-8	2022	Notably, the intrinsic clearance of rivaroxaban catalyzed by CYP2J2 was nearly 39-, 64-, and 100-fold that catalyzed by CYP3A4, 2D6, and 4F3, respectively.	Rivaroxaban	36-47	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	61-67
33411110-9	2022	In addition, rivaroxaban hydroxylation was inhibited by 41.1% in the presence of the CYP2J2-specific inhibitor danazol, which was comparable to the inhibition rate of 43.3% by the CYP3A-specific inhibitor ketoconazole in mixed HLMs.	Rivaroxaban	13-24	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	85-91
33411110-9	2022	In addition, rivaroxaban hydroxylation was inhibited by 41.1% in the presence of the CYP2J2-specific inhibitor danazol, which was comparable to the inhibition rate of 43.3% by the CYP3A-specific inhibitor ketoconazole in mixed HLMs.	Danazol	111-118	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	85-91
33411110-9	2022	In addition, rivaroxaban hydroxylation was inhibited by 41.1% in the presence of the CYP2J2-specific inhibitor danazol, which was comparable to the inhibition rate of 43.3% by the CYP3A-specific inhibitor ketoconazole in mixed HLMs.	Ketoconazole	205-217	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	85-91
33411110-10	2022	Furthermore, molecular simulations showed that rivaroxaban is principally bound to CYP2J2 by pi-alkyl bonds, carbon-hydrogen bonds, and alkyl interactions.	Rivaroxaban	47-58	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	83-89
33411110-11	2022	CONCLUSION: CYP2J2 dominated the hydroxylation of rivaroxaban, which may provide new insight into clinical drug interactions involving rivaroxaban.	Rivaroxaban	50-61	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	12-18
33411110-11	2022	CONCLUSION: CYP2J2 dominated the hydroxylation of rivaroxaban, which may provide new insight into clinical drug interactions involving rivaroxaban.	Rivaroxaban	135-146	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	12-18
33335233-1	2020	Cytochrome P450 2J2 (CYP2J2) is responsible for the epoxidation of endogenous arachidonic acid, and is involved in the metabolism of exogenous drugs.	Arachidonic Acid	78-94	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	0-19
33335233-1	2020	Cytochrome P450 2J2 (CYP2J2) is responsible for the epoxidation of endogenous arachidonic acid, and is involved in the metabolism of exogenous drugs.	Arachidonic Acid	78-94	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	21-27
33335233-7	2020	Molecular docking of a series of compounds including amiodarone, astemizole, danazol, ebastine, ketoconazole, terfenadine, terfenadone, and arachidonic acid to CYP2J2 confirmed the role of those residues in determining substrate binding and specificity of CYP2J2.	Amiodarone	53-63	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	160-166
33335233-7	2020	Molecular docking of a series of compounds including amiodarone, astemizole, danazol, ebastine, ketoconazole, terfenadine, terfenadone, and arachidonic acid to CYP2J2 confirmed the role of those residues in determining substrate binding and specificity of CYP2J2.	Amiodarone	53-63	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	256-262
33335233-7	2020	Molecular docking of a series of compounds including amiodarone, astemizole, danazol, ebastine, ketoconazole, terfenadine, terfenadone, and arachidonic acid to CYP2J2 confirmed the role of those residues in determining substrate binding and specificity of CYP2J2.	Astemizole	65-75	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	160-166
33335233-7	2020	Molecular docking of a series of compounds including amiodarone, astemizole, danazol, ebastine, ketoconazole, terfenadine, terfenadone, and arachidonic acid to CYP2J2 confirmed the role of those residues in determining substrate binding and specificity of CYP2J2.	Astemizole	65-75	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	256-262
33335233-7	2020	Molecular docking of a series of compounds including amiodarone, astemizole, danazol, ebastine, ketoconazole, terfenadine, terfenadone, and arachidonic acid to CYP2J2 confirmed the role of those residues in determining substrate binding and specificity of CYP2J2.	Danazol	77-84	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	160-166
33335233-7	2020	Molecular docking of a series of compounds including amiodarone, astemizole, danazol, ebastine, ketoconazole, terfenadine, terfenadone, and arachidonic acid to CYP2J2 confirmed the role of those residues in determining substrate binding and specificity of CYP2J2.	ebastine	86-94	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	160-166
33335233-7	2020	Molecular docking of a series of compounds including amiodarone, astemizole, danazol, ebastine, ketoconazole, terfenadine, terfenadone, and arachidonic acid to CYP2J2 confirmed the role of those residues in determining substrate binding and specificity of CYP2J2.	ebastine	86-94	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	256-262
33335233-7	2020	Molecular docking of a series of compounds including amiodarone, astemizole, danazol, ebastine, ketoconazole, terfenadine, terfenadone, and arachidonic acid to CYP2J2 confirmed the role of those residues in determining substrate binding and specificity of CYP2J2.	Ketoconazole	96-108	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	160-166
33335233-7	2020	Molecular docking of a series of compounds including amiodarone, astemizole, danazol, ebastine, ketoconazole, terfenadine, terfenadone, and arachidonic acid to CYP2J2 confirmed the role of those residues in determining substrate binding and specificity of CYP2J2.	Ketoconazole	96-108	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	256-262
33335233-7	2020	Molecular docking of a series of compounds including amiodarone, astemizole, danazol, ebastine, ketoconazole, terfenadine, terfenadone, and arachidonic acid to CYP2J2 confirmed the role of those residues in determining substrate binding and specificity of CYP2J2.	Terfenadine	110-121	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	160-166
33335233-7	2020	Molecular docking of a series of compounds including amiodarone, astemizole, danazol, ebastine, ketoconazole, terfenadine, terfenadone, and arachidonic acid to CYP2J2 confirmed the role of those residues in determining substrate binding and specificity of CYP2J2.	Terfenadine	110-121	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	256-262
33335233-7	2020	Molecular docking of a series of compounds including amiodarone, astemizole, danazol, ebastine, ketoconazole, terfenadine, terfenadone, and arachidonic acid to CYP2J2 confirmed the role of those residues in determining substrate binding and specificity of CYP2J2.	terfenadone	123-134	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	160-166
33335233-7	2020	Molecular docking of a series of compounds including amiodarone, astemizole, danazol, ebastine, ketoconazole, terfenadine, terfenadone, and arachidonic acid to CYP2J2 confirmed the role of those residues in determining substrate binding and specificity of CYP2J2.	terfenadone	123-134	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	256-262
33335233-7	2020	Molecular docking of a series of compounds including amiodarone, astemizole, danazol, ebastine, ketoconazole, terfenadine, terfenadone, and arachidonic acid to CYP2J2 confirmed the role of those residues in determining substrate binding and specificity of CYP2J2.	Arachidonic Acid	140-156	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	160-166
33335233-7	2020	Molecular docking of a series of compounds including amiodarone, astemizole, danazol, ebastine, ketoconazole, terfenadine, terfenadone, and arachidonic acid to CYP2J2 confirmed the role of those residues in determining substrate binding and specificity of CYP2J2.	Arachidonic Acid	140-156	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	256-262
33437370-1	2020	OBJECTIVE: This study aimed to explore the function and mechanism of Cytochrome P450 2J2 (CYP2J2) epoxygenase and epoxyeicosatrienoic acids (EETs) in the malignant development of hepatocellular carcinoma (HCC).	eets	141-145	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	69-88
33437370-0	2020	CYP2J2 promotes the development of hepatocellular carcinoma by increasing the EETs production to improve HIF-1alpha stability.	eets	78-82	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	0-6
33312341-0	2020	6,8-Diprenylorobol Induces Apoptosis in Human Hepatocellular Carcinoma Cells via Activation of FOXO3 and Inhibition of CYP2J2.	6,8-Diprenylorobol	0-18	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	119-125
33330047-10	2020	CYP2J2 expression and 11,12-EET release in the supernatant of JWH133-induced M2 microglia were significantly upregulated.	1,1-dimethylbutyl-1-deoxy-Delta(9)-THC	62-68	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	0-6
33330047-12	2020	CYP2J2 knockdown restrained the release of 11,12-EET and significantly enhanced the anti-tumor effect of JWH133 on glioma.	11,12-epoxy-5,8,14-eicosatrienoic acid	43-52	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	0-6
33330047-12	2020	CYP2J2 knockdown restrained the release of 11,12-EET and significantly enhanced the anti-tumor effect of JWH133 on glioma.	1,1-dimethylbutyl-1-deoxy-Delta(9)-THC	105-111	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	0-6
33330047-13	2020	This study showed that targeting CYP2J2 might be a beneficial strategy to enhance the anti-glioma efficacy of JWH133 by inhibiting the pro-angiogenesis function of M2 microglia.	1,1-dimethylbutyl-1-deoxy-Delta(9)-THC	110-116	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	33-39
33312341-8	2020	Interestingly, 6,8-diprenylorobol inhibited CYP2J2-mediated astemizole O-demethylation and ebastine hydroxylase activities with K i values of 9.46 and 2.61 muM, respectively.	ebastine	91-99	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	44-50
33312341-9	2020	CYP2J2 siRNA transfection enhanced the anticancer effect of 6,8-diprenylorobol in HepG2 and Huh-7 cells through the downregulation of CYP2J2 protein expression and upregulation of FOXO3.	6,8-Diprenylorobol	60-78	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	0-6
33437370-1	2020	OBJECTIVE: This study aimed to explore the function and mechanism of Cytochrome P450 2J2 (CYP2J2) epoxygenase and epoxyeicosatrienoic acids (EETs) in the malignant development of hepatocellular carcinoma (HCC).	eets	141-145	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	90-96
33437370-6	2020	Finally, xenograft experiments were established to investigate the function of CYP2J2-EETs metabolism in HCC tumorigenesis in vivo.	eets	86-90	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	79-85
33437370-9	2020	Knockdown of CYP2J2 inhibited growth and metastasis of HCC cells and malignant xenograft, which was obviously reversed by addition of 14, 15-EET.	14,15-epoxy-5,8,11-eicosatrienoic acid	134-144	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	13-19
33239900-3	2020	Giving the importance of epoxyeicosatrienoic acids (EETs) in kidney health, we aimed to study the association between two SNPs in the genes controlling synthesis and degradation of EETs (CYP2J2 rs2280275 and EPHX2 rs751141 respectively) and susceptibility of type 2 diabetes mellitus (T2DM) patients to develop DN.	epoxyeicosatrienoic acids	25-50	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	187-193
33239900-3	2020	Giving the importance of epoxyeicosatrienoic acids (EETs) in kidney health, we aimed to study the association between two SNPs in the genes controlling synthesis and degradation of EETs (CYP2J2 rs2280275 and EPHX2 rs751141 respectively) and susceptibility of type 2 diabetes mellitus (T2DM) patients to develop DN.	eets	52-56	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	187-193
33239900-3	2020	Giving the importance of epoxyeicosatrienoic acids (EETs) in kidney health, we aimed to study the association between two SNPs in the genes controlling synthesis and degradation of EETs (CYP2J2 rs2280275 and EPHX2 rs751141 respectively) and susceptibility of type 2 diabetes mellitus (T2DM) patients to develop DN.	eets	181-185	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	187-193
33312341-9	2020	CYP2J2 siRNA transfection enhanced the anticancer effect of 6,8-diprenylorobol in HepG2 and Huh-7 cells through the downregulation of CYP2J2 protein expression and upregulation of FOXO3.	6,8-Diprenylorobol	60-78	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	134-140
33312341-10	2020	Taken together, this study proposes that 6,8-diprenylorobol treatment may be a useful therapeutic option against HCC by targeting CYP2J2 and FOXO3.	6,8-Diprenylorobol	41-59	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	130-136
33312341-8	2020	Interestingly, 6,8-diprenylorobol inhibited CYP2J2-mediated astemizole O-demethylation and ebastine hydroxylase activities with K i values of 9.46 and 2.61 muM, respectively.	6,8-Diprenylorobol	15-33	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	44-50
33312341-8	2020	Interestingly, 6,8-diprenylorobol inhibited CYP2J2-mediated astemizole O-demethylation and ebastine hydroxylase activities with K i values of 9.46 and 2.61 muM, respectively.	Astemizole	60-70	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	44-50
32224017-1	2020	INTRODUCTION: Cytochrome P450 (CYP) 2J2 is a major enzyme that controls epoxyeicosatrienoic acids biosynthesis, which may play a role in chronic obstructive pulmonary disease (COPD) development.	epoxyeicosatrienoic acids	72-97	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	14-39
31753010-0	2019	Molecular dynamics simulations of the interaction of wild type and mutant human CYP2J2 with polyunsaturated fatty acids.	Fatty Acids, Unsaturated	92-119	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	80-86
32574674-9	2020	More, CYP2J2 reduced LPS-induced reactive oxygen species (ROS) production and mitochondrial depolarization in heart cells, thereby inhibiting NLRP3 inflammasome activation.	Reactive Oxygen Species	33-56	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	6-12
32574674-9	2020	More, CYP2J2 reduced LPS-induced reactive oxygen species (ROS) production and mitochondrial depolarization in heart cells, thereby inhibiting NLRP3 inflammasome activation.	Reactive Oxygen Species	58-61	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	6-12
32249832-8	2020	In addition, hiPSC-IECs oxidatively metabolized terfenadine (CYP3A and CYP2J2 substrate) and midazolam (CYP3A substrate).	Terfenadine	48-59	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	71-77
32024122-6	2020	Reactions selective for flavin-containing monooxygenases (FMOs), CYP1B1, CYP2C9, CYP2J2, and CYP3A4 all show significant rates in human lung microsomal incubations, but all activities are higher when rat lung microsomes are used.	Flavins	24-30	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	81-87
31671426-0	2020	Berberine Induces CYP2J2 Expression in Human U251 Glioma Cells via Regulation of Peroxisome Proliferator-Activated Receptor Alpha.	Berberine	0-9	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	18-24
31671426-2	2020	OBJECTIVES: Using U251 cells in vitro, we investigated whether berberine exerts its neuroprotective effect via regulation of CYP2J2.	Berberine	63-72	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	125-131
31671426-9	2020	At these concentrations, berberine increased the CYP2J2 mRNA levels by 1.31-fold (p &lt; 0.05), 1.48-fold (p &lt; 0.01), and 1.88-fold (p &lt; 0.01), respectively, and increased the PPARalpha mRNA levels 1.17-fold (p &lt; 0.05), 1.29-fold (p &lt; 0.05), and 1.53-fold (p &lt; 0.01), respectively, compared with the respective control groups.	Berberine	25-34	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	49-55
31671426-10	2020	In addition, the CYP2J2 and PPARalpha protein level was also significantly upregulated in U251 cells by berberine (concentrations in 1, 3, and 10 mumol/L) in a dose-dependent manner, compared with the respective control groups.	Berberine	104-113	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	17-23
31132075-0	2020	Associations between CYP2J2 (-76G&amp;gt;T) rs890293 polymorphism and age-related macular degeneration.	Adenosine Monophosphate	34-37	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	21-27
31132075-7	2020	PURPOSE: To determine the relation between early stage and exudative AMD and CYP2J2 (-76G&amp;gt;T) gene rs890293 polymorphism in a Lithuanian population.	Adenosine Monophosphate	90-93	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	77-83
31132075-11	2020	RESULTS: The CYP2J2 (-76G&amp;gt;T) rs890293 TT genotype in patients with early AMD was statistically significantly less frequent than in the control group: 0 % vs. 2.5 % (P=0.028).	Adenosine Monophosphate	26-29	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	13-19
31132075-13	2020	Also, the CYP2J2 (-76G&amp;gt;T) rs890293 TT genotype was statistically significantly less frequent in older early AMD patients (&gt;=65 years) compared to control group persons (&gt;=65 years): 0% vs. 5.4% (P=0.03).	Adenosine Monophosphate	23-26	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	10-16
31132075-14	2020	CONCLUSION: The CYP2J2 (-76G&amp;gt;T) TT genotype may be associated with reduced manifestation of early stage AMD; therefore, a larger sample size is required for further analysis.	Adenosine Monophosphate	29-32	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	16-22
32652311-1	2020	In contrast to other drug-metabolizing cytochrome P450 (CYP) oxygenases, CYP2J2 shows considerable extrahepatic activity and is responsible for the olefin epoxidation of several polyunsaturated fatty acid (PUFA) precursors.	Alkenes	148-154	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	73-79
32652311-1	2020	In contrast to other drug-metabolizing cytochrome P450 (CYP) oxygenases, CYP2J2 shows considerable extrahepatic activity and is responsible for the olefin epoxidation of several polyunsaturated fatty acid (PUFA) precursors.	Fatty Acids, Unsaturated	178-204	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	73-79
32652311-1	2020	In contrast to other drug-metabolizing cytochrome P450 (CYP) oxygenases, CYP2J2 shows considerable extrahepatic activity and is responsible for the olefin epoxidation of several polyunsaturated fatty acid (PUFA) precursors.	Fatty Acids, Unsaturated	206-210	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	73-79
32652311-3	2020	Recent studies suggest a role of selected CYP2J2-derived epoxylipids and their metabolites in chronic pain, as well as angiogenesis, hematopoiesis, metabolic disorders, and tumor growth.	epoxylipids	57-68	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	42-48
32652311-5	2020	Here, we explore the biological functions of CYP2J2-derived epoxylipids and discuss therapeutic implications of the CYP2J2 inhibitors that are known so far.	epoxylipids	60-71	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	45-51
32210298-1	2020	CYP2J2, a member of the Cytochrome P450 family of enzymes, is the most abundant epoxygenase in the heart and has multifunctional properties including bioactivation of arachidonic acid to epoxyeicosatrienoic acids, which, in turn, have been implicated in mediating several cardiovascular conditions.	Arachidonic Acid	167-183	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	0-6
32210298-1	2020	CYP2J2, a member of the Cytochrome P450 family of enzymes, is the most abundant epoxygenase in the heart and has multifunctional properties including bioactivation of arachidonic acid to epoxyeicosatrienoic acids, which, in turn, have been implicated in mediating several cardiovascular conditions.	epoxyeicosatrienoic acids	187-212	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	0-6
31931796-5	2020	The intragastric administration of 3 or 10 mg/kg ZDHXB-101, which is a structural derivative of natural product honokiol and a novel soluble epoxide hydrolase (sEH) inhibitor, daily for 9 weeks significantly increased the level of 14, 15-EETs by inhibiting the expression of sEH and increasing the expression of CYP2J2 in lung tissues.	zdhxb-101	49-58	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	312-318
31902555-1	2020	BACKGROUND: Cytochrome P450 2J2 is mostly expressed in extrahepatic tissues; it metabolizes arachidonic acid to epoxyeicosatrienoic acids, with various cardio protective and anti-inflammatory effects.	Arachidonic Acid	92-108	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	12-31
31902555-1	2020	BACKGROUND: Cytochrome P450 2J2 is mostly expressed in extrahepatic tissues; it metabolizes arachidonic acid to epoxyeicosatrienoic acids, with various cardio protective and anti-inflammatory effects.	epoxyeicosatrienoic acids	112-137	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	12-31
31671426-11	2020	Further investigation indicated that berberine enhances the heterodimerization of PPARalpha and RXRalpha, which together bind to the CYP2J2 promoter to induce the expression of CYP2J2 in U251 cells.	Berberine	37-46	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	133-139
31671426-11	2020	Further investigation indicated that berberine enhances the heterodimerization of PPARalpha and RXRalpha, which together bind to the CYP2J2 promoter to induce the expression of CYP2J2 in U251 cells.	Berberine	37-46	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	177-183
31671426-12	2020	CONCLUSION: Upon exposure of U251 cells to berberine, CYP2J2 expression is induced as a result of PPARalpha stimulation, resulting in a neuroprotective effect.	Berberine	43-52	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	54-60
31753010-1	2019	OBJECTIVES: The data presented here is part of a study that was aimed at characterizing the molecular mechanisms of polyunsaturated fatty acid metabolism by CYP2J2, the main cytochrome P450 enzyme active in the human cardiovasculature.	Fatty Acids, Unsaturated	116-142	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	157-163
31753010-4	2019	DATA DESCRIPTION: The data comprise: (a) a new homology model of CYP2J2, (b) a number of predicted low-energy complexes of CYP2J2 with arachidonic acid, docosahexaenoic acid and eicosapentaenoic acid, produced with molecular docking and (c) a series of molecular dynamics simulations of the wild type and four mutants interacting with arachidonic acid as well as simulations of the wild type interacting with the two other eicosanoid ligands.	Arachidonic Acids	135-151	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	123-129
31753010-4	2019	DATA DESCRIPTION: The data comprise: (a) a new homology model of CYP2J2, (b) a number of predicted low-energy complexes of CYP2J2 with arachidonic acid, docosahexaenoic acid and eicosapentaenoic acid, produced with molecular docking and (c) a series of molecular dynamics simulations of the wild type and four mutants interacting with arachidonic acid as well as simulations of the wild type interacting with the two other eicosanoid ligands.	Docosahexaenoic Acids	153-173	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	123-129
31753010-4	2019	DATA DESCRIPTION: The data comprise: (a) a new homology model of CYP2J2, (b) a number of predicted low-energy complexes of CYP2J2 with arachidonic acid, docosahexaenoic acid and eicosapentaenoic acid, produced with molecular docking and (c) a series of molecular dynamics simulations of the wild type and four mutants interacting with arachidonic acid as well as simulations of the wild type interacting with the two other eicosanoid ligands.	Eicosapentaenoic Acid	178-199	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	123-129
31753010-4	2019	DATA DESCRIPTION: The data comprise: (a) a new homology model of CYP2J2, (b) a number of predicted low-energy complexes of CYP2J2 with arachidonic acid, docosahexaenoic acid and eicosapentaenoic acid, produced with molecular docking and (c) a series of molecular dynamics simulations of the wild type and four mutants interacting with arachidonic acid as well as simulations of the wild type interacting with the two other eicosanoid ligands.	Arachidonic Acids	335-351	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	123-129
31753010-4	2019	DATA DESCRIPTION: The data comprise: (a) a new homology model of CYP2J2, (b) a number of predicted low-energy complexes of CYP2J2 with arachidonic acid, docosahexaenoic acid and eicosapentaenoic acid, produced with molecular docking and (c) a series of molecular dynamics simulations of the wild type and four mutants interacting with arachidonic acid as well as simulations of the wild type interacting with the two other eicosanoid ligands.	Eicosanoids	423-433	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	123-129
30965050-0	2019	Inhibitory effects of antihypertensive drugs on human cytochrome P450 2J2 activity: Potent inhibition by azelnidipine and manidipine.	azelnidipine	105-117	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	54-73
31433338-7	2019	The isoforms CYP2D6, CYP2C19, CYP2B6, and CYP2J2 are inhibited by THC and CBD.	Dronabinol	66-69	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	42-48
31433338-7	2019	The isoforms CYP2D6, CYP2C19, CYP2B6, and CYP2J2 are inhibited by THC and CBD.	Cannabidiol	74-77	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	42-48
30965050-7	2019	A 20-min preincubation of azelnidipine and felodipine in the presence of NADPH potentiated the inhibition of CYP2J2.	NADP	73-78	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	109-115
30965050-8	2019	Furthermore, kinetic analysis of the inactivation showed that azelnidipine caused a preincubation time- and concentration-dependent decrease in CYP2J2 activity yielding kinact/KI value of 105 l/mmol/min, although felodipine showed no preincubation time-dependent inhibition.	azelnidipine	62-74	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	144-150
30965050-10	2019	These results indicated that manidipine is a potent competitive reversible inhibitor while azelnidipine is a potent mechanism-based inactivator of human CYP2J2.	azelnidipine	91-103	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	153-159
31204932-6	2019	CONCLUSIONS: Pioglitazone can reverse the adriamycin-resistance in K562/ADR cells that is closely related to the decrease of protein expression of CYP2C8 and CYP2J2.	Pioglitazone	13-25	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	158-164
31204932-6	2019	CONCLUSIONS: Pioglitazone can reverse the adriamycin-resistance in K562/ADR cells that is closely related to the decrease of protein expression of CYP2C8 and CYP2J2.	Doxorubicin	42-52	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	158-164
30965050-0	2019	Inhibitory effects of antihypertensive drugs on human cytochrome P450 2J2 activity: Potent inhibition by azelnidipine and manidipine.	manidipine	122-132	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	54-73
30965050-7	2019	A 20-min preincubation of azelnidipine and felodipine in the presence of NADPH potentiated the inhibition of CYP2J2.	azelnidipine	26-38	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	109-115
30965050-7	2019	A 20-min preincubation of azelnidipine and felodipine in the presence of NADPH potentiated the inhibition of CYP2J2.	Felodipine	43-53	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	109-115
30823561-5	2019	The metabolism of 25B-NBF was catalyzed by CYP1A1, CYP1A2, CYP2B6, CYP2C9, CYP2C19, CYP2D6, CYP2J2, CYP3A4, and UGT2B7 enzymes.	SSW3KY7SWW	18-25	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	92-98
30861250-3	2019	CYP2J2 is a membrane-bound cytochrome P450 in the heart involved in the metabolism of fatty acids and xenobiotics.	Fatty Acids	86-97	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	0-6
30861250-4	2019	In order to facilitate this metabolism, cytochrome P450 reductase (CPR), transfers electrons to CYP2J2 from NADPH.	NADP	108-113	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	96-102
30861250-6	2019	Differential effects on both NADPH oxidation and substrate metabolism by CYP2J2-CPR are dependent on the lipid composition.	NADP	29-34	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	73-79
30861250-9	2019	Crowding also affects the CYP2J2-CPR-ND system by decreasing both the Km and Vmax for Dextran-based macromolecular crowding agents, implying an increase in substrate affinity but a lack of metabolism.	Dextrans	86-93	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	26-32
29966295-1	2018	Cytochrome P450 2J2 (CYP2J2) is a known arachidonic acid (AA) epoxygenase that mediates the formation of four bioactive regioisomers of cis-epoxyeicosatrienoic acids (EETs).	arachidonic	40-51	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	0-19
30518987-1	2019	This study investigated whether common polymorphisms of cytochrome P450 2J2 (CYP2J2), a major enzyme that controls the biosynthesis of vasoactive epoxyeicosatrienoic acids, are collectively involved in the molecular basis of essential hypertension (EH).	epoxyeicosatrienoic acids	146-171	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	56-75
30518987-1	2019	This study investigated whether common polymorphisms of cytochrome P450 2J2 (CYP2J2), a major enzyme that controls the biosynthesis of vasoactive epoxyeicosatrienoic acids, are collectively involved in the molecular basis of essential hypertension (EH).	epoxyeicosatrienoic acids	146-171	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	77-83
30525564-3	2019	Using molecular design principles, we were able to modify the distance between the catalytic unit and metabolic recognition moiety, allowing us to develop a CYP2J2 selective fluorescent probe using a near-infrared fluorophore ( E)-2-(2-(6-hydroxy-2, 3-dihydro-1 H-xanthen-4-yl)vinyl)-3,3-dimethyl-1-propyl-3 H-indol-1-ium iodide (HXPI).	2-(2-(6-hydroxy-2, 3-dihydro-1 h-xanthen-4-yl	231-276	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	157-163
30525564-3	2019	Using molecular design principles, we were able to modify the distance between the catalytic unit and metabolic recognition moiety, allowing us to develop a CYP2J2 selective fluorescent probe using a near-infrared fluorophore ( E)-2-(2-(6-hydroxy-2, 3-dihydro-1 H-xanthen-4-yl)vinyl)-3,3-dimethyl-1-propyl-3 H-indol-1-ium iodide (HXPI).	)-3,3-dimethyl-1-propyl-3 h-indol-1-ium iodide	282-328	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	157-163
30525564-3	2019	Using molecular design principles, we were able to modify the distance between the catalytic unit and metabolic recognition moiety, allowing us to develop a CYP2J2 selective fluorescent probe using a near-infrared fluorophore ( E)-2-(2-(6-hydroxy-2, 3-dihydro-1 H-xanthen-4-yl)vinyl)-3,3-dimethyl-1-propyl-3 H-indol-1-ium iodide (HXPI).	hxpi	330-334	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	157-163
30525564-6	2019	Upon O-demethylation by CYP2J2, a self-immolative reaction occurred spontaneously via 1,6-elimination of p-hydroxybenzyl resulting in the release of HXPI.	p-hydroxybenzyl	105-120	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	24-30
30525564-7	2019	Allowing BnXPI to be successfully used to monitor CYP2J2 activity in real-time for various living systems including cells, tumor tissues, and tumor-bearing animals.	bnxpi	9-14	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	50-56
31000184-1	2019	BACKGROUND: The cytochrome P-450 2J2 (CYP2J2) is known to be one of the major enzymes of epoxygenase pathway of arachidonic acid in extrahepatic tissues, which produces series of regioisomeric cis-epoxyeicosatrienoic acids (EETs) such as 5,6-, 8,9-, 11,12-, and 14,15-EETs.	Arachidonic Acid	112-128	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	16-36
31000184-1	2019	BACKGROUND: The cytochrome P-450 2J2 (CYP2J2) is known to be one of the major enzymes of epoxygenase pathway of arachidonic acid in extrahepatic tissues, which produces series of regioisomeric cis-epoxyeicosatrienoic acids (EETs) such as 5,6-, 8,9-, 11,12-, and 14,15-EETs.	Arachidonic Acid	112-128	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	38-44
31000184-1	2019	BACKGROUND: The cytochrome P-450 2J2 (CYP2J2) is known to be one of the major enzymes of epoxygenase pathway of arachidonic acid in extrahepatic tissues, which produces series of regioisomeric cis-epoxyeicosatrienoic acids (EETs) such as 5,6-, 8,9-, 11,12-, and 14,15-EETs.	cis-epoxyeicosatrienoic acids	193-222	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	16-36
31000184-1	2019	BACKGROUND: The cytochrome P-450 2J2 (CYP2J2) is known to be one of the major enzymes of epoxygenase pathway of arachidonic acid in extrahepatic tissues, which produces series of regioisomeric cis-epoxyeicosatrienoic acids (EETs) such as 5,6-, 8,9-, 11,12-, and 14,15-EETs.	cis-epoxyeicosatrienoic acids	193-222	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	38-44
31000184-1	2019	BACKGROUND: The cytochrome P-450 2J2 (CYP2J2) is known to be one of the major enzymes of epoxygenase pathway of arachidonic acid in extrahepatic tissues, which produces series of regioisomeric cis-epoxyeicosatrienoic acids (EETs) such as 5,6-, 8,9-, 11,12-, and 14,15-EETs.	eets	224-228	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	16-36
31000184-1	2019	BACKGROUND: The cytochrome P-450 2J2 (CYP2J2) is known to be one of the major enzymes of epoxygenase pathway of arachidonic acid in extrahepatic tissues, which produces series of regioisomeric cis-epoxyeicosatrienoic acids (EETs) such as 5,6-, 8,9-, 11,12-, and 14,15-EETs.	eets	224-228	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	38-44
30285425-0	2018	Endocannabinoid Virodhamine Is an Endogenous Inhibitor of Human Cardiovascular CYP2J2 Epoxygenase.	Endocannabinoids	0-15	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	79-85
30285425-0	2018	Endocannabinoid Virodhamine Is an Endogenous Inhibitor of Human Cardiovascular CYP2J2 Epoxygenase.	virodhamine	16-27	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	79-85
30012976-0	2018	Role of Arginine 117 in Substrate Recognition by Human Cytochrome P450 2J2.	Arginine	8-16	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	55-74
30012976-1	2018	The influence of Arginine 117 of human cytochrome P450 2J2 in the recognition of ebastine and a series of terfenadone derivatives was studied by site-directed mutagenesis.	Arginine	17-25	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	39-58
30012976-1	2018	The influence of Arginine 117 of human cytochrome P450 2J2 in the recognition of ebastine and a series of terfenadone derivatives was studied by site-directed mutagenesis.	ebastine	81-89	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	39-58
29689453-0	2018	Cross-talk of cannabinoid and endocannabinoid metabolism is mediated via human cardiac CYP2J2.	Cannabinoids	14-25	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	87-93
29689453-0	2018	Cross-talk of cannabinoid and endocannabinoid metabolism is mediated via human cardiac CYP2J2.	Endocannabinoids	30-45	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	87-93
29689453-4	2018	CYP2J2, the primary CYP of cardiomyocytes, is responsible for the metabolism of the endocannabinoid, anandamide (AEA), into cardioprotective epoxides (EET-EAs).	Endocannabinoids	84-99	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	0-6
29689453-4	2018	CYP2J2, the primary CYP of cardiomyocytes, is responsible for the metabolism of the endocannabinoid, anandamide (AEA), into cardioprotective epoxides (EET-EAs).	anandamide	101-111	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	0-6
29689453-4	2018	CYP2J2, the primary CYP of cardiomyocytes, is responsible for the metabolism of the endocannabinoid, anandamide (AEA), into cardioprotective epoxides (EET-EAs).	anandamide	113-116	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	0-6
29689453-4	2018	CYP2J2, the primary CYP of cardiomyocytes, is responsible for the metabolism of the endocannabinoid, anandamide (AEA), into cardioprotective epoxides (EET-EAs).	Epoxy Compounds	141-149	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	0-6
29689453-4	2018	CYP2J2, the primary CYP of cardiomyocytes, is responsible for the metabolism of the endocannabinoid, anandamide (AEA), into cardioprotective epoxides (EET-EAs).	eet-eas	151-158	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	0-6
29689453-6	2018	CYP2J2 mainly produces 1"/1""-OH metabolites of these phytocannabinoids.	1"/1""-oh	23-32	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	0-6
29689453-6	2018	CYP2J2 mainly produces 1"/1""-OH metabolites of these phytocannabinoids.	phytocannabinoids	54-71	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	0-6
29689453-7	2018	These phytocannabinoids are metabolized with greater catalytic efficiency compared to the metabolism of AEA by CYP2J2.	anandamide	104-107	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	111-117
29689453-8	2018	We have also determined that the phytocannabinoids are potent inhibitors of CYP2J2-mediated AEA metabolism, with Delta9-THC being the strongest inhibitor.	phytocannabinoids	33-50	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	76-82
29689453-8	2018	We have also determined that the phytocannabinoids are potent inhibitors of CYP2J2-mediated AEA metabolism, with Delta9-THC being the strongest inhibitor.	anandamide	92-95	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	76-82
29689453-8	2018	We have also determined that the phytocannabinoids are potent inhibitors of CYP2J2-mediated AEA metabolism, with Delta9-THC being the strongest inhibitor.	Dronabinol	113-123	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	76-82
29689453-9	2018	Most of the inhibition of CYP2J2 by the phytocannabinoids follow a noncompetitive inhibition model, and therefore dramatically reduce the formation of EET-EAs by CYP2J2.	phytocannabinoids	40-57	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	26-32
29689453-9	2018	Most of the inhibition of CYP2J2 by the phytocannabinoids follow a noncompetitive inhibition model, and therefore dramatically reduce the formation of EET-EAs by CYP2J2.	phytocannabinoids	40-57	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	162-168
29689453-9	2018	Most of the inhibition of CYP2J2 by the phytocannabinoids follow a noncompetitive inhibition model, and therefore dramatically reduce the formation of EET-EAs by CYP2J2.	eet-eas	151-158	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	26-32
29689453-9	2018	Most of the inhibition of CYP2J2 by the phytocannabinoids follow a noncompetitive inhibition model, and therefore dramatically reduce the formation of EET-EAs by CYP2J2.	eet-eas	151-158	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	162-168
29689453-10	2018	Taken together, these data demonstrate that phytocannabinoids are directly metabolized by CYP2J2 and inhibit human cardiac CYP2J2, leading to a reduction in the formation of cardioprotective EET-EAs.	phytocannabinoids	44-61	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	90-96
29689453-10	2018	Taken together, these data demonstrate that phytocannabinoids are directly metabolized by CYP2J2 and inhibit human cardiac CYP2J2, leading to a reduction in the formation of cardioprotective EET-EAs.	phytocannabinoids	44-61	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	123-129
29966295-1	2018	Cytochrome P450 2J2 (CYP2J2) is a known arachidonic acid (AA) epoxygenase that mediates the formation of four bioactive regioisomers of cis-epoxyeicosatrienoic acids (EETs).	eets	167-171	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	21-27
30788785-6	2019	We also describe the measurement of the activity of the cytochrome P450 expressed by taking the example of cytochrome P450 2J2, the primary P450 expressed in the human heart and CYP725A4, the primary cytochrome P450 expressed in the first step of taxol synthesis.	Paclitaxel	247-252	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	107-126
30285425-6	2018	On a separate note, the cytochrome P450 (CYP) epoxygenase CYP2J2 is the most abundant CYP in the heart where it catalyzes the metabolism of AA and AA-derived eCBs to bioactive epoxides that are involved in diverse cardiovascular functions.	ecbs	158-162	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	58-64
30285425-6	2018	On a separate note, the cytochrome P450 (CYP) epoxygenase CYP2J2 is the most abundant CYP in the heart where it catalyzes the metabolism of AA and AA-derived eCBs to bioactive epoxides that are involved in diverse cardiovascular functions.	Epoxy Compounds	176-184	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	58-64
30285425-7	2018	Herein, using competitive binding studies, kinetic metabolism measurements, molecular dynamics, and wound healing assays, we have shown that O-AEA is an endogenous inhibitor of CYP2J2 epoxygenase.	virodhamine	141-146	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	177-183
30285425-8	2018	As a result, the role of O-AEA as an endogenous eCB inhibitor of CYP2J2 may provide a new mode of regulation to control the activity of cardiovascular CYP2J2 in vivo and suggests a potential cross-talk between the cardiovascular endocannabinoids and the cytochrome P450 system.	virodhamine	25-30	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	65-71
30285425-8	2018	As a result, the role of O-AEA as an endogenous eCB inhibitor of CYP2J2 may provide a new mode of regulation to control the activity of cardiovascular CYP2J2 in vivo and suggests a potential cross-talk between the cardiovascular endocannabinoids and the cytochrome P450 system.	virodhamine	25-30	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	151-157
30362120-5	2018	Inhibition studies with chemical inhibitors and antibodies suggested that arachidonic acid, the substrate of CYP2J2, and CYP2J2-specific antibody effectively inhibited the formation of SYL-927-M in HLMs whereas no significant inhibition was observed with the inhibitors for CYP1A1, CYP1A2, CYP2C9, CYP2C19, CYP2D6, CYP2E1 and CYP3A4, demonstrating that CYP2J2 was primarily responsible for the formation of SYL-927-M.	Arachidonic Acid	74-90	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	109-115
29695613-1	2018	Drug-induced cardiotoxicity may be modulated by endogenous arachidonic acid (AA)-derived metabolites known as epoxyeicosatrienoic acids (EETs) synthesized by cytochrome P450 2J2 (CYP2J2).	Arachidonic Acid	59-75	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	158-177
29695613-1	2018	Drug-induced cardiotoxicity may be modulated by endogenous arachidonic acid (AA)-derived metabolites known as epoxyeicosatrienoic acids (EETs) synthesized by cytochrome P450 2J2 (CYP2J2).	Arachidonic Acid	59-75	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	179-185
29695613-1	2018	Drug-induced cardiotoxicity may be modulated by endogenous arachidonic acid (AA)-derived metabolites known as epoxyeicosatrienoic acids (EETs) synthesized by cytochrome P450 2J2 (CYP2J2).	epoxyeicosatrienoic acids	110-135	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	158-177
29695613-1	2018	Drug-induced cardiotoxicity may be modulated by endogenous arachidonic acid (AA)-derived metabolites known as epoxyeicosatrienoic acids (EETs) synthesized by cytochrome P450 2J2 (CYP2J2).	epoxyeicosatrienoic acids	110-135	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	179-185
29695613-1	2018	Drug-induced cardiotoxicity may be modulated by endogenous arachidonic acid (AA)-derived metabolites known as epoxyeicosatrienoic acids (EETs) synthesized by cytochrome P450 2J2 (CYP2J2).	eets	137-141	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	158-177
29695613-1	2018	Drug-induced cardiotoxicity may be modulated by endogenous arachidonic acid (AA)-derived metabolites known as epoxyeicosatrienoic acids (EETs) synthesized by cytochrome P450 2J2 (CYP2J2).	eets	137-141	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	179-185
29966295-1	2018	Cytochrome P450 2J2 (CYP2J2) is a known arachidonic acid (AA) epoxygenase that mediates the formation of four bioactive regioisomers of cis-epoxyeicosatrienoic acids (EETs).	arachidonic	40-51	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	21-27
29966295-1	2018	Cytochrome P450 2J2 (CYP2J2) is a known arachidonic acid (AA) epoxygenase that mediates the formation of four bioactive regioisomers of cis-epoxyeicosatrienoic acids (EETs).	cis-epoxyeicosatrienoic acids	136-165	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	0-19
29966295-1	2018	Cytochrome P450 2J2 (CYP2J2) is a known arachidonic acid (AA) epoxygenase that mediates the formation of four bioactive regioisomers of cis-epoxyeicosatrienoic acids (EETs).	cis-epoxyeicosatrienoic acids	136-165	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	21-27
29966295-1	2018	Cytochrome P450 2J2 (CYP2J2) is a known arachidonic acid (AA) epoxygenase that mediates the formation of four bioactive regioisomers of cis-epoxyeicosatrienoic acids (EETs).	eets	167-171	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	0-19
29759885-0	2018	Terfenadone is a strong inhibitor of CYP2J2 present in the human liver and intestinal microsomes.	terfenadone	0-11	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	37-43
29602797-0	2018	Formation of Both Heme and Apoprotein Adducts Contributes to the Mechanism-Based Inactivation of Human CYP2J2 by 17alpha-Ethynylestradiol.	Heme	18-22	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	103-109
29602797-0	2018	Formation of Both Heme and Apoprotein Adducts Contributes to the Mechanism-Based Inactivation of Human CYP2J2 by 17alpha-Ethynylestradiol.	Ethinyl Estradiol	113-137	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	103-109
29602797-2	2018	Here, we characterized the effect of EE on CYP2J2, a major human P450 isoform that participates in metabolism of arachidonic acid.	Arachidonic Acid	113-129	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	43-49
29689254-5	2018	Taxol 6-hydroxylation and astemizole O-desmethyastemizole were determined as probe activities for CYP2C8 and CYP2J2, respectively.	Paclitaxel	0-5	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	109-115
29689254-5	2018	Taxol 6-hydroxylation and astemizole O-desmethyastemizole were determined as probe activities for CYP2C8 and CYP2J2, respectively.	astemizole o-desmethyastemizole	26-57	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	109-115
29689254-7	2018	The results demonstrated that salvianolic acid A was a competitive inhibitor of CYP2C8 (Ki = 2.5 muM) and mixed-type inhibitor of CYP2J2 (Ki = 7.44 muM).	salvianolic acid A	30-48	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	130-136
29689254-8	2018	Salvianolic acid C had moderate noncompetitive and mixed-type inhibitions on CYP2C8 (Ki = 4.82 muM) and CYP2J2 (Ki = 5.75 muM), respectively.	salvianolic acid C	0-18	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	104-110
29689254-10	2018	Dihydrotanshinone I had moderate noncompetitive inhibition on CYP2J2 (Ki = 6.59 muM), but mechanism-based inhibition on CYP2C8 (KI = 0.43 muM, kinact = 0.097 min-1).	dhts	0-19	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	62-68
29759885-2	2018	In a previous study, we used recombinant CYP2J2 and determined whether danazol, hydroxyebastine, telmisartan, and terfenadone inhibited CYP2J2 by using four representative CYP2J2 substrates, namely albendazole, astemizole, ebastine, and terfenadine.	Astemizole	211-221	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	136-142
29759885-2	2018	In a previous study, we used recombinant CYP2J2 and determined whether danazol, hydroxyebastine, telmisartan, and terfenadone inhibited CYP2J2 by using four representative CYP2J2 substrates, namely albendazole, astemizole, ebastine, and terfenadine.	Astemizole	211-221	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	136-142
29759885-2	2018	In a previous study, we used recombinant CYP2J2 and determined whether danazol, hydroxyebastine, telmisartan, and terfenadone inhibited CYP2J2 by using four representative CYP2J2 substrates, namely albendazole, astemizole, ebastine, and terfenadine.	ebastine	87-95	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	136-142
29602797-6	2018	Inactivation of CYP2J2 by EE was due to formation of a heme adduct as well as an apoprotein adduct.	Heme	55-59	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	16-22
29602797-7	2018	Mass spectral analysis of CYP2J2 partially inactivated by EE showed two distinct protein masses in the deconvoluted spectrum that exhibited a mass difference of approximately 312 Da, which is equivalent to the sum of the mass of EE and one oxygen atom.	Oxygen	240-246	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	26-32
29759885-1	2018	Cytochrome P450 2J2 (CYP2J2) is involved in the metabolism of drugs, including albendazole, astemizole, ebastine, and endogenous substrates.	Albendazole	79-90	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	0-19
29759885-2	2018	In a previous study, we used recombinant CYP2J2 and determined whether danazol, hydroxyebastine, telmisartan, and terfenadone inhibited CYP2J2 by using four representative CYP2J2 substrates, namely albendazole, astemizole, ebastine, and terfenadine.	ebastine	87-95	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	136-142
29759885-2	2018	In a previous study, we used recombinant CYP2J2 and determined whether danazol, hydroxyebastine, telmisartan, and terfenadone inhibited CYP2J2 by using four representative CYP2J2 substrates, namely albendazole, astemizole, ebastine, and terfenadine.	Terfenadine	237-248	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	136-142
29759885-1	2018	Cytochrome P450 2J2 (CYP2J2) is involved in the metabolism of drugs, including albendazole, astemizole, ebastine, and endogenous substrates.	Albendazole	79-90	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	21-27
29759885-2	2018	In a previous study, we used recombinant CYP2J2 and determined whether danazol, hydroxyebastine, telmisartan, and terfenadone inhibited CYP2J2 by using four representative CYP2J2 substrates, namely albendazole, astemizole, ebastine, and terfenadine.	Terfenadine	237-248	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	136-142
29759885-1	2018	Cytochrome P450 2J2 (CYP2J2) is involved in the metabolism of drugs, including albendazole, astemizole, ebastine, and endogenous substrates.	Astemizole	92-102	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	0-19
29759885-4	2018	Among the four CYP2J2 inhibitors tested, terfenadone was strongest inhibitor of CYP2J2-mediated metabolism of albendazole, astemizole, and terfenadine with IC50 values of 0.31, 0.15, and 2.11 muM, respectively, in human liver microsomes (HLMs).	terfenadone	41-52	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	15-21
29759885-1	2018	Cytochrome P450 2J2 (CYP2J2) is involved in the metabolism of drugs, including albendazole, astemizole, ebastine, and endogenous substrates.	Astemizole	92-102	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	21-27
29759885-4	2018	Among the four CYP2J2 inhibitors tested, terfenadone was strongest inhibitor of CYP2J2-mediated metabolism of albendazole, astemizole, and terfenadine with IC50 values of 0.31, 0.15, and 2.11 muM, respectively, in human liver microsomes (HLMs).	terfenadone	41-52	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	80-86
29759885-4	2018	Among the four CYP2J2 inhibitors tested, terfenadone was strongest inhibitor of CYP2J2-mediated metabolism of albendazole, astemizole, and terfenadine with IC50 values of 0.31, 0.15, and 2.11 muM, respectively, in human liver microsomes (HLMs).	Albendazole	110-121	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	15-21
29759885-1	2018	Cytochrome P450 2J2 (CYP2J2) is involved in the metabolism of drugs, including albendazole, astemizole, ebastine, and endogenous substrates.	ebastine	104-112	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	0-19
29759885-4	2018	Among the four CYP2J2 inhibitors tested, terfenadone was strongest inhibitor of CYP2J2-mediated metabolism of albendazole, astemizole, and terfenadine with IC50 values of 0.31, 0.15, and 2.11 muM, respectively, in human liver microsomes (HLMs).	Albendazole	110-121	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	80-86
29759885-1	2018	Cytochrome P450 2J2 (CYP2J2) is involved in the metabolism of drugs, including albendazole, astemizole, ebastine, and endogenous substrates.	ebastine	104-112	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	21-27
29759885-4	2018	Among the four CYP2J2 inhibitors tested, terfenadone was strongest inhibitor of CYP2J2-mediated metabolism of albendazole, astemizole, and terfenadine with IC50 values of 0.31, 0.15, and 2.11 muM, respectively, in human liver microsomes (HLMs).	Astemizole	123-133	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	15-21
29759885-4	2018	Among the four CYP2J2 inhibitors tested, terfenadone was strongest inhibitor of CYP2J2-mediated metabolism of albendazole, astemizole, and terfenadine with IC50 values of 0.31, 0.15, and 2.11 muM, respectively, in human liver microsomes (HLMs).	Astemizole	123-133	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	80-86
29759885-4	2018	Among the four CYP2J2 inhibitors tested, terfenadone was strongest inhibitor of CYP2J2-mediated metabolism of albendazole, astemizole, and terfenadine with IC50 values of 0.31, 0.15, and 2.11 muM, respectively, in human liver microsomes (HLMs).	Terfenadine	139-150	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	15-21
29759885-4	2018	Among the four CYP2J2 inhibitors tested, terfenadone was strongest inhibitor of CYP2J2-mediated metabolism of albendazole, astemizole, and terfenadine with IC50 values of 0.31, 0.15, and 2.11 muM, respectively, in human liver microsomes (HLMs).	Terfenadine	139-150	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	80-86
29759885-6	2018	Danazol, weakly inhibited CYP2J2-mediated metabolism of albendazole and astemizole with IC50 values of 13.8 and 18.3 muM, respectively in HLMs, whereas it strongly inhibited the CYP2J2-mediated ebastine hydroxylase activity in HLMs and HIMs (IC50 = 1.93-1.95 muM).	Danazol	0-7	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	26-32
29759885-2	2018	In a previous study, we used recombinant CYP2J2 and determined whether danazol, hydroxyebastine, telmisartan, and terfenadone inhibited CYP2J2 by using four representative CYP2J2 substrates, namely albendazole, astemizole, ebastine, and terfenadine.	Danazol	71-78	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	136-142
29759885-2	2018	In a previous study, we used recombinant CYP2J2 and determined whether danazol, hydroxyebastine, telmisartan, and terfenadone inhibited CYP2J2 by using four representative CYP2J2 substrates, namely albendazole, astemizole, ebastine, and terfenadine.	Danazol	71-78	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	136-142
29759885-2	2018	In a previous study, we used recombinant CYP2J2 and determined whether danazol, hydroxyebastine, telmisartan, and terfenadone inhibited CYP2J2 by using four representative CYP2J2 substrates, namely albendazole, astemizole, ebastine, and terfenadine.	hydroxyebastine	80-95	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	136-142
29759885-2	2018	In a previous study, we used recombinant CYP2J2 and determined whether danazol, hydroxyebastine, telmisartan, and terfenadone inhibited CYP2J2 by using four representative CYP2J2 substrates, namely albendazole, astemizole, ebastine, and terfenadine.	hydroxyebastine	80-95	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	136-142
29759885-2	2018	In a previous study, we used recombinant CYP2J2 and determined whether danazol, hydroxyebastine, telmisartan, and terfenadone inhibited CYP2J2 by using four representative CYP2J2 substrates, namely albendazole, astemizole, ebastine, and terfenadine.	Telmisartan	97-108	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	136-142
29759885-6	2018	Danazol, weakly inhibited CYP2J2-mediated metabolism of albendazole and astemizole with IC50 values of 13.8 and 18.3 muM, respectively in HLMs, whereas it strongly inhibited the CYP2J2-mediated ebastine hydroxylase activity in HLMs and HIMs (IC50 = 1.93-1.95 muM).	Danazol	0-7	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	178-184
29759885-2	2018	In a previous study, we used recombinant CYP2J2 and determined whether danazol, hydroxyebastine, telmisartan, and terfenadone inhibited CYP2J2 by using four representative CYP2J2 substrates, namely albendazole, astemizole, ebastine, and terfenadine.	Telmisartan	97-108	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	136-142
29759885-6	2018	Danazol, weakly inhibited CYP2J2-mediated metabolism of albendazole and astemizole with IC50 values of 13.8 and 18.3 muM, respectively in HLMs, whereas it strongly inhibited the CYP2J2-mediated ebastine hydroxylase activity in HLMs and HIMs (IC50 = 1.93-1.95 muM).	Albendazole	56-67	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	26-32
29759885-2	2018	In a previous study, we used recombinant CYP2J2 and determined whether danazol, hydroxyebastine, telmisartan, and terfenadone inhibited CYP2J2 by using four representative CYP2J2 substrates, namely albendazole, astemizole, ebastine, and terfenadine.	terfenadone	114-125	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	136-142
29759885-6	2018	Danazol, weakly inhibited CYP2J2-mediated metabolism of albendazole and astemizole with IC50 values of 13.8 and 18.3 muM, respectively in HLMs, whereas it strongly inhibited the CYP2J2-mediated ebastine hydroxylase activity in HLMs and HIMs (IC50 = 1.93-1.95 muM).	Astemizole	72-82	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	26-32
29759885-7	2018	Our data suggest that terfenadone may be used as a general CYP2J2 inhibitor in reaction phenotyping study using HLMs and HIMs regardless of the substrate used.	terfenadone	22-33	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	59-65
29759885-2	2018	In a previous study, we used recombinant CYP2J2 and determined whether danazol, hydroxyebastine, telmisartan, and terfenadone inhibited CYP2J2 by using four representative CYP2J2 substrates, namely albendazole, astemizole, ebastine, and terfenadine.	terfenadone	114-125	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	136-142
29759885-2	2018	In a previous study, we used recombinant CYP2J2 and determined whether danazol, hydroxyebastine, telmisartan, and terfenadone inhibited CYP2J2 by using four representative CYP2J2 substrates, namely albendazole, astemizole, ebastine, and terfenadine.	Albendazole	198-209	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	136-142
29759885-2	2018	In a previous study, we used recombinant CYP2J2 and determined whether danazol, hydroxyebastine, telmisartan, and terfenadone inhibited CYP2J2 by using four representative CYP2J2 substrates, namely albendazole, astemizole, ebastine, and terfenadine.	Albendazole	198-209	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	136-142
29715548-0	2018	Posttranslational regulation of CYP2J2 by nitric oxide.	Nitric Oxide	42-54	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	32-38
29715548-4	2018	In the current study, we tested the NO-mediated regulation of CYP2J2 that metabolizes arachidonic acids to bioactive epoxyeicosatrienoic acids, as well as therapeutic drugs such as astemizole and ebastine.	Arachidonic Acids	86-103	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	62-68
29715548-4	2018	In the current study, we tested the NO-mediated regulation of CYP2J2 that metabolizes arachidonic acids to bioactive epoxyeicosatrienoic acids, as well as therapeutic drugs such as astemizole and ebastine.	epoxyeicosatrienoic acids	117-142	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	62-68
29715548-8	2018	Removal of DPTA from the culture media quickly restored the activity of remaining CYP2J2, and no further CYP2J2 degradation occurred.	dipropylenetriamine-NONOate	11-15	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	82-88
29715548-12	2018	The proteasome inhibitor bortezomib showed small but significant restoration of CYP2J2 levels although stimulated ubiquitination of CYP2J2 was not detected.	Bortezomib	25-35	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	80-86
29433675-1	2018	BACKGROUND: Cytochrome P450 2J2 (CYP2J2) is not only highly expressed in many kinds of human tumors, but also promotes tumor cell growth via regulating the metabolism of arachidonic acids.	Arachidonic Acids	170-187	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	12-31
29580941-0	2018	Increased epoxyeicosatrienoic acids may be part of a protective mechanism in human ulcerative colitis, with increased CYP2J2 and reduced soluble epoxide hydrolase expression.	epoxyeicosatrienoic acids	10-35	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	118-124
29629756-0	2018	An Emerging Pathway of Doxorubicin Cardiotoxicity Mediated through CYP2J2.	Doxorubicin	23-34	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	67-73
29655687-3	2018	PURPOSE: The purpose of this study is to elucidate the inhibitory effect of BCA against CYP2J2 enzyme which is predominantly expressed in human tumor tissues and carcinoma cell lines.	broussochalcone A	76-79	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	88-94
29655687-4	2018	STUDY DESIGN: The inhibitory effect of BCA on the activities of CYP2J2-mediated metabolism were investigated using human liver microsomes (HLMs), and its anti-cancer effect against human hepatoma HepG2 cells was also evaluated.	broussochalcone A	39-42	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	64-70
29655687-5	2018	METHODS: Two representative CYP2J2-specific probe substrates, astemizole and ebastine, were incubated in HLMs with BCA.	Astemizole	62-72	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	28-34
29655687-5	2018	METHODS: Two representative CYP2J2-specific probe substrates, astemizole and ebastine, were incubated in HLMs with BCA.	ebastine	77-85	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	28-34
29655687-5	2018	METHODS: Two representative CYP2J2-specific probe substrates, astemizole and ebastine, were incubated in HLMs with BCA.	broussochalcone A	115-118	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	28-34
29655687-8	2018	RESULTS: BCA inhibited CYP2J2-mediated astemizole O-demethylation and ebastine hydroxylase activities in a concentration dependent manner with Ki values of 2.3 and 3.7 microM, respectively.	broussochalcone A	9-12	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	23-29
29655687-8	2018	RESULTS: BCA inhibited CYP2J2-mediated astemizole O-demethylation and ebastine hydroxylase activities in a concentration dependent manner with Ki values of 2.3 and 3.7 microM, respectively.	Astemizole	39-49	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	23-29
29655687-10	2018	CONCLUSION: Overall, this was the first report of the inhibitory effects of BCA on CYP2J2 in HLMs.	broussochalcone A	76-79	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	83-89
29022765-3	2018	METHODS: In a cohort of 355 patients, we determined the presence of two polymorphisms, CYP2C8*3 and CYP2J2*7, known to affect eicosanoid levels.	Eicosanoids	126-136	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	100-106
29343610-0	2018	CYP2J2 Expression in Adult Ventricular Myocytes Protects Against Reactive Oxygen Species Toxicity.	Reactive Oxygen Species	65-88	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	0-6
29343610-5	2018	CYP2J2 has been shown to be resistant to induction by canonical CYP inducers such as phenytoin and rifampin.	Phenytoin	85-94	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	0-6
29343610-5	2018	CYP2J2 has been shown to be resistant to induction by canonical CYP inducers such as phenytoin and rifampin.	Rifampin	99-107	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	0-6
29343610-9	2018	Findings indicate that CYP2J2 expression increases in response to external ROS or when internal ROS levels are elevated.	Reactive Oxygen Species	75-78	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	23-29
29343610-9	2018	Findings indicate that CYP2J2 expression increases in response to external ROS or when internal ROS levels are elevated.	Reactive Oxygen Species	96-99	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	23-29
29343610-10	2018	In addition, cell survival decreases with ROS exposure when CYP2J2 is chemically inhibited or when CYP2J2 expression is reduced using small interfering RNA.	Reactive Oxygen Species	42-45	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	60-66
29343610-10	2018	In addition, cell survival decreases with ROS exposure when CYP2J2 is chemically inhibited or when CYP2J2 expression is reduced using small interfering RNA.	Reactive Oxygen Species	42-45	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	99-105
29343610-13	2018	This work is the first to determine the consequence of cellular stress, specifically high ROS levels, on CYP2J2 expression in human ventricular myocytes and discusses how this enzyme may play an important role in response to cardiac oxidative stress.	Reactive Oxygen Species	90-93	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	105-111
29655687-11	2018	The present data suggest that BCA is a potential candidate for further evaluation for its CYP2J2 targeting anti-cancer activities.	broussochalcone A	30-33	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	90-96
29223463-0	2018	Terfenadine metabolism of human cytochrome P450 2J2 containing genetic variations (G312R, P351L and P115L).	Terfenadine	0-11	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	32-51
29223463-1	2018	The human cytochrome P450 2J2 is involved in several metabolic reactions, including the oxidation of important therapeutics and epoxidation of endogenous arachidonic acid.	Arachidonic Acid	154-170	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	10-29
29433675-1	2018	BACKGROUND: Cytochrome P450 2J2 (CYP2J2) is not only highly expressed in many kinds of human tumors, but also promotes tumor cell growth via regulating the metabolism of arachidonic acids.	Arachidonic Acids	170-187	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	33-39
29433675-2	2018	CYP2J2 inhibitors can significantly reduce proliferation, migration and promote apoptosis of tumor cells by inhibiting epoxyeicosatrienoic acids (EETs) biosynthesis.	epoxyeicosatrienoic acids	119-144	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	0-6
29433675-2	2018	CYP2J2 inhibitors can significantly reduce proliferation, migration and promote apoptosis of tumor cells by inhibiting epoxyeicosatrienoic acids (EETs) biosynthesis.	eets	146-150	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	0-6
29433675-9	2018	RESULTS: In all candidates, plumbagin showed the strongest inhibitory effect on the CYP2J2-mediated astemizole O-demethylation activity.	Astemizole	100-110	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	84-90
29433675-12	2018	Docking data presented that plumbagin interacted with CYP2J2 mainly through GLU 222 and ALA 223.	Glutamic Acid	76-79	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	54-60
29433675-12	2018	Docking data presented that plumbagin interacted with CYP2J2 mainly through GLU 222 and ALA 223.	Alanine	88-91	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	54-60
28316087-11	2017	Further, CYP2C8*3 and CYP2J2 c.-76G&gt;T SNPs influenced the renal function of these patients and the occurrence of adverse events during treatment with tacrolimus and mycophenolate sodium.	Tacrolimus	153-163	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	22-28
29200270-0	2017	Arachidonic Acid Metabolism by Human Cardiovascular CYP2J2 Is Modulated by Doxorubicin.	Arachidonic Acid	0-16	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	52-58
29200270-0	2017	Arachidonic Acid Metabolism by Human Cardiovascular CYP2J2 Is Modulated by Doxorubicin.	Doxorubicin	75-86	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	52-58
29200270-5	2017	Using kinetic analyses, we show that AA metabolism by CYP2J2 is modulated by DOX.	Doxorubicin	77-80	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	54-60
29200270-6	2017	We show that cytochrome P450 reductase, the redox partner of CYP2J2, metabolizes DOX to 7-deoxydoxorubicin aglycone (7-de-aDOX).	Doxorubicin	81-84	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	61-67
29200270-6	2017	We show that cytochrome P450 reductase, the redox partner of CYP2J2, metabolizes DOX to 7-deoxydoxorubicin aglycone (7-de-aDOX).	7-deoxyadriamycin aglycone	88-115	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	61-67
29200270-6	2017	We show that cytochrome P450 reductase, the redox partner of CYP2J2, metabolizes DOX to 7-deoxydoxorubicin aglycone (7-de-aDOX).	7-de-adox	117-126	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	61-67
29200270-8	2017	Furthermore, molecular dynamics simulations indicate that 7-de-aDOX and AA can concurrently bind to the CYP2J2 active site to produce these changes in the site of AA metabolism.	7-de-adox	58-67	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	104-110
29200270-10	2017	ZRN and 5-IDN inhibit CYP2J2-mediated AA metabolism but do not change the ratio of EET regioisomers.	zorubicin	0-3	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	22-28
29200270-10	2017	ZRN and 5-IDN inhibit CYP2J2-mediated AA metabolism but do not change the ratio of EET regioisomers.	5-iminodaunorubicin	8-13	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	22-28
29200270-11	2017	Altogether, we demonstrate that DOX and 7-de-aDOX inhibit CYP2J2-mediated AA metabolism and 7-de-aDOX binds close to the active site to alter the ratio of cardioprotective EETs.	Doxorubicin	32-35	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	58-64
29200270-11	2017	Altogether, we demonstrate that DOX and 7-de-aDOX inhibit CYP2J2-mediated AA metabolism and 7-de-aDOX binds close to the active site to alter the ratio of cardioprotective EETs.	7-de-adox	40-49	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	58-64
29200270-12	2017	These mechanistic studies of CYP2J2 can aid in the design of new alternative DOX derivatives.	Doxorubicin	77-80	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	29-35
28958841-1	2017	Cardiac enzymes such as cytochrome P450 2J2 (CYP2J2) metabolize arachidonic acid (AA) to cardioprotective epoxyeicosatrienoic acids (EETs), which in turn are metabolized by soluble epoxide hydrolase (sEH) to dihydroxyeicosatrienoic acids (DHETs).	Arachidonic Acid	64-80	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	24-43
28958841-1	2017	Cardiac enzymes such as cytochrome P450 2J2 (CYP2J2) metabolize arachidonic acid (AA) to cardioprotective epoxyeicosatrienoic acids (EETs), which in turn are metabolized by soluble epoxide hydrolase (sEH) to dihydroxyeicosatrienoic acids (DHETs).	Arachidonic Acid	64-80	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	45-51
28958841-1	2017	Cardiac enzymes such as cytochrome P450 2J2 (CYP2J2) metabolize arachidonic acid (AA) to cardioprotective epoxyeicosatrienoic acids (EETs), which in turn are metabolized by soluble epoxide hydrolase (sEH) to dihydroxyeicosatrienoic acids (DHETs).	epoxyeicosatrienoic acids	106-131	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	24-43
28958841-1	2017	Cardiac enzymes such as cytochrome P450 2J2 (CYP2J2) metabolize arachidonic acid (AA) to cardioprotective epoxyeicosatrienoic acids (EETs), which in turn are metabolized by soluble epoxide hydrolase (sEH) to dihydroxyeicosatrienoic acids (DHETs).	epoxyeicosatrienoic acids	106-131	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	45-51
28958841-1	2017	Cardiac enzymes such as cytochrome P450 2J2 (CYP2J2) metabolize arachidonic acid (AA) to cardioprotective epoxyeicosatrienoic acids (EETs), which in turn are metabolized by soluble epoxide hydrolase (sEH) to dihydroxyeicosatrienoic acids (DHETs).	eets	133-137	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	24-43
28958841-1	2017	Cardiac enzymes such as cytochrome P450 2J2 (CYP2J2) metabolize arachidonic acid (AA) to cardioprotective epoxyeicosatrienoic acids (EETs), which in turn are metabolized by soluble epoxide hydrolase (sEH) to dihydroxyeicosatrienoic acids (DHETs).	eets	133-137	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	45-51
28958841-1	2017	Cardiac enzymes such as cytochrome P450 2J2 (CYP2J2) metabolize arachidonic acid (AA) to cardioprotective epoxyeicosatrienoic acids (EETs), which in turn are metabolized by soluble epoxide hydrolase (sEH) to dihydroxyeicosatrienoic acids (DHETs).	dihydroxyeicosatrienoic acids	208-237	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	24-43
28958841-1	2017	Cardiac enzymes such as cytochrome P450 2J2 (CYP2J2) metabolize arachidonic acid (AA) to cardioprotective epoxyeicosatrienoic acids (EETs), which in turn are metabolized by soluble epoxide hydrolase (sEH) to dihydroxyeicosatrienoic acids (DHETs).	dihydroxyeicosatrienoic acids	208-237	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	45-51
28958841-1	2017	Cardiac enzymes such as cytochrome P450 2J2 (CYP2J2) metabolize arachidonic acid (AA) to cardioprotective epoxyeicosatrienoic acids (EETs), which in turn are metabolized by soluble epoxide hydrolase (sEH) to dihydroxyeicosatrienoic acids (DHETs).	dhets	239-244	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	24-43
28958841-1	2017	Cardiac enzymes such as cytochrome P450 2J2 (CYP2J2) metabolize arachidonic acid (AA) to cardioprotective epoxyeicosatrienoic acids (EETs), which in turn are metabolized by soluble epoxide hydrolase (sEH) to dihydroxyeicosatrienoic acids (DHETs).	dhets	239-244	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	45-51
28958841-3	2017	Previously, we demonstrated that dronedarone, amiodarone and their main metabolites, namely N-desbutyldronedarone (NDBD) and N-desethylamiodarone (NDEA), potently inhibit human cardiac CYP2J2-mediated astemizole metabolism in vitro.	Dronedarone	33-44	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	185-191
28958841-3	2017	Previously, we demonstrated that dronedarone, amiodarone and their main metabolites, namely N-desbutyldronedarone (NDBD) and N-desethylamiodarone (NDEA), potently inhibit human cardiac CYP2J2-mediated astemizole metabolism in vitro.	Amiodarone	46-56	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	185-191
28958841-3	2017	Previously, we demonstrated that dronedarone, amiodarone and their main metabolites, namely N-desbutyldronedarone (NDBD) and N-desethylamiodarone (NDEA), potently inhibit human cardiac CYP2J2-mediated astemizole metabolism in vitro.	N-desbutyldronedarone	92-113	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	185-191
28958841-3	2017	Previously, we demonstrated that dronedarone, amiodarone and their main metabolites, namely N-desbutyldronedarone (NDBD) and N-desethylamiodarone (NDEA), potently inhibit human cardiac CYP2J2-mediated astemizole metabolism in vitro.	N-desbutyldronedarone	115-119	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	185-191
28958841-3	2017	Previously, we demonstrated that dronedarone, amiodarone and their main metabolites, namely N-desbutyldronedarone (NDBD) and N-desethylamiodarone (NDEA), potently inhibit human cardiac CYP2J2-mediated astemizole metabolism in vitro.	desethylamiodarone	125-145	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	185-191
28958841-3	2017	Previously, we demonstrated that dronedarone, amiodarone and their main metabolites, namely N-desbutyldronedarone (NDBD) and N-desethylamiodarone (NDEA), potently inhibit human cardiac CYP2J2-mediated astemizole metabolism in vitro.	desethylamiodarone	147-151	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	185-191
28958841-3	2017	Previously, we demonstrated that dronedarone, amiodarone and their main metabolites, namely N-desbutyldronedarone (NDBD) and N-desethylamiodarone (NDEA), potently inhibit human cardiac CYP2J2-mediated astemizole metabolism in vitro.	Astemizole	201-211	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	185-191
28958841-9	2017	Based on our novel findings, we postulate the differential cardiac exacerbation potential of dronedarone and amiodarone is partly associated with their differential inhibition potencies of cardiac CYP2J2 and sEH.	Dronedarone	93-104	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	197-203
28958841-9	2017	Based on our novel findings, we postulate the differential cardiac exacerbation potential of dronedarone and amiodarone is partly associated with their differential inhibition potencies of cardiac CYP2J2 and sEH.	Amiodarone	109-119	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	197-203
28374982-0	2017	Angiotensin II Receptor Blockers Inhibit the Generation of Epoxyeicosatrienoic Acid from Arachidonic Acid in Recombinant CYP2C9, CYP2J2 and Human Liver Microsomes.	epoxyeicosatrienoic acid	59-83	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	129-135
28374982-0	2017	Angiotensin II Receptor Blockers Inhibit the Generation of Epoxyeicosatrienoic Acid from Arachidonic Acid in Recombinant CYP2C9, CYP2J2 and Human Liver Microsomes.	Arachidonic Acid	89-105	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	129-135
28374982-1	2017	Cytochrome P450 (CYP) 2C9, CYP2C8 and CYP2J2 enzymes, which metabolize arachidonic acid (AA) to epoxyeicosatrienoic acids, have cardioprotective effects including anti-inflammation and vasodilation.	Arachidonic Acid	71-87	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	38-44
28374982-1	2017	Cytochrome P450 (CYP) 2C9, CYP2C8 and CYP2J2 enzymes, which metabolize arachidonic acid (AA) to epoxyeicosatrienoic acids, have cardioprotective effects including anti-inflammation and vasodilation.	epoxyeicosatrienoic acids	96-121	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	38-44
28866862-2	2017	An inhibitory effect of acetylshikonin against CYP2J2 activity was discovered recently.	acetylshikonin	24-38	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	47-53
28756208-0	2017	Activation of ALDH1A1 in MDA-MB-468 breast cancer cells that over-express CYP2J2 protects against paclitaxel-dependent cell death mediated by reactive oxygen species.	Paclitaxel	98-108	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	74-80
28756208-0	2017	Activation of ALDH1A1 in MDA-MB-468 breast cancer cells that over-express CYP2J2 protects against paclitaxel-dependent cell death mediated by reactive oxygen species.	Reactive Oxygen Species	142-165	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	74-80
28756208-2	2017	This study evaluated the mechanisms by which MDA-MB-468 breast cancer cells that stably expressed CYP2J2 (MDA-2J2 cells) were protected against killing by the anti-cancer agent paclitaxel.	Paclitaxel	177-187	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	98-104
28756208-7	2017	ALDH1A1 expression and activity was strongly upregulated in MDA-2J2 cells that was attributed to CYP2J2-derived 14,15-epoxyeicosatrienoic acid (14,15-EET); the 8,9- and 11,12-EET regioisomers did not activate ALDH1A1 expression.	14,15-epoxy-5,8,11-eicosatrienoic acid	112-142	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	97-103
29098037-4	2017	Although Akt phosphorylation in both cell lines was significantly attenuated by LY294002, a specific phosphoinositide 3-kinase/Akt signaling inhibitor, the levels of Akt phosphorylation following treatment with LY294002 were higher in CYP2J2-overexpressing HepG2 cells than in wild-type HepG2 cells.	2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one	80-88	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	235-241
29098037-5	2017	Cell counting revealed that proliferation was reduced by LY294002 in both cell lines; however, CYP2J2-overexpressing HepG2 cell numbers were higher than those of wild-type HepG2 cells following treatment with LY294002.	2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one	209-217	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	95-101
29098037-8	2017	However, the doxorubicin-induced reduction in cell viability was significantly attenuated by enhanced upregulation of CYP2J2 expression.	Doxorubicin	13-24	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	118-124
29098037-10	2017	In conclusion, CYP2J2 serves important roles in cancer cell proliferation and resistance to the anticancer agent doxorubicin in HepG2 cells.	Doxorubicin	113-124	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	15-21
28934153-9	2017	Selaginellin and selaginellin M also showed medium inhibitory potential against CYP2C9, CYP2J2, UGT1A1, and UGT1A3 (1 muM &lt; IC50 &lt; 5 muM).	selaginellin S	0-12	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	88-94
28934153-9	2017	Selaginellin and selaginellin M also showed medium inhibitory potential against CYP2C9, CYP2J2, UGT1A1, and UGT1A3 (1 muM &lt; IC50 &lt; 5 muM).	selaginellin M	17-31	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	88-94
28698302-0	2017	Heme Modification Contributes to the Mechanism-Based Inactivation of Human Cytochrome P450 2J2 by Two Terminal Acetylenic Compounds.	Heme	0-4	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	75-94
28698302-0	2017	Heme Modification Contributes to the Mechanism-Based Inactivation of Human Cytochrome P450 2J2 by Two Terminal Acetylenic Compounds.	Alkynes	111-131	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	75-94
28698302-1	2017	The mechanism-based inactivation of human CYP2J2 by three terminal acetylenic compounds: N-(methylsulfonyl)-6-(2-propargyloxyphenyl)hexanamide (MS), 17-octadecynoic acid (OD), and danazol (DZ) was investigated.	acetylenic	67-77	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	42-48
28698302-1	2017	The mechanism-based inactivation of human CYP2J2 by three terminal acetylenic compounds: N-(methylsulfonyl)-6-(2-propargyloxyphenyl)hexanamide (MS), 17-octadecynoic acid (OD), and danazol (DZ) was investigated.	N-methylsulfonyl-6-(2-propargyloxyphenyl)hexanamide	89-142	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	42-48
28698302-1	2017	The mechanism-based inactivation of human CYP2J2 by three terminal acetylenic compounds: N-(methylsulfonyl)-6-(2-propargyloxyphenyl)hexanamide (MS), 17-octadecynoic acid (OD), and danazol (DZ) was investigated.	N-methylsulfonyl-6-(2-propargyloxyphenyl)hexanamide	144-146	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	42-48
28698302-1	2017	The mechanism-based inactivation of human CYP2J2 by three terminal acetylenic compounds: N-(methylsulfonyl)-6-(2-propargyloxyphenyl)hexanamide (MS), 17-octadecynoic acid (OD), and danazol (DZ) was investigated.	17-octadecynoic acid	149-169	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	42-48
28698302-1	2017	The mechanism-based inactivation of human CYP2J2 by three terminal acetylenic compounds: N-(methylsulfonyl)-6-(2-propargyloxyphenyl)hexanamide (MS), 17-octadecynoic acid (OD), and danazol (DZ) was investigated.	17-octadecynoic acid	171-173	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	42-48
28698302-1	2017	The mechanism-based inactivation of human CYP2J2 by three terminal acetylenic compounds: N-(methylsulfonyl)-6-(2-propargyloxyphenyl)hexanamide (MS), 17-octadecynoic acid (OD), and danazol (DZ) was investigated.	Danazol	180-187	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	42-48
28698302-1	2017	The mechanism-based inactivation of human CYP2J2 by three terminal acetylenic compounds: N-(methylsulfonyl)-6-(2-propargyloxyphenyl)hexanamide (MS), 17-octadecynoic acid (OD), and danazol (DZ) was investigated.	Danazol	189-191	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	42-48
28698302-5	2017	Inactivation of CYP2J2 by MS or OD resulted in a loss of the native heme spectrum and a similar decrease in the reduced CO difference spectrum.	Heme	68-72	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	16-22
28698302-6	2017	A heme adduct was observed in the MS-inactivated CYP2J2.	Heme	2-6	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	49-55
28698302-9	2017	Interaction of CYP2J2 with DZ produced a type II binding spectrum with a Ks of 2.8 muM and the IC50 for loss of OHEB carboxylation activity was 0.18 muM.	Potassium	73-75	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	15-21
28698302-10	2017	In conclusion, heme modification by MS and OD was responsible for the mechanism-based inactivation of CYP2J2.	Heme	15-19	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	102-108
28698302-11	2017	The results suggest that the ethynyl moiety of MS and OD faces the heme iron, whereas the isoxazole ring of DZ is preferentially oriented toward the heme iron of CYP2J2.	Isoxazoles	90-99	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	162-168
28698302-11	2017	The results suggest that the ethynyl moiety of MS and OD faces the heme iron, whereas the isoxazole ring of DZ is preferentially oriented toward the heme iron of CYP2J2.	Heme	149-153	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	162-168
28698302-11	2017	The results suggest that the ethynyl moiety of MS and OD faces the heme iron, whereas the isoxazole ring of DZ is preferentially oriented toward the heme iron of CYP2J2.	Iron	154-158	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	162-168
28587983-4	2017	The aim of this research was to investigate whether CYP2J2/EETs-PPARalpha pathway involved in endothelium protective effects of OP-D in human umbilical vein endothelial cells (HUVECs).	ophiopogonin D	128-132	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	52-58
28687674-5	2017	These metabolites were directly produced by direct epoxygenation of the omega-3 endocannabinoids, docosahexanoyl ethanolamide (DHEA) and eicosapentaenoyl ethanolamide (EPEA) by activated BV-2 microglial cells, and by human CYP2J2.	omega-3 endocannabinoids	72-96	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	223-229
28687674-5	2017	These metabolites were directly produced by direct epoxygenation of the omega-3 endocannabinoids, docosahexanoyl ethanolamide (DHEA) and eicosapentaenoyl ethanolamide (EPEA) by activated BV-2 microglial cells, and by human CYP2J2.	docosahexanoyl ethanolamide	98-125	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	223-229
28687674-5	2017	These metabolites were directly produced by direct epoxygenation of the omega-3 endocannabinoids, docosahexanoyl ethanolamide (DHEA) and eicosapentaenoyl ethanolamide (EPEA) by activated BV-2 microglial cells, and by human CYP2J2.	Dehydroepiandrosterone	127-131	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	223-229
28687674-5	2017	These metabolites were directly produced by direct epoxygenation of the omega-3 endocannabinoids, docosahexanoyl ethanolamide (DHEA) and eicosapentaenoyl ethanolamide (EPEA) by activated BV-2 microglial cells, and by human CYP2J2.	Eicosapentaenoyl Ethanolamide	137-166	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	223-229
28687674-5	2017	These metabolites were directly produced by direct epoxygenation of the omega-3 endocannabinoids, docosahexanoyl ethanolamide (DHEA) and eicosapentaenoyl ethanolamide (EPEA) by activated BV-2 microglial cells, and by human CYP2J2.	Eicosapentaenoyl Ethanolamide	168-172	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	223-229
28237650-2	2017	CYP2J2 is a major cardiac CYP450 and primarily metabolizes polyunsaturated fatty acids such as arachidonic acid to cardioactive epoxyeicosatrienoic acids.	Fatty Acids, Unsaturated	59-86	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	0-6
28237650-2	2017	CYP2J2 is a major cardiac CYP450 and primarily metabolizes polyunsaturated fatty acids such as arachidonic acid to cardioactive epoxyeicosatrienoic acids.	Arachidonic Acid	95-111	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	0-6
28237650-2	2017	CYP2J2 is a major cardiac CYP450 and primarily metabolizes polyunsaturated fatty acids such as arachidonic acid to cardioactive epoxyeicosatrienoic acids.	epoxyeicosatrienoic acids	128-153	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	0-6
28237650-4	2017	Additionally, CYP2J2 metabolizes a number of xenobiotics such as astemizole and terfenadine and is potently inhibited by danazol and telmisartan.	Astemizole	65-75	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	14-20
28237650-4	2017	Additionally, CYP2J2 metabolizes a number of xenobiotics such as astemizole and terfenadine and is potently inhibited by danazol and telmisartan.	Terfenadine	80-91	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	14-20
28237650-4	2017	Additionally, CYP2J2 metabolizes a number of xenobiotics such as astemizole and terfenadine and is potently inhibited by danazol and telmisartan.	Danazol	121-128	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	14-20
28237650-4	2017	Additionally, CYP2J2 metabolizes a number of xenobiotics such as astemizole and terfenadine and is potently inhibited by danazol and telmisartan.	Telmisartan	133-144	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	14-20
28237650-7	2017	CYP2J2 inhibitor such as C26 (1-[4-(vinyl)phenyl]-4-[4-(diphenyl-hydroxymethyl)-piperidinyl]-butanone hydrochloride) caused marked reduction in tumor proliferation and migration as well as promoted apoptosis in cancer cells.	c26 (1-[4-(vinyl)phenyl]-4-[4-(diphenyl-hydroxymethyl)-piperidinyl]-butanone hydrochloride	25-115	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	0-6
28461575-0	2017	LKY-047: First Selective Inhibitor of Cytochrome P450 2J2.	LKY-047	0-7	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	38-57
28461575-3	2017	LKY-047 was demonstrated to be a strong competitive inhibitor of CYP2J2-mediated astemizole O-demethylase and terfenadine hydroxylase activity, with Ki values of 0.96 and 2.61 muM, respectively.	LKY-047	0-7	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	65-71
28461575-3	2017	LKY-047 was demonstrated to be a strong competitive inhibitor of CYP2J2-mediated astemizole O-demethylase and terfenadine hydroxylase activity, with Ki values of 0.96 and 2.61 muM, respectively.	Astemizole	81-91	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	65-71
28461575-4	2017	It also acted as an uncompetitive inhibitor of CYP2J2-mediated ebastine hydroxylation with a Ki value of 3.61 muM.	ebastine	63-71	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	47-53
28461575-6	2017	LKY-047 was found to be a selective CYP2J2 inhibitor with no inhibitory effect on other human P450s, such as CYPs 1A2, 2A6, 2B6, 2C8, 2C9, 2C19, 2D6, 2E1, and 3A (IC50 &gt; 50 muM).	LKY-047	0-7	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	36-42
28461575-7	2017	These in vitro data support the use of LKY-047 as a selective CYP2J2 inhibitor with potential application in the identification of P450 isoforms responsible for drug metabolism in reaction phenotyping assays.	LKY-047	39-46	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	62-68
28316087-11	2017	Further, CYP2C8*3 and CYP2J2 c.-76G&gt;T SNPs influenced the renal function of these patients and the occurrence of adverse events during treatment with tacrolimus and mycophenolate sodium.	Mycophenolic Acid	168-188	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	22-28
28053220-2	2017	Studies have revealed that the clearance of rivaroxaban is largely attributed to CYP3A4, CYP2J2 metabolism, and P-glycoprotein (P-gp) efflux pathways.	Rivaroxaban	44-55	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	89-95
28328948-12	2017	Endothelial overexpression of CYP2J2 significantly changed oxylipin profiles, including increased EETs (P &lt; 0.05), increased EpOMEs (P &lt; 0.05), and decreased 8-iso-PGF2alpha (P &lt; 0.05).	8-epi-prostaglandin F2alpha	164-179	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	30-36
28053220-4	2017	Amiodarone, dronedarone, and their major metabolites, N-desethylamiodarone (NDEA) and N-desbutyldronedarone (NDBD), demonstrate inhibitory effects on CYP3A4 and CYP2J2 with U.S. Food and Drug Administration-recommended probe substrates.	N-desbutyldronedarone	109-113	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	161-167
28053220-4	2017	Amiodarone, dronedarone, and their major metabolites, N-desethylamiodarone (NDEA) and N-desbutyldronedarone (NDBD), demonstrate inhibitory effects on CYP3A4 and CYP2J2 with U.S. Food and Drug Administration-recommended probe substrates.	Amiodarone	0-10	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	161-167
28053220-8	2017	In this study, in vitro inhibition assays using rivaroxaban as the probe substrate demonstrated that both dronedarone and NDBD produced reversible inhibition as well as irreversible mechanism-based inactivation of CYP3A4- and CYP2J2-mediated metabolism of rivaroxaban.	Rivaroxaban	48-59	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	226-232
28053220-8	2017	In this study, in vitro inhibition assays using rivaroxaban as the probe substrate demonstrated that both dronedarone and NDBD produced reversible inhibition as well as irreversible mechanism-based inactivation of CYP3A4- and CYP2J2-mediated metabolism of rivaroxaban.	Dronedarone	106-117	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	226-232
28053220-4	2017	Amiodarone, dronedarone, and their major metabolites, N-desethylamiodarone (NDEA) and N-desbutyldronedarone (NDBD), demonstrate inhibitory effects on CYP3A4 and CYP2J2 with U.S. Food and Drug Administration-recommended probe substrates.	Dronedarone	12-23	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	161-167
28053220-8	2017	In this study, in vitro inhibition assays using rivaroxaban as the probe substrate demonstrated that both dronedarone and NDBD produced reversible inhibition as well as irreversible mechanism-based inactivation of CYP3A4- and CYP2J2-mediated metabolism of rivaroxaban.	N-desbutyldronedarone	122-126	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	226-232
28053220-8	2017	In this study, in vitro inhibition assays using rivaroxaban as the probe substrate demonstrated that both dronedarone and NDBD produced reversible inhibition as well as irreversible mechanism-based inactivation of CYP3A4- and CYP2J2-mediated metabolism of rivaroxaban.	Rivaroxaban	256-267	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	226-232
28053220-9	2017	However, amiodarone and NDEA were observed to cause reversible inhibition as well as mechanism-based inactivation of CYP3A4 but not CYP2J2.	desethylamiodarone	24-28	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	132-138
28053220-4	2017	Amiodarone, dronedarone, and their major metabolites, N-desethylamiodarone (NDEA) and N-desbutyldronedarone (NDBD), demonstrate inhibitory effects on CYP3A4 and CYP2J2 with U.S. Food and Drug Administration-recommended probe substrates.	desethylamiodarone	54-74	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	161-167
28053220-4	2017	Amiodarone, dronedarone, and their major metabolites, N-desethylamiodarone (NDEA) and N-desbutyldronedarone (NDBD), demonstrate inhibitory effects on CYP3A4 and CYP2J2 with U.S. Food and Drug Administration-recommended probe substrates.	desethylamiodarone	76-80	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	161-167
28053220-4	2017	Amiodarone, dronedarone, and their major metabolites, N-desethylamiodarone (NDEA) and N-desbutyldronedarone (NDBD), demonstrate inhibitory effects on CYP3A4 and CYP2J2 with U.S. Food and Drug Administration-recommended probe substrates.	N-desbutyldronedarone	86-107	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	161-167
29911373-2	2017	CYP2J2 can convert arachidonic acid (AA) to expoxyeicosatrienoic acids (EETs), which have various biological effects, implying the important role of CYP2J2 in the regulation of cardiovascular system and promotion of tumor progression and metastasis.	Arachidonic Acid	19-35	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	0-6
28030819-6	2017	Increased Hcy level enhanced the neoplastic cellular phenotype, which was reversed by CYP2J2 knockdown in vitro.	Homocysteine	10-13	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	86-92
28160853-0	2017	Identification of acetylshikonin as the novel CYP2J2 inhibitor with anti-cancer activity in HepG2 cells.	acetylshikonin	18-32	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	46-52
28160853-4	2017	STUDY DESIGN: The inhibitory effect of acetylshikonin on the activities of CYP2J2-mediated metabolism were investigated using human liver microsomes (HLMs), and its cytotoxicity against human hepatoma HepG2 cells was also evaluated.	acetylshikonin	39-53	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	75-81
28160853-5	2017	METHOD: Astemizole, a representative CYP2J2 probe substrate, was incubated in HLMs in the presence or absence of acetylshikonin.	Astemizole	8-18	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	37-43
28160853-9	2017	RESULTS: Acetylshikonin inhibited CYP2J2-mediated astemizole O-demethylation activity (Ki = 2.1microM) in a noncompetitive manner.	acetylshikonin	9-23	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	34-40
28160853-9	2017	RESULTS: Acetylshikonin inhibited CYP2J2-mediated astemizole O-demethylation activity (Ki = 2.1microM) in a noncompetitive manner.	Astemizole	50-60	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	34-40
28160853-10	2017	The noncompetitive inhibitory effect of acetylshikonin on CYP2J2 enzyme was also demonstrated using this 3D structure, which showed different binding location of astemizole and acetylshikonin in CYP2J2 model.	Astemizole	162-172	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	58-64
28160853-10	2017	The noncompetitive inhibitory effect of acetylshikonin on CYP2J2 enzyme was also demonstrated using this 3D structure, which showed different binding location of astemizole and acetylshikonin in CYP2J2 model.	Astemizole	162-172	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	195-201
28160853-10	2017	The noncompetitive inhibitory effect of acetylshikonin on CYP2J2 enzyme was also demonstrated using this 3D structure, which showed different binding location of astemizole and acetylshikonin in CYP2J2 model.	acetylshikonin	40-54	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	58-64
28160853-10	2017	The noncompetitive inhibitory effect of acetylshikonin on CYP2J2 enzyme was also demonstrated using this 3D structure, which showed different binding location of astemizole and acetylshikonin in CYP2J2 model.	acetylshikonin	40-54	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	195-201
28160853-13	2017	CONCLUSION: Taken together, our present study elucidates acetylshikonin displays the inhibitory effects against CYP2J2 in HLMs and anti-cancer activity in human hepatocellular carcinoma HepG2 cells.	acetylshikonin	57-71	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	112-118
28867723-4	2017	We recently demonstrated that telmisartan, one of angiotensin II receptor blockers, inhibits AA metabolism by CYP enzymes, including CYP2C8, CYP2C9, and CYP2J2.	Telmisartan	30-41	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	153-159
29911373-2	2017	CYP2J2 can convert arachidonic acid (AA) to expoxyeicosatrienoic acids (EETs), which have various biological effects, implying the important role of CYP2J2 in the regulation of cardiovascular system and promotion of tumor progression and metastasis.	Arachidonic Acid	19-35	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	149-155
29911373-2	2017	CYP2J2 can convert arachidonic acid (AA) to expoxyeicosatrienoic acids (EETs), which have various biological effects, implying the important role of CYP2J2 in the regulation of cardiovascular system and promotion of tumor progression and metastasis.	expoxyeicosatrienoic acids	44-70	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	0-6
29911373-2	2017	CYP2J2 can convert arachidonic acid (AA) to expoxyeicosatrienoic acids (EETs), which have various biological effects, implying the important role of CYP2J2 in the regulation of cardiovascular system and promotion of tumor progression and metastasis.	expoxyeicosatrienoic acids	44-70	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	149-155
29911373-2	2017	CYP2J2 can convert arachidonic acid (AA) to expoxyeicosatrienoic acids (EETs), which have various biological effects, implying the important role of CYP2J2 in the regulation of cardiovascular system and promotion of tumor progression and metastasis.	eets	72-76	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	0-6
29911373-2	2017	CYP2J2 can convert arachidonic acid (AA) to expoxyeicosatrienoic acids (EETs), which have various biological effects, implying the important role of CYP2J2 in the regulation of cardiovascular system and promotion of tumor progression and metastasis.	eets	72-76	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	149-155
29911373-3	2017	Additionally, CYP2J2 plays an indispensable role in the intestinal metabolism of various drugs, such as astemizole, terfenadine and ebastine.	Astemizole	104-114	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	14-20
29911373-3	2017	Additionally, CYP2J2 plays an indispensable role in the intestinal metabolism of various drugs, such as astemizole, terfenadine and ebastine.	Terfenadine	116-127	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	14-20
29911373-3	2017	Additionally, CYP2J2 plays an indispensable role in the intestinal metabolism of various drugs, such as astemizole, terfenadine and ebastine.	ebastine	132-140	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	14-20
27992998-0	2016	Asymmetric Binding and Metabolism of Polyunsaturated Fatty Acids (PUFAs) by CYP2J2 Epoxygenase.	Fatty Acids, Unsaturated	37-64	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	76-82
27992998-0	2016	Asymmetric Binding and Metabolism of Polyunsaturated Fatty Acids (PUFAs) by CYP2J2 Epoxygenase.	Fatty Acids, Unsaturated	66-71	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	76-82
27992998-1	2016	Cytochrome P450 (CYP) 2J2 is the primary epoxygenase in the heart and is responsible for the epoxidation of arachidonic acid (AA), an omega-6 polyunsaturated fatty acid (PUFA), into anti-inflammatory epoxide metabolites.	Arachidonic Acid	108-124	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	0-25
27992998-1	2016	Cytochrome P450 (CYP) 2J2 is the primary epoxygenase in the heart and is responsible for the epoxidation of arachidonic acid (AA), an omega-6 polyunsaturated fatty acid (PUFA), into anti-inflammatory epoxide metabolites.	omega-6 polyunsaturated fatty acid	134-168	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	0-25
27992998-1	2016	Cytochrome P450 (CYP) 2J2 is the primary epoxygenase in the heart and is responsible for the epoxidation of arachidonic acid (AA), an omega-6 polyunsaturated fatty acid (PUFA), into anti-inflammatory epoxide metabolites.	Fatty Acids, Unsaturated	170-174	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	0-25
27992998-1	2016	Cytochrome P450 (CYP) 2J2 is the primary epoxygenase in the heart and is responsible for the epoxidation of arachidonic acid (AA), an omega-6 polyunsaturated fatty acid (PUFA), into anti-inflammatory epoxide metabolites.	Epoxy Compounds	200-207	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	0-25
27992998-3	2016	Herein, we have performed detailed thermodynamic and kinetic analyses to determine how DHA, LA, and EPA modulate the metabolism of AA by CYP2J2.	Docosahexaenoic Acids	87-90	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	137-143
27992998-3	2016	Herein, we have performed detailed thermodynamic and kinetic analyses to determine how DHA, LA, and EPA modulate the metabolism of AA by CYP2J2.	Eicosapentaenoic Acid	100-103	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	137-143
27992998-5	2016	We observe that DHA strongly inhibits CYP2J2-mediated AA metabolism, LA only moderately inhibits AA metabolism, and EPA exhibits insignificant inhibition.	Docosahexaenoic Acids	16-19	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	38-44
27992998-6	2016	We also characterized the binding of these molecules using ebastine competitive binding assays and show that DHA binds significantly tighter to CYP2J2 than AA, EPA, or LA.	Docosahexaenoic Acids	109-112	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	144-150
27992998-8	2016	We show that although all the tested fatty acids form similar contacts to the active site residues, the affinity of DHA for CYP2J2 is tighter because of the interaction of DHA with residues Arg-321, Thr-318, and Ser-493.	Docosahexaenoic Acids	116-119	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	124-130
27992998-8	2016	We show that although all the tested fatty acids form similar contacts to the active site residues, the affinity of DHA for CYP2J2 is tighter because of the interaction of DHA with residues Arg-321, Thr-318, and Ser-493.	Docosahexaenoic Acids	172-175	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	124-130
27992998-8	2016	We show that although all the tested fatty acids form similar contacts to the active site residues, the affinity of DHA for CYP2J2 is tighter because of the interaction of DHA with residues Arg-321, Thr-318, and Ser-493.	Arginine	190-193	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	124-130
27992998-8	2016	We show that although all the tested fatty acids form similar contacts to the active site residues, the affinity of DHA for CYP2J2 is tighter because of the interaction of DHA with residues Arg-321, Thr-318, and Ser-493.	Threonine	199-202	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	124-130
27992998-8	2016	We show that although all the tested fatty acids form similar contacts to the active site residues, the affinity of DHA for CYP2J2 is tighter because of the interaction of DHA with residues Arg-321, Thr-318, and Ser-493.	Serine	212-215	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	124-130
27992998-11	2016	Therefore, using a combined experimental and MD simulation approach, we establish that CYP2J2 inhibition of AA metabolism by DHA, EPA, and LA is asymmetric because of tighter binding of DHA to select residues in the active site.	Docosahexaenoic Acids	125-128	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	87-93
27992998-11	2016	Therefore, using a combined experimental and MD simulation approach, we establish that CYP2J2 inhibition of AA metabolism by DHA, EPA, and LA is asymmetric because of tighter binding of DHA to select residues in the active site.	Eicosapentaenoic Acid	130-133	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	87-93
27992998-11	2016	Therefore, using a combined experimental and MD simulation approach, we establish that CYP2J2 inhibition of AA metabolism by DHA, EPA, and LA is asymmetric because of tighter binding of DHA to select residues in the active site.	Docosahexaenoic Acids	186-189	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	87-93
26899760-0	2016	Marmoset cytochrome P450 2J2 mainly expressed in small intestines and livers effectively metabolizes human P450 2J2 probe substrates, astemizole and terfenadine.	Astemizole	134-144	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	9-28
27720933-2	2016	Cytochrome P450 (CYP) 2J2 (CYP2J2) is upregulated in many human tumors and generates epoxyeicosanoids from arachidonic acid that promote tumorigenesis and metastasis, but at present there is little information on the genes that mediate these actions.	epoxyeicosanoids	85-101	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	0-25
27720933-2	2016	Cytochrome P450 (CYP) 2J2 (CYP2J2) is upregulated in many human tumors and generates epoxyeicosanoids from arachidonic acid that promote tumorigenesis and metastasis, but at present there is little information on the genes that mediate these actions.	epoxyeicosanoids	85-101	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	27-33
27720933-2	2016	Cytochrome P450 (CYP) 2J2 (CYP2J2) is upregulated in many human tumors and generates epoxyeicosanoids from arachidonic acid that promote tumorigenesis and metastasis, but at present there is little information on the genes that mediate these actions.	Arachidonic Acid	107-123	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	0-25
27720933-2	2016	Cytochrome P450 (CYP) 2J2 (CYP2J2) is upregulated in many human tumors and generates epoxyeicosanoids from arachidonic acid that promote tumorigenesis and metastasis, but at present there is little information on the genes that mediate these actions.	Arachidonic Acid	107-123	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	27-33
27796781-0	2016	Computational modelling of the binding of arachidonic acid to the human monooxygenase CYP2J2.	Arachidonic Acid	42-58	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	86-92
27796781-3	2016	In this study we present a computational investigation of the binding of arachidonic acid (AA) to CYP2J2 using homology modelling, induced fit docking (IFD) and molecular dynamics (MD) simulations.	Arachidonic Acid	73-89	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	98-104
27796781-6	2016	Graphical Abstract Arachidonic acid docked in the active site of CYP2J2 assumes a catalytically competent binding mode stabilised by hydrogen bonds to Arg117.	Arachidonic Acid	19-35	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	65-71
27796781-6	2016	Graphical Abstract Arachidonic acid docked in the active site of CYP2J2 assumes a catalytically competent binding mode stabilised by hydrogen bonds to Arg117.	Hydrogen	133-141	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	65-71
26899760-0	2016	Marmoset cytochrome P450 2J2 mainly expressed in small intestines and livers effectively metabolizes human P450 2J2 probe substrates, astemizole and terfenadine.	Terfenadine	149-160	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	9-28
27000802-7	2016	CYP2J2, the major P450 epoxygenase expressed in the heart, is also expressed in the intestine and has previously been reported to oxidize AEA.	aea	138-141	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	0-6
27791151-4	2016	In a drug repurposing screen targeting CYP2J2, the human ortholog of murine CYP2J6, we identified telmisartan, a widely used angiotensin II receptor antagonist, as a potent inhibitor.	Telmisartan	98-109	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	39-45
27000802-0	2016	Metabolism of Anandamide by Human Cytochrome P450 2J2 in the Reconstituted System and Human Intestinal Microsomes.	anandamide	14-24	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	34-53
27000802-8	2016	We have investigated the possibility that it may play a role in AEA metabolism in the gut and have demonstrated that purified human CYP2J2 metabolizes AEA to form the 20-hydroxyeicosatetraenoic acid ethanolamide (HETE-EA) and several epoxygenated products, including the 5,6-, 8,9-, 11,12-, and 14,15-epoxyeicosatrienoic acid ethanolamides (EET-EAs), in the reconstituted system.	aea	64-67	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	132-138
27000802-8	2016	We have investigated the possibility that it may play a role in AEA metabolism in the gut and have demonstrated that purified human CYP2J2 metabolizes AEA to form the 20-hydroxyeicosatetraenoic acid ethanolamide (HETE-EA) and several epoxygenated products, including the 5,6-, 8,9-, 11,12-, and 14,15-epoxyeicosatrienoic acid ethanolamides (EET-EAs), in the reconstituted system.	aea	151-154	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	132-138
27000802-8	2016	We have investigated the possibility that it may play a role in AEA metabolism in the gut and have demonstrated that purified human CYP2J2 metabolizes AEA to form the 20-hydroxyeicosatetraenoic acid ethanolamide (HETE-EA) and several epoxygenated products, including the 5,6-, 8,9-, 11,12-, and 14,15-epoxyeicosatrienoic acid ethanolamides (EET-EAs), in the reconstituted system.	20-hydroxyeicosatetraenoic acid ethanolamide	167-211	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	132-138
27000802-8	2016	We have investigated the possibility that it may play a role in AEA metabolism in the gut and have demonstrated that purified human CYP2J2 metabolizes AEA to form the 20-hydroxyeicosatetraenoic acid ethanolamide (HETE-EA) and several epoxygenated products, including the 5,6-, 8,9-, 11,12-, and 14,15-epoxyeicosatrienoic acid ethanolamides (EET-EAs), in the reconstituted system.	hete-ea	213-220	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	132-138
27000802-8	2016	We have investigated the possibility that it may play a role in AEA metabolism in the gut and have demonstrated that purified human CYP2J2 metabolizes AEA to form the 20-hydroxyeicosatetraenoic acid ethanolamide (HETE-EA) and several epoxygenated products, including the 5,6-, 8,9-, 11,12-, and 14,15-epoxyeicosatrienoic acid ethanolamides (EET-EAs), in the reconstituted system.	5,6-, 8,9-, 11,12-, and 14,15-epoxyeicosatrienoic acid ethanolamides	271-339	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	132-138
27000802-8	2016	We have investigated the possibility that it may play a role in AEA metabolism in the gut and have demonstrated that purified human CYP2J2 metabolizes AEA to form the 20-hydroxyeicosatetraenoic acid ethanolamide (HETE-EA) and several epoxygenated products, including the 5,6-, 8,9-, 11,12-, and 14,15-epoxyeicosatrienoic acid ethanolamides (EET-EAs), in the reconstituted system.	eet-eas	341-348	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	132-138
27000802-10	2016	Human intestinal microsomes, which express CYP2J2, metabolize AEA to give the 5,6-, 8,9-, and 11,12-EET-EAs, as well as 20-HETE-EA.	aea	62-65	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	43-49
27000802-11	2016	Studies using specific P450 inhibitors suggest that although CYP2J2 metabolizes AEA, it is not the primary P450 responsible for AEA metabolism in human intestines.	aea	80-83	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	61-67
26972388-0	2016	Multiple modes of inhibition of human cytochrome P450 2J2 by dronedarone, amiodarone and their active metabolites.	Dronedarone	61-72	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	38-57
26972388-0	2016	Multiple modes of inhibition of human cytochrome P450 2J2 by dronedarone, amiodarone and their active metabolites.	Amiodarone	74-84	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	38-57
26972388-6	2016	The absence of the characteristic Soret peak, lack of recovery of CYP2J2 activity upon dialysis, and biotransformation of dronedarone and NDBD to quinone-oxime reactive metabolites further confirmed the irreversible inactivation of CYP2J2 by dronedarone and NDBD is via the covalent adduction of CYP2J2.	Dronedarone	242-253	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	232-238
26972388-3	2016	As dronedarone is a potent mechanism-based inactivator of CYP3A4 and CYP3A5, a question arose if it exerts a similar inhibitory effect on CYP2J2, a prominent cardiac CYP450 enzyme.	Dronedarone	3-14	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	138-144
26972388-6	2016	The absence of the characteristic Soret peak, lack of recovery of CYP2J2 activity upon dialysis, and biotransformation of dronedarone and NDBD to quinone-oxime reactive metabolites further confirmed the irreversible inactivation of CYP2J2 by dronedarone and NDBD is via the covalent adduction of CYP2J2.	Dronedarone	242-253	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	232-238
26972388-4	2016	In this study, we demonstrated that CYP2J2 is reversibly inhibited by dronedarone (Ki=0.034 muM), amiodarone (Ki=4.8muM) and their respective pharmacologically active metabolites namely N-desbutyldronedarone (NDBD) (Ki=0.55 muM) and N-desethylamiodarone (NDEA) (Ki=7.4 muM).	Dronedarone	70-81	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	36-42
26972388-6	2016	The absence of the characteristic Soret peak, lack of recovery of CYP2J2 activity upon dialysis, and biotransformation of dronedarone and NDBD to quinone-oxime reactive metabolites further confirmed the irreversible inactivation of CYP2J2 by dronedarone and NDBD is via the covalent adduction of CYP2J2.	N-desbutyldronedarone	258-262	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	232-238
26972388-4	2016	In this study, we demonstrated that CYP2J2 is reversibly inhibited by dronedarone (Ki=0.034 muM), amiodarone (Ki=4.8muM) and their respective pharmacologically active metabolites namely N-desbutyldronedarone (NDBD) (Ki=0.55 muM) and N-desethylamiodarone (NDEA) (Ki=7.4 muM).	Amiodarone	98-108	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	36-42
26972388-6	2016	The absence of the characteristic Soret peak, lack of recovery of CYP2J2 activity upon dialysis, and biotransformation of dronedarone and NDBD to quinone-oxime reactive metabolites further confirmed the irreversible inactivation of CYP2J2 by dronedarone and NDBD is via the covalent adduction of CYP2J2.	N-desbutyldronedarone	258-262	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	232-238
26972388-7	2016	Our novel findings illuminate the possible mechanisms of DDIs and cardiac adverse effects due to both reversible inhibition and irreversible inactivation of CYP2J2 by dronedarone, amiodarone and their active metabolites.	Dronedarone	167-178	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	157-163
26972388-7	2016	Our novel findings illuminate the possible mechanisms of DDIs and cardiac adverse effects due to both reversible inhibition and irreversible inactivation of CYP2J2 by dronedarone, amiodarone and their active metabolites.	Amiodarone	180-190	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	157-163
26972388-4	2016	In this study, we demonstrated that CYP2J2 is reversibly inhibited by dronedarone (Ki=0.034 muM), amiodarone (Ki=4.8muM) and their respective pharmacologically active metabolites namely N-desbutyldronedarone (NDBD) (Ki=0.55 muM) and N-desethylamiodarone (NDEA) (Ki=7.4 muM).	N-desbutyldronedarone	186-207	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	36-42
26972388-4	2016	In this study, we demonstrated that CYP2J2 is reversibly inhibited by dronedarone (Ki=0.034 muM), amiodarone (Ki=4.8muM) and their respective pharmacologically active metabolites namely N-desbutyldronedarone (NDBD) (Ki=0.55 muM) and N-desethylamiodarone (NDEA) (Ki=7.4 muM).	N-desbutyldronedarone	209-213	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	36-42
26972388-4	2016	In this study, we demonstrated that CYP2J2 is reversibly inhibited by dronedarone (Ki=0.034 muM), amiodarone (Ki=4.8muM) and their respective pharmacologically active metabolites namely N-desbutyldronedarone (NDBD) (Ki=0.55 muM) and N-desethylamiodarone (NDEA) (Ki=7.4 muM).	desethylamiodarone	233-253	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	36-42
26972388-4	2016	In this study, we demonstrated that CYP2J2 is reversibly inhibited by dronedarone (Ki=0.034 muM), amiodarone (Ki=4.8muM) and their respective pharmacologically active metabolites namely N-desbutyldronedarone (NDBD) (Ki=0.55 muM) and N-desethylamiodarone (NDEA) (Ki=7.4 muM).	desethylamiodarone	255-259	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	36-42
26972388-5	2016	Moreover, time-, concentration- and NADPH-dependent irreversible inactivation of CYP2J2 was investigated where inactivation kinetic parameters (KI, kinact) and partition ratio (r) of dronedarone (0.05 muM, 0.034 min(-1), 3.3), amiodarone (0.21 muM, 0.015 min(-1), 20.7) and NDBD (0.48 muM, 0.024 min(-1), 21.7) were observed except for NDEA.	NADP	36-41	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	81-87
26972388-5	2016	Moreover, time-, concentration- and NADPH-dependent irreversible inactivation of CYP2J2 was investigated where inactivation kinetic parameters (KI, kinact) and partition ratio (r) of dronedarone (0.05 muM, 0.034 min(-1), 3.3), amiodarone (0.21 muM, 0.015 min(-1), 20.7) and NDBD (0.48 muM, 0.024 min(-1), 21.7) were observed except for NDEA.	Dronedarone	183-194	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	81-87
26972388-5	2016	Moreover, time-, concentration- and NADPH-dependent irreversible inactivation of CYP2J2 was investigated where inactivation kinetic parameters (KI, kinact) and partition ratio (r) of dronedarone (0.05 muM, 0.034 min(-1), 3.3), amiodarone (0.21 muM, 0.015 min(-1), 20.7) and NDBD (0.48 muM, 0.024 min(-1), 21.7) were observed except for NDEA.	Amiodarone	227-237	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	81-87
26972388-5	2016	Moreover, time-, concentration- and NADPH-dependent irreversible inactivation of CYP2J2 was investigated where inactivation kinetic parameters (KI, kinact) and partition ratio (r) of dronedarone (0.05 muM, 0.034 min(-1), 3.3), amiodarone (0.21 muM, 0.015 min(-1), 20.7) and NDBD (0.48 muM, 0.024 min(-1), 21.7) were observed except for NDEA.	N-desbutyldronedarone	274-278	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	81-87
26972388-5	2016	Moreover, time-, concentration- and NADPH-dependent irreversible inactivation of CYP2J2 was investigated where inactivation kinetic parameters (KI, kinact) and partition ratio (r) of dronedarone (0.05 muM, 0.034 min(-1), 3.3), amiodarone (0.21 muM, 0.015 min(-1), 20.7) and NDBD (0.48 muM, 0.024 min(-1), 21.7) were observed except for NDEA.	desethylamiodarone	336-340	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	81-87
26334592-8	2016	Finite Difference Time Domain (FDTD) electromagnetic simulation suggested that the blue shift on the nanoLCA is because of the hybridization of plasmon polariton Bloch wave and the electronic resonance of the heme group of CYP2J2.	Heme	209-213	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	223-229